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Abstract  
In addition to their role in fighting infection, mast cells have long been 
implicated in the pathogenesis of allergic and autoimmune inflammatory 
diseases and cancers. Increasingly, however, there is recognition that these 
cells may also play a part in protecting against development of pathologies. 
Indeed, there is increasing evidence that mast cells comprise heterogeneous 
phenotypes that exhibit functional plasticity to allow them to play both pro- 
and anti-inflammatory roles during an immune response. This plasticity 
appears to reflect that immature mast cells are tailored by their particular 
microenvironment not only to trigger protective inflammatory responses but 
also to limit pathology by resolving inflammation and promoting wound 
healing and tissue repair. Mast cells can be activated by a range of stimuli 
including (pathogen-derived) antigen/allergen-mediated crosslinking of 
antibody-bound to Fc receptors, most notably FcεRI, pathogen-associated 
molecular patterns (PAMP) such as bacterial lipopolysaccharide (LPS) acting 
on TLR4, inflammatory cytokines such as IL-33 (via the IL-1R/TLR-like 
receptor ST2) and tissue-derived signals such as SCF (via cKIT).  During 
infection these stimuli provoke a response optimised for pathogen clearance 
however in autoimmune or allergic disease such responses can initiate and 
exacerbate host pathology. Thus the challenge for therapeutic targeting of 
mast cells in inflammatory or malignant disease is to limit mast cells with 
pathogenic phenotypes whilst preserving those contributing to protective 
homeostatic and anti-pathogen responses.   
Thus, as a first step, it was a core aim of these studies to generate in vitro 
mast cell models representing the phenotypic and maturational heterogeneity 
of mast cells in vivo, as these are difficult to isolate and purify due to their 
limited numbers in tissue. Distinct murine mast cell phenotypes, namely 
mature serosal peritoneal-derived mast cells (PDMC), connective tissue-like 
mast cells (CTMC) and mucosal-like mast cells (BMMC), the latter two 
subtypes both derived from bone marrow progenitors, were found to 
differentially respond, in terms of cytokine production and degranulation, to 
important immunoregulatory receptors in health and disease, namely FcεRI 
and TLR4. Consistent with their distinct functional responses, these mast cell 
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subtypes were also found to display differential calcium signalling profiles in 
response to FcεRI and TLR4 signalling, further highlighting the importance in 
investigating phenotypically relevant and microenvironment-specific (serosal 
versus mucosal) mast cells in drug discovery programmes. 
Recently there has been great interest in IL-33, a pro-inflammatory cytokine 
increasingly recognised as playing an important role in a variety of mast cell 
responses associated with allergic inflammatory disorders and tumour 
pathogenesis. Consistent with this, whilst IL-33 can stimulate mast cell 
cytokine production, but not degranulation, via the IL-1R/TLR-like receptor 
ST2, responses to this cytokine are amplified following IgE sensitization 
and/or exposure to SCF or serum. Such augmented responses reflect 
increased calcium mobilization, PLD, SphK, ERK and NF-κB signalling and 
mTOR activation and can be suppressed by existing therapeutics targeting the 
costimulatory signal, for example, Imatinib or Dasatinib for SCF/cKIT and 
potentially Omalizumab for IgE/FcεR1. Moreover, IL-33/ST2 signalling can 
modulate mast cell responses resulting from antigen-mediated crosslinking of 
FcεRI and LPS-TLR4 signalling. Indeed, ST2 signalling can differentially 
modulate LPS/TLR4 responses depending on the presence (enhances) or 
absence (inhibits) of IL-33, as in the latter case ST2 acts to limit LPS cytokine 
production, potentially by sequestering MyD88.  This receptor crosstalk is 
likely to occur under pathological conditions, thus targeting of such 
cooperative signalling may allow the downregulation of hyper-inflammatory 
responses, whilst leaving protective and homeostatic mast cell responses 
intact. 
ES-62 is an immunomodulator produced by filarial nematodes to dampen 
immune responses in order to promote parasite survival and prevent tissue 
damage without immunocompromising the host to infection. As a 
serendipitous side effect of its anti-inflammatory actions, ES-62 exhibits 
therapeutic potential in both allergic and autoimmune inflammatory disease 
and thus to further explore the potential for safe, targeted downregulation of 
pathogenic mast cell responses, the parasite product was exploited in order 
to identify signals regulating mast cell activation. ES-62 was found to be able 
to induce hypo-responsiveness of all three mast cell phenotypes in terms of 
degranulation and cytokine production in response to stimulation of FcεR1-, 
  
iv 
TLR4- or IL-33/ST2, either alone or in combination. ES-62 mediated these 
effects, at least in part, by mechanisms involving downregulation of 
PKCα (and in BMMC, MyD88) expression and calcium mobilisation and, in 
PDMC, potentially by subverting the negative feedback interactions of ST2 on 
TLR4. The precise mechanism of modulation varies both with receptor usage 
and mast cell phenotype as ES-62 exhibits differential effects in PDMC and 
BMMC. Nevertheless, collectively these data support the role of calcium-, 
PKCα- and MyD88- as key regulatory intersection sites in the functional 
crosstalk amongst these important immunoregulatory receptors and 
importantly, suggest they are potential targets for therapeutic intervention in 
pathogenic mast cell responses. 
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1 General Introduction 
1.1 Mast cells 
Mast cells are long-lived haematopoietic cells found in almost all vascularised 
organs [1]. They comprise an extremely heterogeneous cell population, 
varying in morphology, function and localisation, with individual subtypes 
exhibiting different protease expression, quantity and profile of eicosanoids 
and proteoglycan content [1-5]. Mast cells can be generated from multipotent 
haematopoietic stem cells [6, 7] but not the more differentiated 
granulocyte/ macrophage or common myeloid progenitors. Mast cell 
progenitors enter the blood where they migrate to and enter the tissues in an 
immature state [8-10]. They are then influenced by the local tissue resulting 
in the generation of mast cells with multiple innate immune system functions 
(Figure 1.1).  
 
 
1.2 Mast cell development, location and phenotype 
Mast cells reside throughout the body where they are in direct contact with a 
variety of cells including endothelial cells, nerve cells, smooth muscle cells 
and epithelial cells [11, 12]. However, they are often concentrated at 
locations exposed to the outside environment such as in the skin, airways and 
gut, allowing direct interactions with allergens and pathogens; this results in 
production of a range of pro-inflammatory mediators depending on the 
stimuli received [11, 13, 14], but which include SCF, IL-3 and IL-4, from the 
local microenvironment [1, 5]. Mast cell development is not limited to 
inflammatory situations and under homeostatic conditions the precise MC 
protease, proteoglycan and mediator release phenotype generated is driven 
by hormone and cytokine signals in the surrounding tissues [15]. In mice there 
appears to be two major MC subpopulations defined by their location and 
granule proteoglycan content; CTMC, connective tissue resident mast cells 
that have the MC proteases MMCP-4, MMCP-5, MMCP-6 and carboxypeptidase 
A and contain more heparin and histamine than BMMC, mucosal surface 
resident mast cells that contain MMCP-1 and MMCP-2. Interestingly, 
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development of mucosal MC in vivo has been proposed to be T cell dependent 
[1, 11]. In humans, mast cells present in the mucosal tissues contain primarily 
tryptase, whereas skin and submucosal MC contain chymase and 
carboxypeptidase [16]. 
 
1.3 Mast cell activation  
The best-defined mechanism of mast cell activation is that resulting from 
crosslinking of antigen-specific IgE antibodies bound to the FcεRI receptor. 
FcεRI on mast cells is a high affinity receptor for IgE, constitutively expressed 
on mast cells throughout their development [17]. Surface expression of FcεRI 
is heavily regulated to ensure sufficient but controlled mast cell responses 
[18], with the receptor being downregulated quickly in the absence of bound 
IgE [17] and upregulated, both at the cell surface [19] and gene level [20] 
following FcεRI signalling. FcεRI is a tetrameric structure, comprising of α, β 
and γ subunits (αβγ2). The α chain binds IgE, while the β and γ subunits have 
roles of differing importance in signal transduction [21]. Indeed, the β 
subunit is not essential for function but, along with γ, is important in 
translocation of the α chain to the surface [18] and maintenance of receptor 
expression [17].  
 
FcεRI signalling has been comprehensively characterised and reviewed [17, 
22-28] and the key components of IgE–mediated signalling and their relevant 
interactions are shown in Figure 1.2. In brief, crosslinking of antigen-specific 
IgE bound to FcεRI triggers initial signal propagation within plasma 
membrane-associated lipid rafts. Phosphorylation of immunoreceptor 
tyrosine-based activation motifs (ITAMs) in the β and γ chains of FcεRI by a 
series of kinases including Lyn, Fyn and Syk, results in the recruitment of 
adaptor molecules and the construction of a signalling platform from which 
PI3K and PLCγ are activated resulting in calcium production, MAPK and PKC 
activation that drives degranulation and activation of NFκB to promote 
survival, growth, migration and cytokine release [26, 27, 29]. 
 
Although Ag-mediated activation via FcεRI is the best characterised system, 
the range of agonists known to induce mast cell activation are increasing 
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(Table 1.1). Mast cells can be directly activated by pathogens including 
bacteria, viruses and parasites, where pathogen-associated molecular 
patterns (PAMPs), including microbial nuclei acids, lipoproteins and 
carbohydrates, are recognised by receptors located on the MC surface, such 
as TLRs or cytosolic receptors such as NOD-like receptors. Mast cells can 
recognise pathogens specifically using pathogen-specific Ig bound to FcR and 
can be activated by anti-microbial peptides released by epithelial cells such 
as α and β defensins and cathelicidins, complement coated bacteria as well 
as host cell components, such as ATP, released from damaged cells [11-13, 
16, 28, 30-39]. Mast cells can also be directly activated by pathogen 
proteases including those from bee venom, house dust mites or parasites 
[40].   
 
Alongside activation by direct recognition of pathogens, mast cell responses 
are defined by cytokines and chemokines. Cytokines such as TNFα, IL-33 and 
SCF are important in mast cell survival, maturation and under inflammatory 
conditions, they induce proinflammatory responses [41-43]. Likewise, 
chemokines including CCL2 (MCP-1) are crucial for mast cell recruitment to 
sites of inflammation and hence can tailor MC responses to further activation 
[1, 44] [45].  
 
LPS-TLR4, SCF-cKIT and IL33-ST2 signalling appear to be particularly 
important in initiating and regulating responses in mast cells [16, 41, 46-49]. 
 
TLRs are type-1 transmembrane proteins containing leucine-rich repeats that 
recognize bacterial and viral PAMPs not only in the extracellular (TLR1, TLR2, 
TLR4, TLR5, TLR6 and TLR11) but also in the intracellular environment within 
endo-lysosomes (TLR3, TLR7, TLR8, TLR9 and TLR10) [28]. TLR expression 
varies with cell type as for example, there is no TLR5 on murine mast cells or 
TLR8 on human mast cells [46]. TLR activation of MC induces mostly cytokine 
secretion rather than degranulation: however the exact signalling and 
consequent response(s) to each TLR is controversial as the different mast cell 
subsets and culture methods impact on the profile of TLR expression, calcium 
signalling and cytokines produced after TLR ligation [12, 16, 46, 50]. Thus, 
for peritoneal-derived MC (PDMC), lipopolysaccharide (LPS) induces IL-6, 
GMC-CSF, IL-10 and TNFα release whereas in BMMC, this TLR4 ligand releases 
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a far greater range of cytokines including IL-13, IL-5 and IL-1β [46]. 
Unusually, whilst TLR4 forms a complex with MD-2 and CD14 on BMMC to 
recognise LPS, it signals only via the MyD88-dependent but not the MyD88-
independent, TRIF-dependent pathway [28, 48, 51]. Moreover, CD14 
expression is only important for recognition of LPS species without O-chain 
linkages [52-54].  
 
Individual stimuli can also interact to promote amplified responses. Thus, 
prolonged exposure to low levels of SCF-cKIT signalling allows MC 
degranulation at concentrations of Ag concentrations that would otherwise 
fail to induce activation [55, 56]. Similarly cKIT signalling is able to increase 
responses via other MC receptors including TLR4 [57] whilst TLR4 signalling 
can enhance mast cell responses including cytokines production to antigen 
[32, 49, 58, 59]. Reflecting this, in a murine model of asthma, co-
administration of LPS with OVA increases airway hypersensitivity, eosinophil 
infiltration, cytokine and histamine levels in the lung [49].  Moreover, recent 
evidence has indicated the importance of IL-33-ST2 signalling in the increased 
activation of mast cells by antigen [60] and their subsequent, varied, role in 
disease [42, 61-64]. These receptors exhibit intricate crosstalk both at the 
receptor level and in downstream signalling, allowing modulated MC 
responses defined by the combination of ligands present. The interactions 
between TLR4 and ST2 will be discussed in more detail in Chapters 5 and cKIT 
and ST2 interactions in Chapter 6. 
 
 
1.4 Mast cell responses 
The wide range of stimuli interpreted by mast cells produce a specific and 
tailored response that can then influence the development, extent and 
duration of inflammation. Mast cells interact directly with tissues as well as 
innate and adaptive immune cells (Figure 1.3) thus allowing their 
involvement from the initial stages of inflammation where, due to their 
location at the body’s surfaces, they can immediately detect and respond to 
breaches of epithelial barriers, through to the later stages of inflammation to 
promote the clearance of exhausted inflammatory cells and tissue healing. 
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MC mediator storage can adapt throughout a response as due to their 
longevity they can be present throughout an infection and remain at the site 
of inflammation after the response is terminated, providing a sort of innate 
memory cell. Although this reflects their roles in maintaining a healthy host 
via the clearance of infection, it also explains how they also perpetuate 
chronic inflammation, contributing to disease pathology.  
 
When mast cells are activated by crosslinking of IgE bound to FcεRI the 
subsequent aggregation of FcεRI initiates signalling that results in the 
extracellular release by exocytosis (degranulation) of cytoplasmic granules 
(Figure 1.4). The precise content of granule release is time-dependent as 
these can contain preformed mediators, such as histamine, proteoglycans and 
proteases or those synthesised de novo, which include lipid mediators 
prostaglandins and cytokines, chemokines and growth factors (summarised in 
Table 1.2 [11, 13]). Such mast cell mediators can have both local and 
systemic effects, where they can be disseminated via the blood or packaged 
in microsomes, tiny granule-like structures, for delivery to lymph nodes, 
affecting the distant development of the adaptive immune response [65].  
Involved in both acute and chronic conditions, mast cell-derived mediators 
modulate vasodilation, recruitment of innate and adaptive immune cells and 
tissue remodelling, all of which can negatively affect the function of the 
organ involved in the response via tissue destruction, fibrosis and reduced 
oxygen supply [66, 67]. However, in addition to driving inflammatory 
responses, mast cell-derived mediators have also been proposed to play roles 
in tissue homeostasis, where they appear to be important in homeostatic 
regulation of vasculature. Mast cell mediators such as heparin, tryptase and 
chymase all promote endothelial cell migration and new vessel formation [68-
71] whilst VEGF and PDGF promote wound healing by inducing proliferation of 
epithelial cell and fibroblasts [11, 72, 73]. Importantly, they also play anti-
inflammatory roles, as secretion of IL-10 and TGFβ can suppress inflammation 
and promote tissue healing [36, 74-77]. Both pro- and anti-inflammatory 
responses may be occurring simultaneously or sequentially, potentially 
defining the level of pathology, and affecting the duration and resolution of 
inflammation.  
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1.4.1 Mast cell involvement in the adaptive immune response. 
The immune system is composed of two branches; innate and adaptive 
immunity. Innate immunity is a localised, non-specific response to a variety 
of infectious pathogens and is the first line of defence. Adaptive immunity is 
more specific and robust, involving DC, T and B cells. This response can be 
further defined by the distinct cytokine patterns produced by the T cells, for 
example Th1, Th17, Th2 T cell responses. These categories are not fixed or 
exclusive and all display evidence of plasticity with interchanging T cell 
phenotypes. Th1 T cells, are driven by the presence of IL-12 in an immune 
response and are characterised by IFNγ and TNFα production. They have an 
important role in promoting cytolytic activity of CD8 T cells and innate 
immune cells such as macrophages, to combat infections by intracellular 
pathogens. Interestingly, therefore, Th1 T cells are also involved in the 
pathology of autoimmune disease such as rheumatoid arthritis and diabetes. 
By contrast, Th2 cells, thought to be induced by IL-4, produce IL-4, IL-5, IL-9, 
IL-10 and IL-13, important cytokines in the development of antibody-
mediated responses, resistance to extracellular pathogens and mucosal 
immunity. Excessive Th2 activity, however, can lead to allergic disease and 
asthma. Whilst also important for fighting infection, Th17 cells are becoming 
increasingly recognised as playing important roles in the initiation and 
maintenance of pathology of both a variety of autoimmune disease such as 
multiple sclerosis, rheumatoid arthritis, psoriasis as well as allergic 
responses. Th17 T cells are driven by TGFβ, IL-6 and IL-23 and produce IL-17A 
and IL-17F [78-81]. 
 
The balance between Th1, Th17 and Th2 phenotypes is important in 
determining the duration and outcome of autoimmune disease [82], parasitic 
infections [83] and allergies [84]. Thus, a key role for mast cells in immune 
responses is their ability to influence the development of each phenotype 
through rapid and robust cytokine responses at the onset of inflammation, 
driving DC maturation and/or directly influencing T cell maturation [30, 33, 
39, 85].  Although mast cells are mostly thought to bias the development of 
Th2 responses, due to the variety of mast cell-derived mediators, they are 
also able to drive alternative phenotypes. 
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Mast cells and DC are found in close proximity at body surfaces allowing their 
direct interaction and cooperation in their activation. For example, use of a 
diptheria toxin-based MC deletion method demonstrated a crucial role for MC 
in the development of contact hypersensitivity where they drive DC 
maturation and migration [86]. Mast cells are also able to assist in antigen 
presentation by DC whereby they internalise antigen then apoptose, passing 
antigen on to antigen-presenting cells such as DCs [87]. In addition, they can 
modulate the T cell-priming/polarising effects of DC by increasing DC 
cytokine production and co-stimulatory molecule expression [88-94]. For 
example in vitro, histamine released by mast cells drives the maturation and 
phenotypic regulation of DC to promote the development of Th2 T cells [89].  
 
Alongside their ability to modulate DC-mediated maturation of T cells, MC 
can also directly influence T cell activity [30, 33, 39, 95]. This is because MC 
constitutively express MHC Class I molecules whilst expression of MHC II can 
be upregulated following exposure to LPS, TNF or IFNγ [11, 96-98]. Thus, 
when coupled with OX40L, CD80 and CD86 expression this allows direct 
antigen-presentation to, and costimulation of, naïve T cells [12, 75, 95, 99]. 
MHC II and OX40L expression on BMMC has been shown to allow direct 
induction of Th2 T cells from naïve T cells [100], however others have found 
that this response still requires T cells to have been at least partially 
activated via TCR/CD3 by professional antigen-presenting cells such as DCs 
[101]. Moreover, mast cells can also enhance the proliferation and cytokine 
production of Th1, Th2 and Th17 T cells via their secretion of cytokines, 
including TNF, and/or direct cell contact. Thus, BMMC and PDMC were found 
to support activated T cell proliferation and function via interactions with 
MHC II, costimulatory molecules, such as ICAM-1, OX40L and ICOSL, and 
cytokine production [96, 97]. These effects appear to be strongest when MC 
have been activated via FcεRI.  
 
MC can similarly influence development of immune responses via effects on B 
cells. Thus, MC-derived IL-4, IL-5, IL-6, IL-13 [39] and CD40L expression [102] 
support B cell development and function and where MC can drive the 
proliferation of naïve B cells [103] and subsequent class switching to IgE in 
the absence of T cells [104]. Mast cells can also directly migrate to lymph 
nodes, to promote lymph node enlargement and T cell recruitment [105].  All 
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of these interactions drive and shape the development of the adaptive 
immune response and are reciprocal, with DC, T cells and B cells influencing 
mast cell activation via the production of immunoglobulin and cytokines 
[106].  
 
1.5 Mast cells in infection 
Although mast cells are commonly associated with atopy and asthma, it 
should not be forgotten that their primary roles are to generate protective 
inflammation and subsequently, its safe resolution and wound healing. Due to 
their location in lining surfaces, which allows direct interaction with 
triggering factors such as LPS and parasite-derived molecules, mast cells are 
frequently the first to respond during infection [75]. This is evident by the 
important role played by mast cells in bacterial and parasitic infections [16, 
107-109]. 
 
1.5.1 Mast cells in bacterial infection 
Supporting their key role in fighting infection, mast cells express almost the 
full range of TLRs, including the receptor for bacterial endotoxin (LPS), TLR4 
[46] and can initiate early responses to bacterial infections [12, 110, 111]. 
Consistent with this, mast cell-deficient mice are less efficient at clearing 
bacteria and have higher mortality [11]. Involvement of MC in the resolution 
of bacterial infection has been reported in multiple murine infection models 
including those involving peritonitis, either by cecal ligation and puncture or 
introduction of intraperitoneal bacteria as well as those involving intranasal 
or intracutaneous exposure to bacteria [77], indicating the role of MC in 
fighting bacterial infection at multiple invasive locations. 
 
Although mast cells can directly kill such pathogens by phagocytosis and the 
consequent release of reactive oxygen species and antimicrobial peptides, 
the relatively low levels of these cells in tissues suggest this is not their 
predominant role in fighting infection [112]. Rather their activation in tissue 
is more likely to lead to recruitment of neutrophils, via TNFα, LTC4 and LTB4, 
[108, 113] as these are the cells responsible for the bulk of early phagocytosis 
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and mediator release. Histamine, which is released during early 
degranulation of mast cells, is an important vasodilator facilitating such 
inflammatory cell influx [112]. 
 
Many other mast cell mediators such as cytokines then act to promote 
activation of the adaptive immune system by recruiting DC and T cells, as 
well as their direct antigen presentation [112], to influence the Th phenotype 
of an immune response and consequently define the outcome of infection.  
 
It is important to note that, while such mast cell responses may act to 
increase host defence locally at the site of infection, over-production of mast 
cell proteases, histamine and cytokines can also have deleterious effects on 
the outcome of infection by exacerbating inflammation and prolonging 
responses that increase tissue damage [77, 114]. 
 
 
1.5.2  Mast cells in helminth infection  
Although the high IgE levels and strong Th2 responses induced by helminth 
infections suggest a role for mast cells in combating such infections, their 
precise role in immunity to nematodes, tapeworms and schistosomes, is 
unknown. However, during helminth infection, mast cell precursors are 
increased [12] and increases in Th2 cytokine production augment levels of 
non-specific IgE [38], increasing MC survival and enhancing their activation 
[115]. Nevertheless, the role of MC in parasite infection appears to vary 
depending on the location of infection and parasite species involved [77]. For 
example, mast cells are not essential for expulsion of Nippostrongylus 
brasiliensis [116]. By contrast, although MC are absent from tissue adjacent 
to Heligmosomoides polygyrus granulomas, structures created by the immune 
response to contain the parasite, increased mast cell numbers in the mucosa 
correlate with a more resistant phenotype to H. polygyrus [117]. Moreover, 
mast cells have been shown to be important in the expulsion of Trichinella 
spiralis infections by mechanisms thought to involve mast cell protease 1, 
TNFα and IL-4 signalling [11, 117-119].  
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In addition, although MC may not be essential for clearance of infection they 
act to promote immunity.  Thus, during parasite infection, MC can be directly 
recruited to the gut or skin, in response to chemokines and via interactions 
with cell surface adhesion molecules [45], where they play a protective role 
via increased IL-5-mediated recruitment of eosinophils that specifically target 
the parasite [120] as well as IL-10 production, to limit destructive 
inflammation [75, 77]. Similarly, IL-13 release can increase smooth muscle 
contractions and mucus production to promote parasite expulsion [112]. 
Indeed, it appears that the mast cell response can be tailored to fight 
particular types of infection as indicated in a murine model of schistosomiasis 
which demonstrated differential localisation of individual mast cell subtypes 
relating to the length of infection, where mucosal MC are present during the 
acute phase and connective tissue MC during the chronic phase of infection 
[121]. 
 
 
1.6 Modulation of immune responses by ES-62 
The immune response to helminth infections is the product of prolonged co-
evolution between the host and parasite designed to create a cooperative 
relationship. Parasites need to survive within the host without being 
destroyed by the immune system but must allow the host to prevent itself 
being harmed by further infections. Conversely, the host has to generate an 
effective immune response to remove the parasite but not destroy host 
tissues in the process. This dynamic interaction has created a model whereby 
helminths manipulate immune responses to prevent hyperinflammatory 
responses and a beneficial side-effect of this immunoregulation is reflected 
by increasing evidence of low prevalence of autoimmune and allergic 
inflammation in areas of the world endemic for parasitic helminths. This 
inverse correlation of infection and inflammatory diseases has been 
supported by evidence where clearance of the helminth infection can result 
in a resurgence of these diseases [122-124]. Thus, in the search for 
development of novel therapies for autoimmune and allergic disease, the 
harnessing of such parasite-driven immunomodulation is being intensively 
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investigated with one potential candidate being ES-62, an immunomodulator 
secreted by the filarial nematode Acanthocheilonema viteae [125-135]. 
 
ES62 is the major secreted glycoprotein of this rodent filarial nematode and 
homologue of molecules found in filarial nematodes that parasitize humans 
(77% with that secreted by Brugia malayi). The molecule consists of a 
tetramer of identical monomers of 62kDa that contain a parasite-specific 
post-translational modification where phosphorylcholine (PC) is attached to 
the protein backbone via N-type glycans. 
 
ES-62 has demonstrated ability to reduce pathology in murine models of Th1 
and Th17-mediated inflammatory diseases such as arthritis. Rather 
surprisingly, given the Th2 responses exhibited towards helminths and ES-62 
itself, ES-62 has also shown inhibitory effects in Th2-mediated diseases such 
as asthma (reviewed in [136]). This rather counter-intuitive finding has 
recently been shown to be mediated by targeting Th17 responses [135], 
consistent with increasing evidence that IL-17 can act as a master regulator 
of inflammation in asthma [137] as well as in autoimmune inflammation. ES-
62 can affect a range of different cell populations, either directly or 
indirectly, depending on the varying context of the interaction, differing 
receptor usage by ES-62 and the individual signalling abilities of the cells.  
For example, studies in MyD88 -/- and TLR4 -/- macrophages and DCs indicate 
both molecules are important for ES-62 activity. Although ES-62’s effects are 
dependent on TLR4 [138], ES-62 is still effective in macrophages obtained 
from C3H/HeJ mice that express a mutant TLR4 with a point mutation that 
prevents LPS-mediated pro-inflammatory signalling [132]. This indicates that 
ES-62 does not interact, or signal via TLR4 in the same way as LPS. 
Importantly, MC express TLR4 and respond to ES-62 [126]. Using human 
BMMC, ES-62 was found to inhibit degranulation, prostaglandin and cytokine 
production resulting from crosslinking of FcεRI. This effect was not due to 
modulation of FcεRI surface expression but was associated with a reduction in 
intracellular calcium mobilisation and NFκB activation.  This was found to be 
due to reduced PLD and SPHK activation and the subsequent release of 
calcium from internal stores consequent to the sequestration of PKCα from 
FcεRI and its subsequent degradation via a proteasome-independent 
mechanism. 
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1.7 Mast cells in asthma and allergic disease 
Mast cell recruitment and activation is clearly important during infection but 
increased numbers in the wrong location or incorrect and excessive activation 
can drive disease, as seen in asthma and allergy where, for example, 
elevated cell numbers are found in the bronchial lavage of asthmatic patients 
[139]. Mast cell-associated disease symptoms depend on the tissue affected 
and reflect the diverse characteristics of the mast cells in terms of their 
release of different mediators, the surrounding immune population 
phenotype as well as the responses from non-immunological cells in each 
organ affected.  
 
MC crucially mediate responses to allergens. During initial exposure to 
allergen MC FcεRI receptors are sensitized by allergen-specific IgE produced 
by B cells responding to the elicited Th2 immune response. During secondary 
exposure, allergen binds to IgE, crosslinking FcεRI to stimulate degranulation 
of MC releasing mediators, cytokine and eicosanoid production. The 
symptoms of allergy depend on the location of allergen exposure and the 
mediators released, for example eicosanoids induce bronchoconstriction in 
the lungs but swelling and itching in the skin. Moreover, the pro-
inflammatory mediators released can also recruit additional immune cells 
such as eosinophils, basophils and T cells to perpetuate and expand the 
response [30]. IgE-dependent reactions have been implicated in allergic 
asthma, rhinitis, conjunctivitis, atopic dermatitis, food allergies and 
anaphylaxis [16] and using an inducible mast cell deletion model, mast cells 
were found to be involved in passive cutaneous anaphylaxis, IgE-mediated 
passives systemic anaphylaxis and IgE-mediated chronic allergic 
inflammation, the latter where the absence of mast cells reduced airway 
hyper-responssiveness in an OVA-induced asthma model [140]. 
 
1.8 Mast cells in autoimmune disease 
Although much interest has focused on allergy, the pathological responses of 
mast cells can also promote inflammation in autoimmune diseases such as 
rheumatoid arthritis and multiple sclerosis. Autoimmunity occurs when the 
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immune system targets “self” tissues rather than pathogens, damaging the 
host. Autoimmunity is usually prevented by tolerising the immune system to 
host tissues during development of the adaptive immune system, which 
involves checkpoints ensuring potentially harmful self-reactive B and T cells 
are deleted. However, under conditions involving breakdown of such 
tolerance, innate cells are important in perpetuating the response and are 
responsible for much of the pathology and tissue destruction [101, 141-143]. 
 
For example, mast cells have been shown to be directly involved in the 
development of MS, a disease characterised by immune-mediated 
demyelination of nerves within the CNS. MS is a spontaneous disease; very 
little is known about its development and disease characteristics vary greatly 
between sufferers. [141]. However, the murine model, EAE, is driven by the 
development of immune responses to a myelin peptide and, although 
incompletely representing human disease, allows a useful tool for study. The 
exact role of MC in EAE has not been defined, however use of MC-deficient 
mice has demonstrated a clear role for MC in the development of disease 
[142, 144]. Mast cells normally reside adjacent to nerves and blood vessels 
with the brain and so are well placed to be involved in inflammation at this 
site [141]. In EAE, greater numbers of degranulating MC are observed within 
the brain [145] and it has been proposed that these may be responding 
directly to myelin protein [146] or may act, following activation by anti-
myelin antibodies outside the areas of demyelination, to release cytokines 
such as TNFα and hence exacerbate inflammation within the brain [142, 147]. 
In humans, MC [148, 149] and MC-specific gene expression [150] are found to 
be elevated in CNS lesions. Consistent with this, tryptase, a potent MC 
protease released during degranulation, has also been identified in the 
cerebrospinal fluid of MS patients [151].  
In rheumatoid arthritis, a condition characterised by inflammation in the 
synovial joints, MC are increasingly being implicated in disease pathology. For 
example, when arthritogenic, anti-collagen antibodies are directly introduced 
into murine joints, mast cell degranulation is observed [152], suggesting a 
role for mast cells in linking autoantibodies with an increase in 
proinflammatory mediators within the joint. Similarly, mast cells have been 
reported to accumulate and degranulate in joints of mice with collagen-
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induced arthritis (CIA), a murine model of rheumatoid arthritis, [153]. They 
have also been found to be present in synovial fluid and joint tissue from 
human patients [154] where their production of TNFα and IL-1β can recruit 
further inflammatory cells and activate proinflammatory responses in 
surrounding tissues. 
In autoimmunity that is driven by auto-antibodies there is a clear role for 
mast cells in driving pathology that has been proposed to result from either 
complement-mediated activation or via crosslinking of FcR by immune 
complexes. However MC activation can also result from exposure to 
inflammatory mediators, including cytokines such as IL-33 and neuropeptides 
released from the synovial membrane during RA, which can induce TNFα and 
IL-1 production from MC [155]. Moreover, cytokine production may drive 
autoantibody production by polarizing the phenotype of T and B cells [142] 
and indeed, mast cell-T cell interactions are well documented and may 
provide a potential crosstalk method of activation. Likewise, direct 
interactions of mast cells with tissues, via the release of proteases that 
induce tissue destruction, may contribute to the epitope spreading proposed 
to be involved in autoimmunity [142].  
 
Finally, the release of tryptase, histamine and eicosanoids mediate an 
increase in vascular permeability and endothelial cell activation, allowing 
greater influx of immune cells including neutrophils, contributing to 
pathology. Moreover, the persistence of mast cells, normally crucial to the 
resolution of inflammation and tissue healing, may result in tissue 
reorganisation and fibrosis, leading to loss of function under conditions of 
autoimmune disease. 
 
 
1.9 Aims of the Thesis  
Mast cells are important for fighting infection, resolving inflammation and 
promoting wound healing: however, they are increasingly being implicated as 
playing pathogenic roles in cancer as well as in allergic and autoimmune 
diseases.  These pleiotropic functions reflect that mast cells can exhibit 
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phenotypic and functional plasticity.  It was therefore the core aim of this 
thesis to characterise the phenotype of distinct subtypes of murine mast cells 
(mature peritoneal-derived mast cells, PDMC; mucosal-like bone marrow-
derived mast cells, BMMC and connective tissue-like bone marrow derived 
mast cells, CTMC) and their functional responses to stimulation via a range 
and combination of immunoregulatory receptors (FcεRI, TLR4, ST2 and c-KIT) 
as a first step to identifying key regulatory targets that might ultimately be 
exploited in the development of mast cell-targeted therapeutics.  
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Figure 1.1 Maturation and location of mast cells in vivo. 
 
Mast cell progenitors derived from haematopoietic stem cells enter the blood 
to circulate throughout the body from where they can then enter the tissues. 
Signals from the microenvironment including SCF, IL-3 and IL-4 stimulate 
heterogeneous maturation into cKIT+, FcεRI+, ST2+ mast cell populations with 
varying receptor, cytokine, protease and proteoglycan expression that can 
respond differentially to distinct stimuli. Mast cells in different locations can 
be developed to optimally target the potential pathogens within that site [1, 9, 
38, 75]. 
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Table 1.1 Common mast cell activatory receptors, their ligands and the 
responses induced.  
 
Expression depends on species and maturational factors [38]. 
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Figure 1.2 Kinetics of Mast cell activation and degranulation. 
 
Cross-linking of FcεRI stimulates activation and degranulation of mast cells 
with defined kinetics. Binding of antigen to IgE-sensitized mast cells induces 
crosslinking of FcεRI; within seconds preformed mediators such as histamine 
are exocytosed from the cell in the process of degranulation. This does not 
affect cell viability and mast cells then begin synthesis of prostaglandins and 
leukotrienes and subsequently cytokines. Granule generation and exocytosis is 
maintained but not indefinitely. Under conditions of chronic mast cell 
activation, the constituents of the granules can alter to streamline a more 
specific response. This effect is driven by receptor ligation, “programming” the 
cell to target a specific pathogen. After the resolution of infection, some mast 
cells are removed by apoptosis while others persist within the site and can 
proliferate to form a store of “memory” mast cells. This activation process is 
not fixed and individual stimuli may regulate activation with alternative 
kinetics or without inducing degranulation [9, 26, 38, 75]. 
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Table 1.2 Summary of mast cell mediators and their release mechanism. 
 
Expression depends on species and maturational factors. 
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Figure 1.3 Mast cells interact with a variety of immune and non-immune 
cells. 
 
Mast cells play both inflammatory and anti-inflammatory roles in an immune 
response. Depending on their location in tissues throughout the body, they can 
interact with T and B cells, antigen presenting cells and innate immune cells, 
as well as endothelial and epithelial cells and tissue cells including smooth 
muscle cells and fibroblasts. During infection these interactions result in 
pathogen clearance by enhanced recruitment of and phagocytosis by 
neutrophils, development of specific immune responses, increased vascular 
permeability to facilitate further immune cell recruitment and increased 
smooth muscle contraction to expel pathogens [75, 77, 156]. 
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Figure 1.4 FcεRI signalling pathway that leads to mast cell activation. 
 
Crosslinking by antigen initiates signalling via the Lyn mediated 
phosphorylation of ITAMs on the γ chain of FcεRI to recruit and activate, Syk. 
Syk phosphorylates LAT, which then serves as a scaffold for recruitment of Sos, 
Vav1 and PLCγ.  Sos and Vav1 mediate Ras activation by promoting exchange of 
GDP for GTP and to initate activation of MAPK pathways resulting in 
ERK/JNK/p38 activation. Fyn and Syk recruit and activate PI3K that can 
maintain PLCγ activation and activate Akt and PLD to produce PA to initiate 
S1P production by SphK. S1P then induces an increase in cytoplasmic calcium 
concentration. PLCγ induces the catalysis of PIP2 to DAG and IP3. IP3 induces the 
release of intracellular calcium and DAG, when coupled with Ca2+, activates 
classical PKC isoforms, including PKCα. PKC can activate PLD and promote 
activation of NFκB via degradation of IκB by IKK. Lyn; src-family protein 
tyrosine kinase, ITAM; immunoreceptor tyrosine activatory motif, FcεRI; high 
affinity IgE receptor, Syk; tyrosine kinase, LAT; linker of activated T cells, Sos; 
guanine nucleotide exchange factor, Vav1; guanine nucleotide exchange 
factor, PLCγ; Phospholipase D gamma, Ras; GTPase, GDP; guanosine 
diphosphate, GTP; guanosine triphosphate, MAPK; serine/threonine specific 
protein kinase, ERK; extracelluar signal-regulated kinase, JNK; c-Jun N-
terminal kinase, p38; mitogen-activated protein kinase, Fyn; protein tyrosine 
kinase, PI3K; phosphatidylinositide 3-kinase, Akt; serine/threonine protein 
kinase, PLD; phospholipase D, PA; phosphatidic acid, S1P; sphingosine-1-
phosphate, SphK; sphingosine kinase, PIP2; phosphatidylinositol 4, 5-
biphosphate, DAG; diacylglycerol IP3; inositol trisphosphate, Ca2+; calcium, 
PKC; protein kinase C, NFκB; transcription factor, IKK; IκB kinase, IκB; inhibitor 
of NFκB [13, 17, 26-28].
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2 Materials and Methods 
2.1 Animals 
Wild type (WT) BALB/c and C57Bl/6 mice were obtained from Harlan Olac 
(Bicester, Oxon, UK). CD200R1 gene knockout C57BL/6 were obtained from 
Professor Alan Mowat, GBRC, University of Glasgow, originally from 
I.Boudakov [157]. ST2 gene knockout BALB/c mice have a deletion within the 
ST2 gene that involves the majority of exons 4 and 5 [158]. These mice had 
previously been obtained from Professor Andrew Mackenzie, BBRC, University 
of Cambridge. Mice were maintained under standard specified pathogen-free 
animal house conditions with free access to both water and standard rodent 
pellets at the University of Glasgow Central Research Facilities in accordance 
with local and Home Office regulations. 
 
2.2 Cell Culture  
2.2.1 Reagents 
All cell culture reagents were purchased from Invitrogen Life Technologies. 
All other reagents were obtained from Sigma-Aldrich unless otherwise stated.  
 
2.2.2 Murine Mast Cell Culture 
During initial culture optimisation cells were grown in collaboration with Dr 
Hwee Kee Tay. 
2.2.2.1 Isolation of peritoneal derived mast cells  
After removing abdominal skin, the peritoneal cavity was filled with 5 ml 
sterile, cold RPMI 1640 using a 23G needle then vigorously massaged. The 
liquid was then removed using a 25G needle, ensuring minimum red blood 
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cell contamination. Any wash containing significant red blood cell volumes 
was discarded. Cells were then pelleted at 1250 rpm for 5 mins and 
resuspended in fresh complete RPMI before being incubated at 5x106 cell/ml 
for 2 h at 37oC in tissue culture-treated dishes (Corning) to separate the 
adherent from the suspended cells. These cells were gated on SSC and FSC 
(Figure 2.1 A) then the relative mast cell population in each fraction was 
defined by their CD117+ and FcεRI+ expression (Figure 2.1 B), where there is 
very little difference in size and granularity. The non-adherent cells were 
slightly enriched for double positive mast cells (2.7%) (Figure 2.1 B, D) and 
had a high frequency (Figure 2.1 E) and level of ST2 expression (Figure 2.1 F). 
Light microscopy imaging of the cells with toludine blue (Figure 2.2 A) 
confirms the presence of mast cells in these cell fractions and further 
staining of the suspended cells using toludine blue (Figure 2.2 B) and tryptase 
staining (Figure 2.2 C) again demonstrates that there is a population of 
mature mast cells that can be harvested from the peritoneal cavity.  
Malbec et al [159] derived their PDMC from the adherent cell population but in contrast to 
this, for the studies in this thesis, the suspension culture was enriched for mast cells after 
expansion for a further 28 days, resulting in a homogenous mast cell culture as defined by 
universal toludine blue (Figure 2.3 B) and tryptase staining (Figure 2.3 A).  
 
2.2.2.2 Isolation of bone marrow–derived mast cells  
Intact femurs and tibias were dissected from 6-8 week mice. Under sterile 
conditions the proximal and distal ends were removed and the shaft flushed 
with PBS through a 23G needle. A single cell suspension was made by passing 
through a 100 µm nylon monofilament gauze (Cadisch Precision Meshes, 
London). If the resulting cell pellet contained high levels of blood 
contamination, red blood cell lysis was performed for 1 minute at 22oC. Cells 
were washed once with PBS before culture. 
 
2.2.2.3 Culture of primary murine mast cells 
To prepare PDMC, the cells were cultured at 0.3x106/ml in complete RPMI 
with 10% FCS, 4 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
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streptomycin, 1 mM sodium pyruvate, 100 µM non-essential amino acids and 
50 µM β-mercaptoethanol, supplemented with 4% KLS-C conditioned media. 
To prepare BMMC the cells were cultured at 0.5x106/ml in complete RPMI 
with 10% FCS, 2mM L-Glutamine, 100U/ml penicillin, 100ug/ml streptomycin, 
1mM Sodium Pyruvate, 10mM Hepes and 50uM β-mercaptoethanol, 
supplemented with 1% KLS-C conditioned media and 3% TOP3 conditioned 
media. 
To prepare CTMC the cells were cultured at 0.8x106/ml in RPMI with 10% FCS, 
4 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM 
sodium pyruvate, 100 µM non-essential amino acids and 50 µM β-
mercaptoethanol, supplemented with 1% KLS-C conditioned media and 1 
ng/ml recombinant murine IL-4 (Peprotech). 
All cells were incubated at 37°C in a humidified incubator supplemented with 
5% CO2 in tissue culture-treated flasks (Greiner Bio-one) for 28 days.  Non-
adherent cells were retained for further culture whilst adherent and 
contaminating cells were discarded. All cell culture work was carried out 
under sterile conditions and wash steps were performed using warmed, 
sterile RPMI followed by centrifuge at 1250 rpm for 5 minutes  (Jouan CR3i 
centrifuge) unless otherwise stated. A purity of >95% was identified by 
surface expression of CD117, FcεRI and ST2. Viability was confirmed using 
0.1% Trypan Blue staining.   
 
2.2.3 Human Mast Cell Culture 
2.2.3.1 Culture of HMC-1 
HMC-1s (human mast cell leukaemia cells) were generously donated by JH 
Butterfield. The cell line was cultured in IMDM (Lonza) supplemented with 
10% FCS, 2 mM L-glutamine, 25 nM HEPES, 65 µl α-thioglycate, 100 U/ml 
penicillin and 100 µg/ml streptomycin at 37oC, 5% CO2. The population was 
passaged into clean flasks twice a week.  Cells were kept for up to 3 months. 
Viability was confirmed using 0.1% Trypan Blue staining.   
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2.2.4 Production of conditioned media 
2.2.4.1 TOP3 Culture 
The cell line TOP3 is a hybridoma that produces IL-3 and was a kind gift from 
Dr Massimo Gadina, NIH. Cells were cultured at 37oC in RPMI (GIBCO) with 5% 
FBS, 2 mM L-Glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM 
sodium pyruvate and 50 µM β-mercaptoethanol. IL-3-producing cells were 
selected using 0.4 mg/ml G418. IL-3- enriched supernatant was filtered to 
remove cell debris and the concentration determined by ELISA. For mast cell 
culture the stock concentration was adjusted with PBS to 550 ng/ml to be 
used at a final concentration of 16.5 ng/ml.  
 
2.2.4.2 KLS-C Culture 
KLS-C is a CHO (Chinese Hamster Ovary) cell line that produces SCF and was a 
kind gift from Dr Xiaoping Zhong, Duke University Medical Centre. Cells were 
cultured at 37oC in Minimum Essential Medium Alpha (MEMα) without 
nucleosides (GIBCO) with 10% FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin. SCF-producing cells were selected with 2.5 µM methotrexate. 
SCF- enriched supernatant was filtered to remove cell debris and the 
concentration determined by ELISA. For mast cell culture the stock 
concentration was adjusted with PBS to 1000 ng/ml to be used at a final 
concentration of 10 ng/ml for BMMC and 40 ng/ml for PDMC.   
 
2.3 Cell Stimulation 
Unless otherwise stated, mast cell FcεRI were sensitized with 0.5 µg/ml 
murine anti-DNP IgE for 18 h prior to stimulation. In experiments where ES-62 
was used, cells were incubated with 2 µg/ml for 18 h simultaneously with IgE. 
Cells were stimulated at 1x106 cells/ml except where indicated. Addition of 
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0.5 µg/ml DNP-HSA cross-links the FcεRI to stimulate the cell. Unless 
otherwise stated IL-33 (Peprotech) was used at 10 ng/ml, LPS (Salmonella 
minnesota) at 0.5 µg/ml and SCF at 100 ng/ml (Table 2.1). Cell signalling 
inhibitors were used at the indicated concentrations (Table 2.2) unless 
otherwise specified. Media alone or PBS was used in control cultures. Each 
condition was replicated in duplicate or triplicate. After the desired culture 
period cells were centrifuged at 1250 rpm and supernatant was aspirated and 
stored separately to the remaining cell pellet. All samples were stored at -
20oC until analysed. 
 
2.4 Preparation of ES-62 
ES-62 was purified to homogeneity from spent culture medium of adult A. 
viteae using endotoxin-free reagents by Dr L Riyami and Dr J Rzepecka at the 
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
Strathclyde, Glasgow, UK as previously described [132]. In detail, ES-62 was 
prepared from 500ml of spent medium (endotoxin- free RPMI 1640; Invitrogen 
Life Technologies, Paisley, UK, with added endotoxin- free glutamine (2 mM), 
endotoxin- free penicillin (100 U/ml) and endotoxin- free streptomycin (100 
µg/ml)) following culture of adult A. viteae. To remove larval forms  
(microfilariae) released by the adult female worms, the medium was passed 
through a 0.22 µm filter (Sigma, Poole, UK). It was then transferred to a 
stirred ultracentrifuge unit containing YM10 membrane (Amicon, Stonehouse, 
UK). After reducing the volume of the sample to 5-10 ml and transferring the 
holding medium to endotoxin-free PBS, pH 7.2 (Cambrex Bioscience, 
Berkshire, UK), it was further concentrated to 200-300 µl using Centricon 
microconcentrators with a 30kDa cut-off membrane (Amicon). The sample 
was applied to a 30 x 1 cm Superose 6 column (HR 10/30; Pharmacia, Milton 
Keynes, UK) fitted to an isocratic fast protein liquid chromatography system 
(Pharmacia) previously equilibriated with endotoxin-free PBS (pH 7.2) at 
room temperature. The column was eluted at a flow rate of 0.5 ml/min and 
monitored for absorbance at 280 nm. More than 95% of the protein elutes as a 
single peak that represents ES-62. Purity and identity of each batch was 
confirmed by a combination of SDS-PAGE and Western blotting, the latter 
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employing a rabbit antiserum specific for ES-62. Finally, the level of 
endotoxin in the ES-62 sample was confirmed using an Endosafe kit (Charles 
River Laboratories, Kent, UK). ES-62 is used at a working concentration that 
has an endotoxin reading of <0.003 endotoxin units/ml. 
 
2.5 Enzyme–histochemical Staining and Light 
Microscopy. 
2.5.1 Toludine Blue staining 
Toludine Blue was used to identify heparin content, crucial to mast cell 
function as it is responsible for the stable expression and activation of many 
of the proteases present in mast cell granules [160]. 0.01x106 cells were spun 
onto glass slides (Superfrost Plus) using a Shandon Cytospin3 
(ThermoShandon, Runcorn, UK) at 500 rpm for 5 minutes. Slides were air 
dried before staining with 0.5% Toludine Blue in 0.5 M HCl for 10-15 minutes.   
 
2.5.2 Tryptase staining 
For tryptase staining, a colour solution (10 mM z-Gly-Pro-Arg-MNA in 
dimethylformamide (Bachem), 0.5 M Tris-HCl pH 7.5, 5 mg/ml Fast garnet 
GBC (SIGMA) and dH2O (1:1:2:6) was added for 5-30 minutes. Excess stain was 
washed with dH2O and the slides air dried before viewing by light microscopy. 
Images of cytospins obtained at x 10 and x 40 magnification using an Olympus 
BX41TF microscope. 
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2.6 Analysis of mast cell marker expression by flow 
cytometry  
2.6.1 Surface staining 
Cells were washed with cold PBS at 1500 rpm for 6min, 4oC. The cells were 
pre- incubated with 50 µl Fc receptor (FcR) blocking buffer (anti-CD16/32, 
clone 2.4G2, hybridoma supernatant, 10% mouse serum, 0.1% sodium azide) 
for 20 minutes at 4oC to reduce non-specific binding of antibodies to the high 
levels of FcR present on mast cells. The appropriate flurochrome-conjugated 
antibodies (2 µg/ml) (Table 2.3), suspended in 50 µl Fc Block, were added for 
30 minutes, 4oC. Biotinylated antibodies required a two-step staining 
protocol. Firstly the biotinylated primary antibody was added for 30 minutes 
at 4oC, followed by a wash step before flurochrome-conjugated streptavidin 
was added for a further 30 minutes at 4oC. After labelling cells were washed 
twice with 3 ml FACS buffer (PBS containing 2% FBS and 2 mM EDTA) at 1500 
rpm for 6 min, 4oC then resuspended in 100-300 µl FACS buffer. To enable 
exclusion of dead cells from the analyses cells were either stained with 
Live/Dead® Viability/Cytotoxicity Kit (Invitrogen) before commencement of 
staining or by the addition of 1 µl 7AAD (Ebioscience), a fluorescent dye with 
high affinity for DNA, immediately prior to data acquisition. Cellular 
fluorescence data was acquired using a Becton Dickinson LSR II or 
FACSCalibur™ flow cytometer and analysed using FlowJo software (Tree Star 
Inc, OR, USA) Analysis was performed on a minimum of 10 000 events and 
gating is demonstrated in Figure 2.4. 
 
2.6.2 Intracellular staining 
Cells were prepared as for surface staining except that after surface labelling 
the cells were fixed for 10 minutes at RT with 200 µL fixation buffer 
(Ebioscience) before washing twice with 1X permeabilisation buffer 
(Ebioscience). All antibodies for intracellular staining were added in 
permeabilisation buffer for 30 minutes at 4oC. After labelling, cells were 
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washed twice in the permeabilisation buffer before being resuspended in 100-
300 µl FACS buffer immediately prior to analysis. 
 
2.7 Calcium Mobilisation 
Cells were loaded with 5 µM of the fluorescent calcium-sensing dye Fura-
2/AM (Invitrogen) in HBSS buffer (145 mM NaCl, 5mM KCl, 1 mM MgSO4, 1 mM 
CaCl2, 10 mM) supplemented with 0.18% (w/v) D-glucose (Sigma) and 0.2% 
(w/v) BSA (Sigma) for 30 minutes at 37oC in the dark. Fura-2 AM quantifies 
intracellular calcium concentration by emitting light after being excited with 
light of a varying wavelength depending on whether it is in a bound or 
unbound state (Figure 2.5).  Where necessary, removal of intracellular 
calcium was performed by the addition of 10 mM BAPTA during Fura-2/AM 
treatment. Cells were washed twice to remove excess dye at 1250 rpm for 5 
minutes and resuspended in a volume of buffer with 1 mM Ca2+ before 
stimulation. For removal of extracellular calcium Ca2+ free buffer, HBSS 
without 1 mM CaCl2  supplemented with 100 µM EGTA, was used. Cells were 
used at 0.75x106 cells/ml. From this 1.5 ml was added to a stirred glass 
cuvette in a Hitachi F-700 fluorescence spectrophotometer at 37oC. 
Stimulation was added at 50 s and measurements acquired for a total of 180 
s. Calcium levels were detected every 500 ms using excitation-emission ratios 
of 340/380 nm to correct for potential variables in Fura-2 AM concentration 
or cell volume and for a decline in fluorescent signal over time [161]. 
Following each experiment Rmax values were calculated by the addition of 
1% Triton-X. Rmin was subsequently determined by the addition of 20 mM 
EGTA (pH 7.4). These values allowed removal of background signal but were 
omitted from the final graphs. All treatments were performed in triplicate.  
 
2.8 Cytokine and Prostaglandin D2 ELISA 
ELISAs were performed according to the suppliers’ recommendations (Table 
2.4). Briefly, COSTAR Immunlon plates were incubated overnight at 4oC in 
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buffer recommended in the manufacturer’s protocol. Plates were blocked for 
1 h with assay buffer. Samples and standards, diluted in assay buffer, were 
incubated for 2 h at room temperature or overnight at 4oC. Detection 
antibodies and avidin or steptavidin (supplied with the kits) were incubated 
for 1 h and 30 minutes respectively at room temperature. Plates were washed 
at least four times between stages. Finally, plates were developed using TMB 
substrate and absorbances determined using TECAN Sunrise Microplate 
reader. Concentrations were determined using a standard curve. The S1P 
ELISA was performed using single wells. All other ELISAs were performed in at 
least duplicate. 
 
2.9 Analysis of Mast Cell Degranulation 
2.9.1 Measurement of β-hexosaminidase release 
The level of degranulation was determined using a modified colorimetric 
assay to assess release of β-hexosaminidase. 0.2x106 cells were suspended in 
200 µL Tyrodes buffer supplemented with 1% FCS. Stimuli were added for 30 
minutes at 37oC. Cells were centrifuged at 2000 rpm and 50 µL of supernatant 
(released β-hexosaminidase) aliquoted in triplicate in a 96 well plate. The 
cell pellets and remaining supernatant were lysed by the addition of 150 µL 
1% Triton-X 100 (Sigma) in dH20. 50 µL of lysate (total cell content) was then 
aliquoted in the same manner as the supernatant.  200 µL of 1 mM p-
nitrophenyl-N-acetyl-β-d-glucosamine (NAG, Sigma) substrate solution (1 mM 
in 0.05 M citrate buffer, pH 4.5) was added. After incubation in the dark at 
37oC for 1 h the reaction was quenched by the removal of 62.5 µL of the 
reaction mix into a clean well and the addition of 125 µL/well 0.1 M sodium 
bicarbonate buffer. Optical density was read on Tecan Sunrise microplate 
reader at 405 nm. Degranulation was calculated as a percentage of released 
β-hexosaminidase compared to total cell content. 
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2.9.2 Measurement of Lamp1 surface expression 
An alternative method of quantifying degranulation based on the Lamp1 
expression method developed for CD8+ T-cells [162] was adapted for mast 
cells. This method works on the principle that Lamp1, usually expressed on 
lysosomes and intracellular vesicles, is presented on the cell membrane 
surface during exocytosis. By quantifying the geometric mean fluorescence 
intensity (GMFI) of Lamp1 on the cell surface, a level of cell degranulation 
can be determined similar to β-hexosaminidase release. Lamp1 expression is 
biphasic, with the high expression peak to the right representing Lamp1 after 
degranulation (Figure 2.6). The advantages of this technique include the 
increased sensitivity to low-level degranulation and the ability to distinguish 
exocytosis that perhaps does not results in β-hexosaminidase release. 
After sensitization cells were washed with PBS at 1250rpm for 5 mins, 4oC and 
resuspended in complete RPMI. The cells were allowed to equilibriate at 37oC 
before stimuli was added for 30 mins. The cells were then washed and pre- 
incubated with 50 µL Fc receptor (FcR) blocking buffer (anti-CD16/32, clone 
2.4G2, hybridoma supernatant, 10% mouse serum, 0.1% sodium azide) for 20 
minutes at 4oC to reduce non-specific binding of antibodies to the high levels 
of FcR present on mast cells. The appropriate flurochrome-conjugated 
antibodies (2 µg/ml), suspended in 50 µl Fc Block, were added for 30 minutes 
at 4oC. Cells were washed twice with 3 ml FACS buffer (PBS containing 2% FBS 
and 2 mM EDTA) at 1500rpm for 6 min, 4oC then resuspended in 100-300 µl 
FACS buffer.  Immediately prior to data acquisition 1 µL 7AAD (Ebioscience) 
was added to each sample to enable exclusion of dead cells from the 
analysis. Cellular fluorescence data was acquired using a Becton Dickinson 
FACSCalibur™ flow cytometer and analysed using FlowJo software (Tree Star 
Inc, OR , USA). Analysis was performed on a minimum of 20000 events and 
gating is demonstrated in Figure 2.6. 
 
  
36 
2.10 Western Blotting 
In order to determine the involvement of downstream molecules ERK and 
NFκB in receptor signalling, ERK phosphorylation and IκB degradation was 
determined by Western blotting. ERK marks the terminal end of the MAPK 
pathway and phosphorylation results in its activation, where it then in turn is 
able to phosphorylate and activate a variety of transcription factors. The 
activation of NFκB requires the targeted degradation, via ubiquitination, of 
two inhibitor molecules IκBα and IκBβ. After this NFκB is free to translocate 
to the nucleus where it can act directly on the DNA to initiate transcription of 
genes important for proinflammatory responses.  
 
2.10.1 Whole Cell Lysate Preparation  
Either murine mast cells or HMC-1 cells were stimulated in 2x106/ml as 
indicated. The reaction was then terminated and washed by the addition of 
ice-cold PBS 1250 rpm, 4oC, 5 minutes. Lysis was performed by the addition 
of 50 µL ice-cold, modified RIPA lysis buffer (50 mM Tris buffer, pH 7.4 
containing 150 mM sodium chloride, 2% (v/v) NP40, 0.25% (w/v) sodium 
deoxycholate, 1 mM EGTA, 10 mM sodium othovanadate, 0.5 mM 
phenylmethylsulfonylfluoride, chymostatin (10 µg/ml), leupeptin (10 µg/ml), 
antipain (10 µg/ml) and pepstatin A (10 µg/ml)). After vortexing the cells 
were incubated on ice for 30 minutes before centrifugation of lysates at 
12000 rpm for 15 minutes. The resulting supernatants (whole cell lysate) 
were stored at -20oC before being used for Western Blot analysis. 
 
2.10.2 Gel Electrophoresis 
Equal protein loadings of whole cell lysate (30-40 µg protein per lane), 
determined by BCA protein assay (Thermo Pierce), were resolved on the XCell 
SureLock Mini-Cell kit with NuPAGE Novex high-performance pre-cast Bis-Tris 
gels and NuPAGE buffers and reagents (Invitrogen). Lysates were diluted in 
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lysis buffer to a constant final volume and the appropriate volume of 4 x 
NuPAGE LDS sample buffer and 10 x NuPAGE reducing agent were added prior 
to heating samples to 70oC for 10 minutes. Samples were resolved using 
NuPAGE MOPS running buffer supplemented with NuPAGE antioxidant at 150V 
for 70 minutes. The gel was then transferred onto nitrocellulose (Amersham) 
or PVDF membrane (pre-activated in methanol for 30 seconds, washed in 
dH20 for 1 minute then washed in transfer buffer for 5 minutes) using NuPAGE 
transfer buffer with 20% (v/v) methanol at 30V for 120 minutes.  
 
2.10.3 Western Blot Analysis 
Following transfer, the presence of protein on the membranes was checked 
using Ponceau Red (Sigma). Membranes were washed in Tris-buffered saline 
(TBS) (0.5 M NaCl and 20 mM Tris pH7.5) with 0.1% (v/v) Tween-20 
(TBS/Tween) and blocked for 1 h in TBS/Tween with 5% non-fat milk 
(Marvel). Membranes were then incubated overnight at 4oC with the 
appropriate primary detection antibody (Table 2.5). All antibodies were 
diluted in TBS/Tween with either 5% non-fat milk or 5% BSA. Following 
incubation with primary antibody the membranes were washed (3 x 8 
minutes) with TBS/Tween and incubated in the appropriate horseradish 
peroxidise (HRP)-conjugated secondary antibody for 2 h at room 
temperature. Membranes were then washed (3 x 8 minutes) with TBS/Tween 
and protein bands visualised using the ECL detection system. This involved 
incubation of membranes with a mixture of equal volumes ECL solution A (2.5 
mM luminol, 0.4 mM p-coumaric acid and 100 mM Tris pH8.5) and ECL 
solution B (0.002% hydrogen peroxide and 100 mM Tris pH8.5) for 1 minute 
before exposing membranes to Kodak X-Ray film. Densitometry was 
performed using Image J software. 
 
2.10.4 Stripping Western Blots 
Membranes were sometimes stripped between alternate primary antibodies. 
Membranes were stripped at room temperature for 1 h in stripping buffer 
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(100 mM 2-mercaptoethanol, 2% SDS and 62.5 mM Tris pH 6.7) then washed 
thoroughly in TBS/Tween before re-starting the Western Blotting protocol. 
 
2.11 Measurement of Phospholipase D Activity 
The PLD assay involves loading the cells with a radiolabelled fatty acid that is 
then incorporated into the lipid compartments of the cells allowing 
quantitation of PLD activity via scintillation counting of the radiolabelled 
product. PLD activity is measured by a transphosphatidylation assay which 
exploits the finding that primary alcohols preferentially act as acceptors, 
relative to water, for the PLD product and hence in the presence of ethanol, 
phosphatidylethanol (PE) rather than phosphatidic acid is generated. This 
phosphatidylethanol accumulates within the cells as it cannot be metabolised 
and can be quantitated as it will contain the radiolabelled fatty acids in its 
diacyl-side chains. Cellular lipids are obtained by the Bligh-Dyer two-phase 
separation and PE identified relative to standards using thin-layer 
chromatography. PLD activity can be specifically and directly quantified with 
the levels of PE in each sample being normalised to the total cell 
incorporation of the fatty acid radiolabel, thus determining the relative 
production of PE for each cell treatment. 
Murine mast cells were incubated with 2 µCi/ml 3H palmitic acid overnight at 
37oC. Following labelling cells were washed twice in HBSS (pH 7.4) 
supplemented with 1 g/L BSA and 1 g/L D-glucose. Cells were then 
resuspended at 2x106/150 µL/treatment in HBSS buffer with 1% ethanol for 20 
minutes at 37oC. Where used, inhibitors were added prior to the ethanol for 
20 minutes. The cells were then aliquoted into glass tubes. A control sample 
was kept untreated and immediately lysed after treatment with 1% ethanol. 
Cell stimulation over the indicated time course was initated by the addition 
of stimuli and incubation at 37 oC. Reactions were terminated by the addition 
of 0.75 mL ice-cold chloroform: methanol (1:2 v/v) for 10 minutes on ice 
followed by 0.25 mL of chloroform and 0.3 mL 1M NaCl (final ratio 0.9:1:1 
aqueous: methanol: chloroform). To achieve phase separation, the samples 
were vortexed and centrifuged at 2000rpm for 5 minutes. 
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Whatman silica gel (G-150) TLC plates were pre-run in solvent (2,2,4 
trimethylpentane: ethyl acetate: dH2O: acetic acid (5: 11: 10: 2) in a TLC 
tank for approximately 2 h then the plates air dried before being activated at 
110oC for 15 mins. An aliquot (180 µL) of the lower chloroform phase of each 
sample was removed into clean glass tubes, spiked with 25 µg/ml 
phosphatidylethanol and dried by vacuum centrifugation. A further aliquot 
(180 µL) was removed for direct liquid scintillation counting (total cell 
incorporation). Each dried sample was re-dissolved in 50 µL 
chloroform:methanol (19:1) and applied to a pre-absorbent strip of the TLC 
plate. The plate was then developed in a tank with the solvent mix until the 
solvent front reached the top of the plate. Phosphatidylethanol was located 
by exposure of the plate to iodine vapour and the radioactivity of each 
sample was determined by scraping 1 cm segments and combined with 
OptiPhase Supermix Cocktail (Perkin Elmer). Liquid scintillation counting was 
performed using Perkin Elmer 1450 MicroBeta TriLux LSC and Luminescence 
counter. The activity of PLD was determined by the relevant percentage of 3H 
palmitic acid incorporation into phosphotidyethanol compared to the total 
cell incorporation. Each treatment was performed in triplicate. 
 
2.11.1 Optimization of PLD assay in mast cells. 
Several steps were taken to optimise the experiment to determine the best 
protocol for mast cells. The cellular incorporation of several candidate 
radiolabelled fatty acids was analysed in order to optimise the assay in mast 
cells including oleic acid, myristic acid, arachidonic acid and palmitic acid. 
[3H] Palmitic acid showed the highest total levels of incorporation as 
determined by scintillation counting of the cells directly (Figure 2.7 A), 
presumably reflecting the predominance of di-palmityl PtdCho in these cells. 
Nevertheless, although the other fatty acids were only poorly incorporated in 
the cells lipid compartments, stimulation with PMA, a pharmacological 
activator of PLD, after the percentage of PE produced and thus the activity of 
PLD was calculated, cells labelled with [3H] arachidonic acid showed the 
highest production of PE as a percentage of total incorporation (Figure 2.29 
B).  Although PMA did not induce detectable PE production by myristate-
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labelled cells, it also stimulated PE production from oleate- and palmitate-
labelled cells (Figure 2.29 C). Thus, although the % production of PMA-
stimulated PE was low in palmitate-labelled cells, this assay was most robust 
due to the high total cell incorporation (cpm). Prior studies with many cell 
types, including mast cells, had used butan-1-ol as the alcohol acceptor. The 
inactive butan-2-ol is used as a control as comparison of functional responses 
in cells treated with these primary and secondary alcohols allows for probing 
of the role of a (not necessarily PtdCho-specific) PLD signal in such responses 
and also controls for the effect of adding alcohols to cells. However, in these 
experiments, no FcεRI stimulation of PE could be detected in the presence of 
butan-1-ol. However, ethanol is also routinely used as an acceptor, and under 
these conditions, FcεRI-coupled PLD activity could be detected (Figure 2.7 
D). Interestingly from these results an increase in basal activity was noted 
between 10 minutes and 60 minutes, and a further experiment demonstrated 
significant PLD activity in unstimulated cells (Figure 2.7 E) after 60 minutes 
hence in order to determine the level of constitutive PLD activity and its 
possible effects, experiments incorporated both  “zero” time (Control) and 
“unstimulated” (Basal) controls.  
 
2.12 Measurement of Sphingosine Kinase Activity   
To determine sphingosine kinase activity in mast cells an assay was used that 
exploits a fluorescently-labelled sphingosine analogue JP02 as a SphK 
substrate, which when phosphorylated by SphK alters its fluorescence 
emission characteristics, allowing the levels of kinase activity to be 
determined by quantifying the levels of fluorescence. This assay protocol 
does not allow the determination of particular isoform involvement however 
using this method it was possible to identify the activation kinetics of SphK. 
Mast cells at 2 ml of 1x106 cells/ml were stimulated with DNP (0.5 µg/ml) or 
IL-33 (10 ng/ml) for selected timepoints at 37oC. The reaction was 
terminated with 1 ml ice-cold PBS and washed at 1250 rpm for 5 minutes, 4 
oC. The resulting pellet was dried thoroughly to remove all trace of PBS.  
Lysis was performed by the addition of 100 µl ice-cold modified RIPA buffer 
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and the solution passed through a 25 G needle 5 times. After vortexing the 
cells were incubated on ice for 30 minutes before centrifugation of lysates at 
12000rpm for 15 minutes. The protein quantity of the resulting supernatants 
was analysed by BCA and 160 µg/sample was combined with assay buffer (20 
mM Tris-HCl, 20% glycerol, 1 mM β-mercaptoethanol, 1 mM EDTA and Halt 
Protease and Phosphatase Inhibitors) to make a final volume of 90 µl. The 
substrate JF02 (15-NBD-Sph-BSA) (20 µM) followed by 1 mM ATP was added 
and vortexed well. A sample with cell lysate omitted was used as a control. 
The samples were then incubated for 30 minutes at 37 oC. The reaction was 
stopped with 100 µl 1M potassium phosphate (pH 8.5) followed by 500 µl 
chloroform:methanol mix (2:1) and the phases separated at 5000 rpm for 5 
minutes. The upper phase was removed and 75 µl aliquots made in triplicate 
in a black 96 well plate (Greiner Bio-one). Equal volumes of the fluorescence 
enhancer, dimethylformamide (DMF) were added to each well before 3 
minutes of gentle shaking. Fluorescence was determined using an EnVision 
Multilabel reader (Perkin Elmer) at excitation 485 nm, emission 535 nm and 
gain 300. 
 
2.13 Measurement of DNA synthesis using 3H-
Thymidine 
To quantify proliferation the level of thymidine incorporation into newly 
synthesised DNA was determined. 0.2x106 cells were cultured in triplicate in 
round bottom microtitre plates in the presence of the indicated stimuli for 24 
h at 37 oC. 3H-thymidine  (0.5 µCi/well, Amersham) was added for 12 h at 37 
oC before cell harvesting with an automated cell harvester (Perkin Elmer). 
Incorporated label was analysed by liquid scintillation analysis (Microbeta 
Trilux, Perkin Elmer). 
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2.14 Ovalbumin-induced asthma 
The ovalbumin-induced asthma model was induced and maintained by Dr 
Jennifer Coltherd, Department of Immunology, University of Glasgow. Briefly, 
6-8 week old female BALB/c mice were sensitized to whole ovalbumin (OVA) 
by intraperitoneal injection of 100 µg OVA in 1% alum (Alhydrogel; Brenntag 
Biosector, Fredriksund, Denmark) on days 0 and 14. On day 14 mice were 
additionally challenged intranasally with 50 µg aerosolised OVA in phosphate 
buffered saline (PBS) (after anaesthesia was induced with isopentanol). On 
days 25, 26 and 27 mice were anaesthetised and rechallenged with 50 µg 
aerosolised OVA in PBS, administered intranasally. Control mice received PBS 
in place of OVA, Mice were euthanized on day 28. Blood was obtained from 
each mouse by cardiac puncture. This was centrifuged for 10 minutes to 
separate serum and blood cells. The serum was transferred to a separate 
tube and stored at -20oC. Bronchoalveolar lavage was perfomed on the mice 
by flushing the airways with 1 ml PBS. The BAL was centrifuged and the BAL 
fluid stored at -20oC. 
 
2.15 S1P ELISA 
S1P concentrations were analysed from murine serum and BALf obtained from 
Dr Jennifer Coltherd, cell lysates and supernatants using a S1P ELISA (Echelon 
Biosciences) according to manufacturers protocol. 
 
2.15.1 Treatment of cells for S1P ELISA.  
PDMC were sensitized overnight at 2x106 cells/ml. Cells were stimulated with 
100 ng/ml IL-33 in RPMI supplemented with 1% FCS for the described time 
course. To terminate reaction cells were centrifuged 1250 rpm, 5 minutes at 
4oC. The supernatant and cell pellet were retained separately and stored at -
20oC.  
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2.15.2 Preparation of samples for S1P ELISA 
Murine serum, BALf and cell supernatant was diluted 1:10 with delipidized 
human serum before use. Cells were lysed using specified lysis buffer (20 mM 
PIPES, 150 mM NaCl, 1 mM EGTA, 1% v/v Triton X-100, 1.5 mM MgCl2, 0.1% 
SDS, 1 mM sodium sorthovanadate, 1X Halt Protease Inhibitor without EDTA, 
pH 7 (Thermo Pierce). Protein concentration was determined by BCA protein 
assay (Thermo Pierce) and adjusted to 3 mg/ml. The lysate was then diluted 
1:10 with delipidized human serum. 
 
2.16 Statistical Analysis 
All statistical analysis was performed using Graphpad Prism 5.0 (Graphpad 
Software Inc). Statistical analysis was by paired or unpaired t-test or one-way 
ANOVA with Tukey’s post-test and p is significant at * p< 0.05, ** p< 0.01, *** 
p< 0.001 and **** p< 0.0001. 
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Figure 2.1  Phenotyping peritoneal wash. 
 
Exemplar plots of mast cell phenotyping by flow cytometric analysis (A-C). 
Peritoneal washes were performed on 10 week old Balb/C mice. The resulting 
wash (Initial Wash) was incubated for 2 h at 37oC on tissue-culture treated 
plates. Cells that adhered to the plate were gently scraped free (Adherent) 
and cells that remained in suspension (Suspended) were harvested. FSC and 
SSC parameters of the peritoneal wash (A) and gating (relative to isotype 
controls, not shown) of the CD117+ FcεRI+ cells (B) prior to analysis of ST2+ 
expression (C) are shown. Isotype controls represented by grey shaded plots. 
Frequency of CD117+ FcεRI+ cells was determined using isotype controls (D), 
these cells were then further analyzed to determine the % frequency of ST2+ 
cells (E) and the geometric mean fluorescence of ST2 (F). Data is 
representative of 2 independent experiments. 
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Figure 2.2  Histochemical phenotyping of peritoneal wash. 
 
Exemplar plots of mast cell phenotyping by toluidine blue (A-B) and tryptase 
staining (C). Peritoneal washes were performed on 10 week old Balb/C mice. 
The resulting wash (Initial Wash) was then incubated for 2 h at 37oC on tissue-
culture treated plates. Cells that adhered to the plate were gently scraped 
free (Adherent) and cells that remained in suspension (Suspended) were 
harvested. The cells were stained with toluidine blue and imaged at 10 x 
magnification (A). The Suspended population was stained for tryptase (C) 
alongside toluidine blue (B) and imaged at 10 x and 40 x magnification (B). 
Data is representative of 2 independent experiments. 
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Figure 2.3  Histochemical phenotyping of cultured peritoneal-derived mast 
cells. 
 
Exemplar plots of mast cell phenotyping by toluidine blue (A) and tryptase  (B) 
staining. The suspended cell fraction was prepared from peritoneal washes of 
10 week BALB/c mice and the cells cultured in vitro for 28 days in RPMI 
supplemented with 4% SCF-containing KLS-C conditioned media to generate 
PDMC. Toludine blue and tryptase staining of these cells was performed as 
described and imaged at 10 x and 40 x magnification. Data is representative of 
3 independent experiments. 
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Table 2.1 Compounds used for stimulation of murine mast cells. 
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Table 2.2 Inhibitors used for stimulation of murine and human mast cells.
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Table 2.3 Antibodies used for fluorescence assisted cell sorting of murine 
and human mast cells. 
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Figure 2.4 Exemplar plotting scheme for flow cytometric analysis of 
murine mast cells 
 
Exemplar plots of mast cell phenotyping by flow cytometric analysis. Size of 
cells, defined by forward scatter (FSC), and granularity, defined by side scatter 
(SSC) was used to place an initial gate to exclude cell debris and particles. 
Single cells were then identified using FSC-A and FSC-H and the viability of 
these cells determined using 7AAD staining. A positive control of heat-killed 
cells was used to identify gating position. 7AAD negative cells were then gated 
for CD117 and FcεRI expression with gates placed using isotype staining. Double 
positive cells were then further analysed as described for individual 
experiments. 
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Figure 2.5 Activity of Fura-2 AM in the detection of calcium mobilisation. 
 
Fura-2 AM works on the assumption that fluorescent light emitted following 
excitation at two wavelengths reflects the intracellular calcium concentration. 
Cells loaded with Fura-2 AM are exposed to light altering between two 
excitation wavelengths. Fura 2-AM is excited by light of two wavelengths 
depending on its bound (340 nm) or unbound (380 nm) status and emits light at 
510 nm [163]. These wavelengths are used to form a ratio (340/380 nm) which 
reduces the effects of experimental variation such as concentration of Fura-2 
AM loading, cell volume or loss of fluorescence over time. The 
fluorospectrophotometer used for the experiments calculates the 
concentration of free calcium within the cytoplasm from the levels of light 
emitted after each excitation as a ratio of bound and unbound. Fura 2 AM has a 
high affinity and is able to detect changes in concentration occurring slower 
than 10 ms meaning any changes in calcium detection are clearly visualised 
[161]. A problem when performing fluorescence-based calcium studies is that 
too large a concentration of a high affinity indicator, such as Fura-2 can buffer 
cytosolic calcium [161]. In this thesis a concentration was used that minimised 
this effect. Similarly the Fura-2 AM can be hydrolysed within the cell, passively 
or actively be removed from the cells, sequestered in non-cytoplasmic 
compartments (organelles) or photobleached.  
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Table 2.4 Cytokine and prostaglandin ELISAs for murine and human mast 
cells. 
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Figure 2.6 Exemplar plotting scheme for fluorescent Lamp1 staining of 
murine mast cells for quantitation of degranulation. 
 
Exemplar plots of mast cell phenotyping by flow cytometric analysis. Size of 
cells, defined by forward scatter (FSC), and granularity, defined by side scatter 
(SSC) was used to place an initial gate to exclude cell debris and particles. The 
viability of these cells was determined using 7AAD staining. A positive control 
of heat-killed cells was used to identify gating position. 7AAD negative cells 
were then gated for ST2 and FcεRI expression with gates placed using isotype 
staining. Double positive cells were then further analysed for Lamp1 
expression, positive expression was defined by the peak displaying higher 
expression. 
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Table 2.5 Primary and secondary antibodies used in Western blots for the 
detection of signalling molecules. 
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Figure 2.7 Optimisation of PLD assay. 
 
PDMC were treated with 5 µCi [3H] palmitate, [3H] oleic acid, [3H] myristic acid 
or [3H] arachidonic acid and murine anti-DNP IgE (0.5 µg/ml) overnight. Cells 
were loaded with ethanol (1%) (B-E), butan-1-ol (0.3%) or butan-2-ol (0.3%) (D) 
for 20 mins at 37oC. After alcohol loading a sample was taken and the reaction 
terminated (0 mins) (E). Cells were stimulated with PMA (1 µM) (B-D) or 
unstimulated (E) for 60 mins or the indicated time course. Results represent 
scintillation counting (A) or a percentage of scintillation count activity of the 
samples run by TLC to the corresponding total cell incorporation count (B-E). 
(C) represents treatments with Arachidonic acid omitted. Data represents a 
single experiment performed in triplicate (A-C). For (D) results were 
normalized to determine the fold increase using 0 min as a basal value which 
was assigned the value “1”. Data is representative of a single (A-C), at least 2 
(D) or 8 (E) independent experiments performed in triplicate. 
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3 Mast cell subsets and their functional 
modulation by the Acanthocheilonema viteae 
product ES-62. 
3.1 Introduction 
3.1.1 Mast cell development and function 
Whilst mast cells are recognised as playing important roles in initiating 
inflammation resulting in immunity or driving pathogenesis in a variety of 
allergic and autoimmune diseases [156, 164], there is increasing evidence of 
their participation in tissue repair and resolution of inflammation [12, 75, 
159], as well as for them exhibiting protective roles in cancer [36].  
 
Such contradictory reports relating to mast cell function most likely reflects 
that mast cells, which are haematopoietic cells found in all vascularised 
organs [1, 11, 165], constitute a heterogeneous cell population [3] varying in 
morphology, function and location with subpopulations being characterised 
by their differential protease, eicosanoid and proteoglycan content [2-4, 11, 
38]. Such heterogeneity arises because bone marrow-derived mast cell 
progenitors [6, 166], arrive in tissue before they are fully matured [8] 
allowing the different cytokines, hormones and reactive oxygen and/or 
nitrogen species produced by various microenvironments to essentially create 
‘custom-made’ site-specific mast cells [3, 11]. Moreover, the functional 
response of mast cells depends on the stimuli received; for example following 
classical activation of the IgE receptor, FcεRI, mast cells degranulate rapidly 
(within seconds) to exocytose prostaglandins and leukotrienes as well as 
preformed cytokines, tryptase, histamine, heparin and platelet activating 
factor (PAF) whilst de novo synthesised cytokines exhibit a more delayed 
(hours) release [36, 43].  
 
Mast cells can also be activated independently of FcεRI by cytokines or other 
pro-inflammatory mediators, reflecting direct interaction with triggering 
factors such as LPS, parasite molecules or allergic stimuli in the skin or 
mucosa. Due to their placement at environmental barriers, mast cells are 
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frequently the first cell type to respond during inflammation [75], as 
evidenced by the important roles played by mast cells in bacterial and 
parasitic infections [16, 107-109] where they are able to influence disease 
progress, both directly via release of pro-inflammatory mediators, and 
indirectly via their effects on other immune cells, including DC, T and B cells 
and macrophages [75]. 
 
 
3.1.2 In vitro mast cell culture 
The development of individual mast cell populations with the ability to 
interpret subtle signals to mould their response is crucial, allowing the 
immune response to be tailored in individual areas, increasing efficiency and 
reducing unwanted or excessive responses, thereby limiting tissue damage 
and conserving energy. This heterogeneity is mirrored in vitro by the 
different responses generated by mast cell populations created by varying 
culture conditions.  Although most protocols for generating mast cells are 
similar, even subtle changes have dramatic functional effects, especially 
when related to in vivo mast cells that have their maturation intricately 
tailored by their environment. 
 
However, isolation of in vivo mast cells for direct study can be complicated 
and expensive. They represent a numerically negligible population in tissues 
so retrieval of MC, both mechanically and to obtain a suitable purity, is 
complex [159] and so several techniques have been optimized to generate 
larger yields with fewer experimental difficulties [167]. However in order to 
perform larger experiments this quantity still needs to be improved and thus, 
the current best solution remains the use of in vitro differentiated MC. 
 
Further development of in vitro culture methods is essential, not just to 
increase quantity but to select the phenotype most appropriate to the 
disease model. Mast cells occupying different tissues have distinct 
characteristics and it is thus important to generate cells comparable to the in 
vivo population of interest. To date, studies are most commonly performed 
using mast cell lines such as RBL-2H3 and transformed BMMC (tBMMC). As with 
all transformed cell lines, these cells have limitations as their biology can be 
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far removed from the primary cells they are meant to represent. Thus, a 
better solution is to develop the in vitro culture and differentiation of 
primary mast cells.  Currently there are several protocols employed to 
culture primary murine mast cells that produce mast cell populations with 
distinct phenotypic and functional characteristics. For example, whilst each 
of these populations can be defined as mast cells by their expression of 
CD117, FcεRI and ST2, differences in their granular phenotype and response 
to stimulation indicate their functional heterogeneity. 
 
Protocols developed in the 1980s allowed the differentiation of bone marrow-
derived mast cells (BMMC), which can be generated in large numbers and 
hence are commonly used to study mast cell activation and signaling [168]. 
These are often used to represent mucosal mast cells [1] although 
phenotypically, they more closely resemble immature cells and have no 
identifiable physiological equivalent in tissues [11, 159]. Such BMMC can 
repopulate both mucosal and serosal mast cell compartments when given to 
mast cell deficient mice [3]. This latter property further indicates that BMMC 
may represent precursors of mature tissue mast cells that, given the correct 
maturation signals, can undergo additional development, that would be 
difficult to achieve in vitro as the signals required are complex and individual 
to the location [11]. 
 
Connective tissue mast cells (CTMC) are traditionally produced by co-culture 
of BMMC with fibroblasts [169] and are used as a model system to represent 
serosal MC [1]. More recently, it has been shown that they can also be 
developed by differentiation from bone marrow precursors using SCF and IL-4 
[3, 170].  Although not as frequently studied as BMMC, CTMC have been 
implicated as being involved in autoimmunity [142] and contact 
hypersensitivity [171]. 
 
Finally, although they constitute <5% of the peritoneal cell population, when 
cultured with SCF, mature mast cells can be expanded in vitro [159]. These 
cells, peritoneal-derived mast cells (PDMC), are fully mature, serosal-type 
mouse mast cells that retain most of the morphological phenotypic and 
functional features of freshly isolated mast cells [159]. PDMC differ in their 
functional responses when compared to BMMC, producing less lipid mediators, 
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chemokines and cytokines but exhibiting greater degranulation responses 
[159].   
 
Culture of all these mast cell models in vitro requires SCF, consistent with 
this chemokine being essential for MC development and survival in vivo [172]. 
BMMC require IL-3, as this is crucial for their development into a uniform 
population [173, 174], whereas CTMC do not require IL-3 but rather need IL-4 
for their differentiation [175]. SCF also ensures the generation of MC rather 
than basophils, as the latter are also induced as a result of IL-3 treatment 
[176].  
 
 
3.1.3 ES-62  
The phosphorylcholine (PC)-containing excretory-secretory filarial nematode 
product, ES-62 exhibits broad anti-inflammatory properties including 
desensitisation of FcεRI-mediated mast cell responses.  Consistent with this, 
ES-62 displays therapeutic potential in associated mucosal allergic 
inflammatory disorders such as asthma [126, 177]. As ES-62 is also protective 
in autoimmune and allergic connective tissue inflammatory pathologies such 
as arthritis and contact hypersensitivity [126, 177], we have therefore 
investigated the effects of ES-62 on mature PDMC and also on both 
connective tissue (CTMC)- and mucosal (BMMC)-type mast cell function in 
order to better understand mast cell biology as a first step to producing 
disease tissue-targeted therapeutics based on ES-62 action.  
 
 
3.2 Aims 
Characterisation of phenotypic, functional and signalling differences between 
three in vitro mast cell subtypes. 
Identify potential modulation of mast cell responses to FcεRI and LPS by ES-62 
and investigate the method of inhibition. 
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3.3 Results and Discussion  
3.3.1 Mast cell subtype comparison 
As previously discussed there is an increasing requirement for in vitro 
cultured MC. This chapter will investigate the differences observed between 
BMMC, CTMC and PDMC, MC derived from three culture methods described in 
the Materials and Methods (Chapter 2.2). After an initial identification of the 
phenotypic differences between the subsets, the functional responses of 
differing mast cells subsets to two key stimuli, LPS and antigen-mediated 
crosslinking of FcεRI, were characterised. Signalling via TLR4 and FcεRI are 
key activation mechanisms for mast cells and demonstrate the diversity of 
potential stimulation received by mast cells in disease. To compare the 
different responses to these stimuli in each mast cell subset, degranulation 
and cytokine production were analysed. Components released by mast cells 
including chemokines such as MCP-1 and cytokines such as IL-6 and IL-13, are 
responsible for the optimum recruitment and activation of innate cells, 
including mast cells, and adaptive immune cells during infection and 
inflammation. The relative release of each mediator can vary the immune 
response to individual pathogens ultimately influencing disease outcome.  To 
provide a mechanism for the differential responses between subtypes, 
calcium signalling, crucial for the initiation of degranulation and cytokine 
release in mast cells, and downstream PKCα expression were analysed.  The 
differential response to inhibition by the filarial nematode product, ES-62, 
was also investigated to highlight and compare the differences between the 
subtypes and their responses. 
 
3.3.1.1 Phenotypic analysis of mast cell subtypes. 
Flow cytometric analysis revealed that all three mast cell phenotypes display 
a similar size, as defined by forward scatter (FSC), and granularity, as 
defined by side scatter (SSC), although the CTMC population appear slightly 
less granular (Figure 3.1 A). FACs analysis of the surface marker expression of 
the different mast cell populations revealed that essentially all (> 98%) of the 
cells express both FcεRI and CD117 (cKIT), the classic mast cell markers, as 
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homogeneous populations (Figure 3.1 B). Similarly, all the mast cell subtypes 
express the LPS signalling receptor, TLR4-MD2 (Figure 3.1 C), PDMC, 
peritoneal-derived mast cells, have increased expression when compared to 
the bone marrow derived mast cells, BMMC and CTMC. ST2, the IL-33 
receptor, is also expressed on all cell types, however CTMC appear to have 
the greatest expression (Figure 3.1 D). This expression of both ST2 and TLR4-
MD2 is interesting when the recently proposed inhibitory effect of ST2 on 
TLR4 signalling is considered [178, 179]. The interaction between these two 
receptors is discussed further in Chapter 5. 
 
 
3.3.1.2 Mast cell subtypes exhibit differential granule phenotypes. 
After mast cells are stained with toludine blue their granularity, size and 
morphology is easily identified with clear staining of heparin-containing 
granules in all the different mast cell phenotypes (Figure 3.2). Staining of the 
PDMC is predominantly uniform while BMMC, although all positively stained, 
exhibit varying levels of staining. Mast cells are extremely heterogeneous in 
vivo and their maturation within tissues is driven by micro-environmental 
factors with, for example, tracheal MC expressing a different protease profile 
to skin MC, and this is defined by the surrounding tissues [15]. Similarly, this 
variation in BMMC phenotype is most likely a reflection of the SCF used in cell 
culture, previously shown to increase heparin expression and granularity in 
BMMC that normally express little or no heparin [41]. Such plasticity allows 
BMMC to further differentiate to repopulate both serosal and mucosal 
compartments in vivo [38]. CTMC granule content was found to be even more 
heterogeneous than that of BMMC. Unlike PDMC and BMMC that have small, 
dense, strongly stained granules, a population within the CTMC have large, 
open, vacuole-like, unstained granules giving them a slightly ‘swiss cheese’ 
appearance. This visible phenotypic difference may explain the slightly 
reduced granularity seen in the FACs staining (Figure 3.1 A). As the granule 
profile of mast cells is highly variable and affected by multiple factors it is 
possible that they are granules that contain different proteases to those 
found in heparin-containing granules such as carboxypeptidase A [160]. 
 
 
 67 
3.3.1.3 Mast cell subsets display different functional responses. 
To examine the relationship between subtypes and ensure that variation in 
MC progenitors, culture and experimental conditions amongst experiments 
were not affecting responses, BMMC, CTMC and PDMC were derived from the 
same cohort of mice and mast cell degranulation investigated. Mast cell 
degranulation in response to FcεRI crosslinking (and PMA/Ionomycin) is 
observed in all mast cell phenotypes (pooled data from multiple experiments 
are shown in Table 3.1) whilst LPS does not induce degranulation by any 
phenotype. Overall, PDMC display greater degranulation responses, both to 
PMA/Ionomycin a pharmacological stimulus that is independent of receptor 
signalling, and to Ag-induced crosslinking of FcεRI (FcεRI-XL), when compared 
to bone marrow-derived MC, BMMC and CTMC. This perhaps suggests that 
PDMC have received a maturational signal in vivo that licences recruitment of 
degranulation-associated signalling pathways by the PDMC that are uncoupled 
in bone-marrow derived-MCs. 
 
The observed differential degranulation responses are unlikely to be a result 
of reduced granularity as CTMC, which have the lowest granularity and 
toluidine blue staining (Figure 3.1 and 3.2) exhibit higher levels of 
degranulation than BMMC. It should be noted, however, that the granule 
constituents are not completely defined for each subtype and may vary. In 
addition, degranulation here is being assessed on the basis of a single granule 
component, β-hexosaminidase, rather than exocytosis in general. Although 
this does allow a general idea of the ability of cells to exocytose in response 
to a specific stimuli it does not reveal the nature or relative levels of 
individual granule components. This is important in a cell type that tailors 
mediator release depending on the environment and stimulus. Indeed, a 
method that determines exocytosis [162] by quantitating Lamp1 expression at 
the cell surface after granule-plasma membrane fusion may give a better 
overall assessment of the level of degranulation and has been adapted for MC 
and employed later in this thesis.  
 
MC degranulation stimulates prostaglandin production [180]. Prostaglandins, 
including PDG2, are synthesised from arachidonic acid released by the 
cytosolic phospholipase A2 (cPLA2)-mediated breakdown of membrane 
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phospholipids. PDG2 is one of the initial pro-inflammatory mediators released 
by MC and, as it is rapidly degraded in vivo, its effects, although potent, are 
often short-lived [181]. PGD2 is produced at high levels by all subtypes, 
particularly the BM-derived MC, even in the absence of stimulus. FcεRI-XL 
fails to initiate a strong PDG2 response above basal from PDMC or CTMC 
compared to that seen with BMMC. CTMC respond better to LPS than FcεRI-XL 
and produce greater levels of PDG2 than BMMC under these conditions. 
Collectively, these data suggest that in vitro, PGD2 production by mouse MC 
subtypes may be largely constitutive and not closely coupled to 
degranulation. 
 
IL-6, IL-13, TNFα and MCP-1 are cytokines important for both homeostatic 
and inflammatory functions of mast cells. Similarly to what was observed for 
PDG2 production, PDMC produce less cytokines than either CTMC or BMMC, 
the later of which produce the greatest overall cytokine responses.  
Moreover, whilst cytokine production by PDMC and CTMC is greatest after LPS 
treatment, FcεRI XL of BMMC induces the strongest cytokine responses. 
BMMC, but not PDMC or CTMC, also produce high levels of TNFα, both 
spontaneously and after stimulation via FcεRI. It has been reported that 
BMMC and freshly isolated PDMC derived from C57BL/6 mice exhibited higher 
levels of degranulation and had lower levels of cytokine production than 
those from BALB/c mice [182] but this trend was not found to be significantly 
reproducible in this study (data not shown). 
 
BMMC can differentiate into mucosal or serosal cells [38] and perhaps 
consistent with this, CTMC appear to be an intermediate between BMMC 
(mucosal) and PDMC (serosal) as evidenced by their intermediate cytokine 
and degranulation profiles.  BMMC seem to exhibit a functional phenotype 
more skewed towards cytokine and prostaglandin production whilst 
degranulation appears to be a more specialised function restricted to the 
more mature PDMC. As immature MC have been suggested to play a 
regulatory role in localised immune responses [183], this functional bias may 
allow their involvement in the early immune response where strong cytokine 
responses act to recruit inflammatory cells and coordinate the subsequent 
immune phenotype [45]. 
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3.3.2 Effect of ES-62 on mast cell function 
3.3.2.1 ES-62 modulates degranulation in mast cell subsets 
As each MC subset appears to exhibit differential functional responses, it was 
important for the development of potential therapeutics to define any 
variation in their responses to ES-62. ES-62 was found to significantly inhibit 
the degranulation of BMMC and PDMC resulting from FcεRI- XL (Figure 3.3 A). 
CTMC degranulation was unaffected however FcεRI- XL does not stimulate a 
strong response in this subtype. Likewise, degranulation responses to LPS 
were consistently and uniformly very low, preventing detection of any 
significant ES-62 effect (Figure 3.3 B). By contrast, PMA/Ionomycin responses 
were significantly reduced by ES-62 in PDMC. BMMC and CTMC degranulation 
was reduced but as this was only performed as a single experiment, the 
reproducible significance of this could not be determined (Figure 3.3 C). 
 
 
3.3.2.2 ES-62 modulates cytokine production in mast cell subsets 
ES-62 was found to significantly inhibit the production of FcεRI-induced IL-6, 
IL-13 and MCP-1 from BMMC (Figure 3.4 A). By contrast, for LPS stimulation of 
BMMC, IL-13 release was reduced although ES-62 only significantly inhibited 
IL-6 production. Neither TNFα nor MCP-1 production was inhibited by ES-62 
(Figure 3.4 B) in 2 and 3 independent experiments respectively.  Similarly, 
PMA/Ionomycin-induced IL-6 and IL-13 from BMMC is unaffected by ES-62 
treatment (Figure 3.4 C), although this may reflect that ES-62-mediated 
inhibition of FcεRI signalling occurs further upstream than that mimicked by 
PMA/Ionomycin stimulation.  
 
Rather similar effects were seen with CTMC although in this case only FcεRI-
mediated production of IL-13 (single experiment) (Figure 3.5 A) and LPS-
stimulated IL-6 and TNFα production were significantly inhibited by ES-62 
(Figure 3.5 B). Although MCP-1 production appears to be routinely inhibited, 
this is not significant perhaps due to the strong spontaneous production of 
this chemokine. 
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Interestingly, although the responses are very low, ES-62 significantly inhibits 
FcεRI-mediated IL-13 and IL-6 production by PDMC (Figure 3.6 A) and all 
detectable cytokine responses to both LPS (Figure 3.6 B) and PMA/Ionomycin-
induced cytokines (Figure 3.6 C) are significantly inhibited by ES-62. 
 
Unlike with macrophages and DCs, where ES-62 can directly stimulate IL-6, 
IL-12 and TNFα production [184], ES-62 does not stimulate cytokine 
production by any MC subtype. Moreover, despite ES-62 differentially 
inhibiting cytokine production by MC in response to the described stimuli, it 
does not completely ablate such pro-inflammatory mediator release. This 
preservation, although at reduced levels, of signalling and the subsequent 
functional responses indicates that rather than being completely suppressed, 
MC can still perform functions during an immune response but with an ES-62-
tailored phenotype.  
 
 
3.3.2.3 ES-62 does not affect receptor surface expression 
As a first step to investigating the mechanism(s) of action of ES-62 in 
suppressing degranulation and cytokine production by MC subsets, the effects 
of ES-62 on surface expression of FcεRI, CD117 and ST2 were determined by 
flow cytometry. Sensitized (Figure 3.7 B) and non-sensitized (Figure 3.7 A) 
PDMC were stained for these receptors, crucial for full mast cell function, 
after treatment with ES-62. Regardless of the sensitization status there was 
no obvious effect on their surface expression after an 18 h treatment with ES-
62. Although TLR4 expression was not analysed, these results suggest that the 
modulation of MC responses by ES-62 is not a consequence of downregulation 
of these key mast cell receptors but rather via targeting of their downstream 
signalling.  
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3.3.3 ES-62 targets calcium and PKCα signalling in mast cells.  
As ES-62 does not affect receptor expression, the effect of the parasite 
product on calcium mobilisation and PKCα expression was investigated. These 
signalling parameters were examined as both signalling components have 
previously been identified as important in both MC cytokine and 
degranulation signalling [185, 186] as well as targets of ES-62 in its inhibition 
of antigen receptor-mediated B cell [187] and FcεRI-driven human MC [126, 
177] responses.  
 
 
3.3.3.1 Calcium mobilisation in mast cell subsets.  
One of the major regulators of mast cell signalling is calcium; intracellular 
mobilisation of calcium ions (Ca2+), a universal second messenger, is crucial 
to the response of FcεRI- XL.  By contrast, the TLR4 ligand, LPS has previously 
been reported to fail to stimulate calcium mobilisation in BMMC [31, 188]. 
Most MC functions have been reported to rely on calcium mobilisation, 
including proliferation, gene expression, secretion, adhesion and migration of 
mast cells [189-191]. 
 
FcεRI-mediated activation of calcium mobilisation has been reported to 
involve several components highlighted in Figure 3.8. Following its generation 
by phospholipase C (PLC) activation, IP3 binds IP3R on the membrane of the 
endoplasmic reticulum (ER) and activates SOCE (store-operated calcium 
entry) channels, releasing luminal ER calcium. PKC can also activate IP3R 
directly, bypassing IP3, to induce Ca2+ release [190]. As a result of this calcium 
depletion from the ER, STIM1, normally associated with the ER membrane, 
translocates to the plasma membrane to associate with Orai/CRACM1 [192]. 
The channel formed by this complex allows an influx of extracellular Ca2+ to 
maintain the intracellular calcium concentration and helps replenish the ER 
stores [190]. CRAC are not the only SOC in mast cells but are the most 
dominant [193].  
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In addition to IP3, S1P can also initiate calcium mobilisation, however the 
precise role of S1P is controversial [194, 195]. Whilst S1P can be exported 
from the cell to trigger calcium influx via cell surface S1P receptor signalling 
[196, 197], there is also evidence for ER membrane-associated SphK 
generating S1P that can directly mediate calcium release from the ER [198-
200], although it is currently thought that S1P plays a more important role in 
influx rather than ER release [190, 201]. 
 
Although producing equivalent maximum calcium responses, S1P stimulates a 
more transient calcium signal whereas IP3 induces more sustained responses 
reflecting additional influx. Inhibition of SphK suppresses the calcium 
response but leaves IP3 signalling intact indicating that S1P is signalling 
alongside and cooperating with, rather than instead of, IP3. [194].  
 
The regulation of the concentration, duration, location and pattern of 
calcium responses [190, 191], is extremely important in determining the 
outcome of the response in mast cells. In MC, degranulation is dependent on 
intracellular Ca2+ release via SOCE [202] whereas cytokine release is 
independent of intracellular calcium mobilisation [192, 203] indicating that 
the phenotype of the calcium response directly affects the subsequent 
signalling outcomes. 
 
To investigate the role of calcium signalling in all three mast cell subtypes, 
the cells were stimulated by cross-linking of FcεRI (XL) (Figure 3.9 A) or 
addition of LPS (Figure 3.9 B). The profiles observed for all subtypes 
demonstrated similar kinetics after cross-linking (XL), with a rapid increase in 
intracellular calcium levels within seconds of administration of DNP, the 
crosslinking agent, at 50s. This is followed by a further, steadier increase to a 
maximum concentration after a further 50 s before the intracellular calcium 
signal begins to return to basal levels. Although the maximum cytosolic 
calcium concentration for each subtype is different (typically, PDMC> BMMC> 
CTMC), direct comparison is hazardous as the maximum calcium signalling 
response can be affected by a variety of factors including culture and 
experimental conditions.  
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Ca2+ movement within the cells comes in many forms; puffs, waves and 
oscillations. Calcium microdomains are pockets of Ca2+ in the cytoplasm 
formed in the immediate area of release from either ER or influx. 
Immediately after release these initial localised “puffs” at receptor sites are 
followed by transduction of the signal in “waves” through the cytosol 
facilitated by release from the ER. Oscillations are formed as the ER luminal 
stores replenish using influxed calcium, allowing successive and repeating 
Ca2+ release from ER triggered by IP3 [190, 204]. 
 
The dynamics of calcium fluctuations may define functional responses [204], 
for example in RBL-2H3, oscillations are linked to degranulation [205, 206]. 
Although this rapid fluctuation still obeys a pattern of increasing then 
decreasing levels of total intracellular calcium the amplitude and duration of 
these oscillations add another level of variation to the calcium response and 
its outcome. Oscillations reduce the overall threshold of calcium required to 
activate NFκB, allowing activation even after low levels of stimulation. The 
frequency of the oscillations also dictates the activation of individual 
transcription factors; NFAT is only activated after rapid oscillations, whereas 
NFκB can also respond to lower frequency oscillations. This variety in 
transcription factor activation is translated into cytokine production [207]. 
These oscillations cannot be determined using this experimental method and 
require single cell analysis, a potential future experiment. 
 
Stimulation with LPS (Figure 3.9 B) induces a different profile of calcium 
mobilisation as the increase in intracellular calcium concentration is slower 
and does not reach the same maximum levels observed following crosslinking 
of FcεRI (XL). Moreover, the different mast cell subtypes clearly have varied 
responses as demonstrated by PDMC that display only a weak response to LPS 
relative to that seen with CTMC and particularly, BMMC. Degranulation is 
regulated by calcium [190, 191], so the weak calcium profile seen in response 
to LPS stimulation compared to XL may be inadequate to initiate 
degranulation (Table 3.1).  
 
To determine the relative contribution of intracellular and extracellular 
calcium sources in the responses induced by XL and LPS, the involvement of 
each was inhibited by BAPTA and EGTA respectively as these ion-chelators 
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have extremely high affinity with Ca2+ [161]. BAPTA-AM, a potent cell 
permeable calcium chelator, binds and sequesters intracellular calcium ions. 
Removal of this calcium signal ablates the calcium responses to stimulation 
with either LPS or XL in all subtypes, resulting in nothing more than basal 
calcium movement. This demonstrates the essential role of the initial release 
of calcium from cytosolic stores, such as the ER, in initiating the subsequent 
influx of extracellular calcium in mast cells. 
 
To remove extracellular calcium sources, calcium can be omitted from the 
buffer and a calcium chelator, EGTA, added. Stimulation of cells under these 
conditions preserves the initial release of calcium from intracellular stores 
and consistent with this, after XL, in the absence of extracellular calcium, 
the initial rapid peak of calcium is observed but not the secondary steady 
increase, resulting in a rapid return to basal levels. This initial peak 
represents the involvement of intracellular calcium release, which is rapid 
and transient in mast cells after XL. The different subtypes have a maximum 
concentration produced by the intracellular stores of 100-200 µM, typically 
<50% of the concentration observed in the presence of extracellular calcium. 
By contrast, when cells were stimulated with LPS in the absence of 
extracellular calcium, calcium mobilisation was essentially abrogated with 
only a small intracellular calcium mobilisation signal remaining in the BMMC.  
 
The variation in calcium responses to FcεRI (XL) between subtypes is unlikely 
to be due to variable levels of receptor expression between the subtypes 
(Figure 3.1 B) but is potentially a reflection of the differing expression of 
calcium mobilisation machinery or the effects of regulatory mechanisms on 
signal strength propagated upstream of calcium release.  
 
Although LPS has not previously been reported to stimulate calcium in BMMC 
[31, 188], it has been reported to increase FcεRI-driven calcium mobilisation 
by upregulating the Orai1 and Stim1 subunits of the SOC channel RBL-2H3 
[49]. Here LPS was found to induce varying levels of calcium amongst the 
mast cell subtypes. As with FcεRI signalling, the strength of LPS-induced 
calcium mobilisation is perhaps unlikely to be regulated by TLR4 expression 
as the weak calcium profile observed in PDMC does not reflect the rank order 
of TLR4-MD2 expression (Figure 3.1 C). The ability of BMMC to respond most 
 75 
strongly to LPS and to exhibit a greater involvement of mobilisation of 
intracellular calcium may be a reflection of their stage of maturation. As 
BMMC appear to represent a more immature MC, perhaps there is a bias 
towards TLR4 signalling which allows, for example, shaping of the mast cell 
activity in response to bacterial infection as occurring in a physiological 
setting where they represent MC as they first enter tissues. During infection 
MC are one of the first cell types to respond and progenitors are further 
recruited during infection [45]. Perhaps these freshly recruited cells are 
hardwired to be more sensitive to TLR ligands so they can respond 
immediately, before full maturation [183]. 
 
Consistent with the key role played by calcium mobilisation in MC responses, 
both FcεRI- and LPS-mediated calcium mobilisation can be inhibited by ES-62 
pre-treatment (18h; Figure 3.10). In both cases, this inhibition appears to 
target the influx of extracellular calcium and this may reflect that whilst 
LPS/TLR4 signalling induces SOCS, ES-62 in subverting TLR4 signalling acts to 
suppress assembly of this calcium mobilisation machinery. ES-62 does not 
affect the loading of Fura 2/AM or basal calcium levels in PDMC as 
represented by the equivalent calcium concentration before addition of 
treatment observed without baseline adjustment.  
 
The “classical” PKC, PKCα has been reported to be involved in the coupling of 
Fc receptors to calcium mobilisation via PLD (Figure 1.4) [126, 208] and in 
addition, Ca2+ and DAG act to further recruit and activate PKCα [209]. ES-62 
has previously been shown to desensitise human FcεRI-mediated MC responses 
and consistent with this, it was found that ES-62 could induce downregulation 
of PKCα (Figure 3.11 A and HK Tay and MM Harnett, unpublished) in PDMC, 
BMMC and CTMC [134], confirming the results seen in human mast cells [126] 
and the generality of this effect of ES-62 in MC, regardless of subtype.  
 
During activation PKC translocates to plasma membrane where it is able to 
phosphorylate membrane-localised substrates. This response only lasts 2-5 
minutes before PKC is returned to the cytosol [209]. Prolonged activation of 
PKC happens at a more peri-nuclear location, perhaps at the ER or in 
recycling endosomes [209, 210]. The downregulation of PKCα activity and 
expression has been investigated in rat intestinal epithelial cells where PKCα 
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activity can be reduced by two methods, potentially acting simultaneously. 
Firstly, caveolar internalisation to a peri-nuclear location, PKCα 
dephosphorylation and subsequent proteasome-independent degradation 
using a lysosomal route and alternatively, ubiquitination of phosphorylated 
PKCα at the plasma membrane then degradation by the 2G S proteasome 
[211]. 
 
Previous work suggests that ES-62 uses the lysosomal route to modulate PKCα 
signalling. Thus, in human MC, ES-62-mediated PKCα downregulation could be 
prevented by nystatin, an inhibitor of caveolae/lipid raft trafficking [126] 
whilst in B cells, the cysteine protease inhibitor, leupeptin, preserved PKCα 
expression after ES-62 treatment indicating lysosomal involvement [212]. To 
identify the regulatory mechanism(s) involved in ES-62-mediated 
downregulation of PKCα in the three mouse MC subsets, inhibitors of PKCα 
localisation and processing were used to investigate both regulation pathways 
(Figure 3.11 B). To exclude inhibitor toxicity influencing the results, FACs 
analysis of cell viability was determined. Overall cell death, as determined by 
% of cells incorporating 7AAD, did not exceed 6% regardless of the inhibitor 
concentration or the duration of incubation (Figure 3.12).  
 
With CTMC, similar results to human mast cells were observed as nystatin and 
the lysosomal inhibitors, E64d plus pepstatin A, but not lactacystin 
(proteosomal) preserved PKCα expression, preventing ES-62 downregulation. 
However, with PDMC and BMMC, the picture was more complicated with both 
routes involved in BMMC and incomplete involvement in PDMC. 
 
This differing response between subtypes, summarised in Figure 3.11 C, 
confirms previous reports that PKCα regulation can occur using both pathways 
simultaneously, even in response to a single ligand. The relative role of each 
pathway is suggested to be defined by temporal and spatial factors [209, 211] 
and perhaps for MC the level of maturity and culture conditions. The 
different PKCα regulatory profiles seen in each MC phenotype provide a 
mechanism for the fine-tuning of MC responses and allow PKCα to be a point 
whereby receptor signal strength could dictate downstream signal strength. 
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3.3.4 Is CD200R a potential target of ES-62 in mast cells?  
Preliminary data from a microarray screen of targets of ES-62 suggested that 
CD200R was upregulated by small molecular analogues (SMAs) of the parasite 
product that mimicked it’s anti-inflammatory actions (J Rzepecka & W 
Harnett, unpublished) and so to address whether ES-62 was mediating its 
desensitising effects on FcεRI- and LPS-coupled responses in MC cells via this 
receptor, functional responses of MC from WT and CD200R-deficient mice 
were compared. CD200R is a member of the Ig-superfamily, generally 
restricted to cells of myeloid lineage [213] and perhaps consistent with its 
potential as a mediator of the effects of ES-62, CD200R -/- mice [157] display 
increased symptoms of EAE and CIA due to over-activation of monocytes and 
macrophages [214, 215]. However, although these mice respond to LPS with 
slightly elevated cytokine responses, they did not display uncontrolled 
inflammatory responses indicating that CD200R is non-essential in TLR4 
signalling regulation. Corroborating studies demonstrated that prevention of 
CD200R ligation in CD200-/- mice allows for TLR2 and TLR4 upregulation and 
an increase in LPS-induced cytokines [213].  Moreover, and of particular 
interest to the present studies, mouse mast cells grown in vitro express 
CD200R, [216] and CD200 ligation of CD200R was found to inhibit FcεRI-
mediated mast cell degranulation without the need for co-ligation [217, 218]. 
Overall, therefore, these studies suggested a role for CD200R in limiting both 
FcεRI- and LPS-mediated responses in mast cells and hence suggested that 
CD200R could be a potential molecular target for ES-62. 
 
 
3.3.4.1 PDMC from WT and CD200R KO exhibit comparable functional 
and signalling responses 
As a first step to determining whether CD200R was important in the ES-62-
mediated regulation of either TLR4 or FcεRI signaling in mast cells, 
phenotyping of PDMC from WT and CD200R -/- C57BL/6 mice was performed 
to rule out any developmental or phenotypic effects. PDMC from CD200R -/- 
mice show comparable expression of FcεRI, ST2 and TLR4 expression to WT 
cells (Figure 3.13), indicating that any effects seen in CD200R -/- cells are 
not a consequence of modulation of such receptor expression.  
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Analysis of FcεRI- and LPS -mediated functional responses of PDMC derived 
from WT and CD200R -/- mice showed no significant differences in terms of 
degranulation (Figure 3.14 B) or cytokine secretion (Figure 3.14 A). This was 
somewhat surprising given the postulated negative regulatory role of CD200R 
in these cells but these findings were supported by analysis of calcium 
mobilisation after FcεRI XL (Figure 3.14 E) or LPS treatment (Figure 3.14 F) 
and PLD activation, which showed negligible effects of CD200R deficiency on 
these responses induced by FcεRI-signaling (Figure 3.14 C, D).  The only clear 
effect was an increase in PMA/Ionomycin-induced IL-13 production in the 
CD200R -/- cells. Although these data are somewhat at odds with previously 
published studies they may be restricted to the PDMC phenotype.  
 
An alternative explanation for the seemingly redundant role for CD200R in MC 
is that the effects of CD200R may be very subtle in mast cells. BMMC were 
found to require an overexpression of CD200R and for the receptor to be 
crosslinked, preferably by membrane bound CD200, to inhibit responses [218, 
219]. Moreover, MC in vivo may be more susceptible to CD200R inhibition as 
freshly isolated skin MC have more CD200R than cultured MC and in a model 
of PCA, activation of the receptor using anti-CD200R antibodies inhibited IgE-
dependent vascular permeability [218]. Nevertheless, the results presented 
here suggest that ES-62 is unlikely to mediate its effects, at least on PDMC, 
via CD200R-signaling.  
 
 
3.4 Conclusions 
Mast cells are extremely heterogeneous and their maturation within tissues is 
driven by micro-environmental factors. In this study, the three murine mast 
cell subtypes display strong variation in receptor expression, functional 
response and signaling profiles (Table 3.2) reflecting previous findings that 
the mast cell phenotype is very flexible and can change in response to 
helminth infection [15]. Consistent with this, ES-62, derived from helminths, 
has been shown to inhibit MC responses. Collectively, ES-62 induces a 
hyporesponsive functional response in both serosal and mucosal MC after a 
variety of stimuli (Table 3.2). Both immature MC, represented by BMMC and 
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mature MC, PDMC and CTMC, can be modulated by ES-62. The ability to 
inhibit even immature MC presents the possibility that ES-62 can alter MC 
function during maturation, allowing ES-62 to alter MC phenotype early in 
their development regardless of the potentially proinflammatory maturation 
signals in the microenvironment.  This mirrors the response previously seen in 
bone-marrow progenitors of macrophages and dendritic cells exposed to ES-
62 in vivo, under normal or inflammatory conditions, which can develop an 
anti-inflammatory phenotype in vitro, even after ES-62 withdrawal. [131, 
135]. It would be interesting to determine if ES-62 is able to modulate 
immature MC throughout their maturation and to establish whether any 
changes in phenotype are stable.  
 
ES-62 does not appear to act by modulating the cell surface expression of 
these receptors key to MC function. Rather, together with the differential 
effects of ES-62 on calcium and PKCα responses, these data indicate that the 
effects of ES-62 are on downstream signaling elements, which depend not 
only on the cell but also on the stimulus.  The differing effect of ES-62 on 
each response may reflect that ES-62 has selective actions, important if being 
used in a therapeutic setting where it is crucial to preserve homeostatic MC 
activation. [37] 
 
The ability of mast cells to differentiate into two functionally distinct subsets 
from the same progenitors with the only difference in culture conditions 
being the presence of IL-3 (BMMC) or IL-4 (CTMC) highlights their delicate 
interpretation of surrounding influences not only in their maturation but also 
in their subsequent responses. This makes MC both an excellent target for 
therapeutics, but also a tricky cell to manipulate into a particular, anti-
inflammatory phenotype. Although mast cell targeting drugs are limited in 
both their specificity and efficacy, there is huge potential for further 
development. ES-62 may provide a starting block for a tailored therapeutic 
that preserves some function while removing pro-inflammatory features of 
their response. 
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Figure 3.1  Phenotyping of mast cell subsets 
 
Exemplar plots of mast cell phenotyping by flow cytometric analysis (A-D). FSC 
and SSC parameters of PDMC, BMMC and CTMC cultured in vitro for 28 days (A) 
and gating (relative to isotype controls, not shown) of the CD117+ FcεRI+ cells 
(B) prior to analysis of TLR4-MD2+ expression (C). Expression of ST2 on the 
CD117+ FcεRI+ cells was performed in parallel (D). Isotype controls are 
represented by grey shaded plots. Data are representative of 3 independent 
experiments. 
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Figure 3.2 Histochemical phenotyping of mast cell subsets. 
 
Exemplar images of mast cell phenotyping by toluidine blue staining. BMMC, 
CTMC and PDMC derived by in vitro culture for 28 days, were stained with 
toluidine blue. Representative images were taken at 10 x and 40 x 
magnification. Data are representative of 3 independent experiments. 
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Table 3.1 Summary of mast cell subset responses to FcεRI, LPS and 
PMA/Ionomycin 
 
Statistical analysis between treated cell values and basal values determined 
using unpaired, two-tailed t-test. * p<0.05, ** p<0.01, *** p<0.001, **** p< 
0.0001. 
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Figure 3.3  ES-62 modulates degranulation of mast cell subsets. 
 
PDMC, BMMC and CTMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) 
overnight in the presence or absence of ES-62 (2 µg/ml) then stimulated with 
either DNP (0.5 µg/ml) to induce FcεRI cross-linking (XL) (A), LPS (0.5 µg/ml) 
(B) or PMA (1 µM) plus Ionomycin (1 µM) (C) for 30 mins at 37oC. Degranulation 
was determined as the % β-hexosaminidase released relative to the total 
activity of the cells. Results are from a single experiment representing at least 
2 independent experiments. Error bars represent SD. Statistical analysis using 
one-way ANOVA with Tukey’s multiple comparison test. * p< 0.05 and *** p< 
0.001. 
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Figure 3.4 ES-62 modulates cytokine production from BMMC. 
 
BMMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight in the 
presence or absence of ES-62 (2 µg/ml) then stimulated with either DNP (0.5 
µg/ml) to induce FcεRI cross-linking (XL) (A), LPS (0.5 µg/ml) (B) or PMA (1 µM) 
plus Ionomycin (1 µM) (C) for 24 h at 37oC. Release of IL-13, IL-6, MCP-1 or 
TNFα was measured by ELISA. Results are from a single experiment 
representative of at least 2 independent experiments. Error bars represent SD. 
Statistical analysis using one-way ANOVA with Tukey’s multiple comparison 
test. ** p< 0.01 and *** p< 0.001. 
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Figure 3.5 ES-62 modulates cytokine production from CTMC. 
 
CTMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight in the 
presence or absence of ES-62 (2 µg/ml) then stimulated with either DNP (0.5 
µg/ml) to induce FcεRI cross-linking (XL) (A), LPS (0.5 µg/ml) (B) or PMA (1 µM) 
plus Ionomycin (1 µM) (C) for 24 h at 37oC. Release of IL-13, IL-6, MCP-1 or 
TNFα was measured by ELISA. Results are from a single experiment 
representative of at least 2 independent experiments. Error bars represent SD. 
Statistical analysis using one-way ANOVA with Tukey’s multiple comparison 
test. ** p< 0.01 and *** p< 0.001. 
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Figure 3.6 ES-62 modulates cytokine production from PDMC. 
 
PDMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight in the 
presence or absence of ES-62 (2 µg/ml) then stimulated with either DNP (0.5 
µg/ml) to induce FcεRI cross-linking (XL) (A), LPS (0.5 µg/ml) (B) or PMA (1 µM) 
plus Ionomycin (1 µM) (C) for 24 h at 37oC. Release of IL-13, IL-6, MCP-1 or 
TNFα was measured by ELISA. Results are from a single experiment 
representative of at least 2 independent experiments. Error bars represent SD. 
Statistical analysis using one-way ANOVA with Tukey’s multiple comparison 
test. * p< 0.05, ** p< 0.01 and *** p< 0.001. 
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Figure 3.7 Effect of ES-62 on mast cell phenotype. 
 
Plots of mast cell phenotyping by flow cytometric analysis (A-D). CD117, FcεRI 
and ST2 expression by resting PDMC, BMMC and CTMC (A) or mast cells 
sensitized (B) with murine anti-DNP IgE (0.5 µg/ml) overnight in the presence 
or absence of ES-62 (2 µg/ml) are shown. Isotype controls are represented by 
grey shaded plots. 
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Figure 3.8  Role of calcium signaling in FcεR1-mediated responses. 
 
Following FcεRI crosslinking, PLCγ converts PIP2, associated with the plasma 
membrane, to IP3 and DAG. IP3 binds IP3R on the endoplasmic reticulum (ER) 
and activates SOCE (store-operated calcium entry), releasing luminal ER 
calcium. PKC can also activate IP3R directly, inducing Ca2+ release, bypassing 
IP3 [190]. Calcium depletion from the ER activates STIM1, normally associated 
with the ER membrane, to translocate to the plasma membrane to associate 
with Orai/CRACM1 [192]. The channel formed by this complex allows an influx 
of extracellular Ca2+.  
S1P can also initiate calcium mobilisation, however the role of S1P is 
controversial. [194, 195]. S1P can be exported from the cell to trigger calcium 
influx via S1P-R signaling [196, 197] and/or directly stimulate calcium release 
from the ER [198-200], although recent data suggest that S1P plays a more 
important role  in mobilising influx rather than ER release[190, 201]. 
To regulate intracellular calcium concentrations, CRAC channels are 
inactivated by a calcium-dependent mechanism and define PMCA, found 
associated with the plasma membrane in mast cells, pumps Ca2+ back out into 
the extracellular space, returning cytosolic levels to basal. Cytosolic calcium is 
also removed by define SERCA on the ER, which replaces depleted luminal ER 
stores. Ca2+ is also released and taken up by mitochondria that remove 
cytosolic calcium adjacent to ER and CRAC channels promoting further ER store 
depletion and increasing the duration of CRAC activation [189, 190].  
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Figure 3.9 Calcium mobilisation in mast cell subsets. 
 
Fura-2/AM loaded resting or IgE-sensitised (murine anti-DNP IgE; 0.5 µg/ml) 
sensitized BMMC, CTMC and PDMC were stimulated at 50s with DNP (0.5 µg/ml) 
to induce cross-linking (XL) of FcεRI (A) or 0.5 µg/ml LPS to stimulate TLR4 (B). 
Intracellular calcium mobilisation and influx were recorded in real-time using 
excitation-emission ratios of 340/380 nm. For the analysis of intracellular 
mobilisation alone, the cells were stimulated in calcium-free buffer 
supplemented with 100 µM EGTA to remove all extracellular calcium (EGTA). 
Calcium levels were calculated from Rmax and Rmin values and the data 
presented as the mean calcium values of triplicate samples (baseline calcium 
values subtracted) from a single experiment representative of at least 3 
independent experiments. Error bars represent SD. 
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Figure 3.10 ES-62 modulates calcium mobilisation in mast cells. 
 
PDMC were sensitized (murine anti-DNP IgE; 0.5 µg/ml) overnight in the 
presence or absence of ES-62 (2 µg/ml). Following Fura-2/AM loading the PDMC 
were stimulated at 50s with DNP (0.5 µg/ml) to induce cross-linking (XL) of 
FcεRI (A) or 0.5 µg/ml LPS to stimulate TLR4 (B). The intracellular calcium 
mobilisation and influx were recorded in real-time using excitation-emission 
ratios of 340/380 nm. Calcium levels were calculated from Rmax and Rmin 
values and the data presented as the mean calcium values of triplicate samples 
(baseline calcium values subtracted) from a single experiment representative 
of at least 3 independent experiments. Error bars represent SD. Statistical 
analysis using paired t-test. **** p< 0.0001. 
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Figure 3.11 ES-62 modulates PKCα expression in mast cell subsets. 
 
CTMC, BMMC and PDMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) 
overnight then cultured with ES-62 (2 µg/ml) for the indicated times and 
expression of PKCα analysed by Western blotting (A). Sensitized CTMC, BMMC 
and PDMC were preincubated for 1 h with inhibitors of proteosomal 
degradation (10 µM lactacystin), caveolae/lipid raft trafficking (50 µg/mL 
nystatin) and lysosomal degradation (E64d + pepstatin A, both 10 µg/mL), 
before culture with ES-62 (2 µg/ml) for the indicated times and expression of 
PKCα analysed by Western blotting (B). β-actin was used as a loading control. 
Results summarised are representative of at least 2 independent experiments 
(C). 
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Figure 3.12 Endosomal and Proteosomal Inhibitors do not affect mast cell 
viability within 18 hours of culture. 
 
PDMC viability following treatment with indicated concentrations of inhibitors 
for 6 h and 18 h, was assessed by 7AAD uptake using flow cytometric methods 
as described in Materials and Methods 2.6. Data are from a single experiment. 
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Figure 3.13 CD200R expression does not affect FcεRI, ST2 or TLR4 
expression of murine mast cells. 
 
PDMC derived from WT or CD200R -/- C57BL/6 mice was phenotyped by flow 
cytometric analysis.  FcεRI (A), ST2 (B) and TLR4 (C) expression are shown. As 
TLR4 expression was very low in these cultures, the TLR4+ gate is also shown 
on an expanded scale to allow comparative analysis (D).  Isotype controls are 
represented by grey shaded plots and data are from a single experiment. 
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Figure 3.14 CD200R expression does not affect FcεRI or TLR4-induced 
responses or PLD and calcium signaling in murine mast cells. 
 
PDMC derived from WT or CD200R -/- C57BL/6 mice sensitized with murine 
anti-DNP IgE (0.5 µg/ml) were stimulated with DNP (0.5 µg/ml) to induce FcεRI 
cross-linking (XL), LPS (0.5 µg/ml) or PMA (1 µM) plus Ionomycin (1 µM) for 24 h 
(A) or 30 min (B) at 37oC. IL-13 release in culture supernatants was analysed by 
ELISA (A). Degranulation was determined as the % β-hexosaminidase released 
relative to the total activity of the cells (B). PDMC treated overnight with 
murine anti-DNP IgE (0.5 µg/ml) and 5 µCi [3H] Palmitate (C, D) were incubated 
with 1% ethanol for 20 mins at 37oC then stimulated with DNP (0.5 µg/ml) to 
induce cross-linking (XL) or LPS (0.5 µg/ml) for the indicated time course. 
Results represent the level of [3H]PtdEtOH expressed as a percentage of the 
total [3H] palmitate incorporated into cells. PtdEtOH was resolved by TLC 
relative to standards (C) then baseline adjusted for each timepoint (D). Results 
from a single experiment (A-D). Error bars represent SD. Statistical analysis 
using one-way ANOVA with Tukey’s multiple comparison test. **** p< 0.0001. 
Fura-2/AM loaded, murine anti-DNP IgE (0.5 µg/ml) sensitized WT or CD200R -
/- PDMC were stimulated at 50s with DNP (0.5 µg/ml) to induce cross-linking 
(XL) of FcεRI (E) or 0.5 µg/ml LPS (F). Intracellular calcium mobilisation and 
influx were recorded in real-time using excitation-emission ratios of 340/380 
nm. For intracellular mobilisation alone, the cells were stimulated in calcium-
free buffer supplemented with 100 µM EGTA to remove all extracellular 
calcium (-Ca2+).  Calcium levels were calculated from Rmax and Rmin values 
and the data presented as the mean calcium values of triplicate samples 
(baseline calcium values subtracted) from a single experiment representative 
of at 2 independent experiments. Error bars represent SD.  
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Table 3.2 Murine mast cell characterisation. 
 
A summary of mast cell subtype generation and responses to FcεRI crosslinking 
and LPS treatment. 
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Table 3.3 ES-62 modulation of murine mast cell responses. 
 
A summary of functional response modulation in mast cell subtypes by ES-62 
treatment.  
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4 IL-33 signaling in murine mast cells and the 
involvement of IgE sensitization. 
4.1 Introduction 
Recently identified as the ligand for the orphan receptor ST2, the cytokine IL-
33 is a member of the IL-1 superfamily, alongside IL-1α, IL-1β and IL-18 [220]. 
Despite its relatively recent emergence, IL-33 is recognised as being involved 
in many diseases including allergy, cardiovascular disease and rheumatoid 
arthritis, where it generally plays a proinflammatory role [221, 222].  
 
 
4.1.1 Production of IL-33 
IL-33 is produced by a wide variety of cells. Thus, in mice, IL-33 (mRNA) is 
detected in resting DC, resting and activated macrophages [223] as well as in 
epithelial cells of the stomach, lung, gastrointestinal tract, skin and in the 
spinal cord and brain [220]. Lower quantities are found in lymphoid tissue, 
spleen, pancreas, kidney and heart [220, 224]. Similarly, in humans, IL-33 
mRNA expression has been recorded in smooth muscle cells, endothelial and 
epithelial cells, activated dermal fibroblasts and keratinocytes with lower 
quantities in activated DC and macrophages [220]. Although IL-33 mRNA is 
expressed by many cells, the processing and secretion mechanism(s) required 
to generate the bioactive cytokine have still not been defined.  Initially it 
was speculated [225, 226] that caspase 1[220], caspase 8 and calpain [227] 
mediated the appropriate cleavage of IL-33, in a similar manner to their 
processing of other IL-1 family members. However, although IL-33 can be 
cleaved by caspase 1 in vitro [220], recent studies using knockout mice and 
caspase inhibitors indicate that the processing and release of IL-33 are 
independent of caspases, which rather inactivate IL-33 and prevent its 
signaling via ST2 [223, 224]. Indeed, the full-length form of IL-33 has now 
been confirmed to exhibit biological activity [228-231]. Interestingly, 
therefore, although cleavage by caspases and calpain inactivate IL-33, 
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processing at different sites by neutrophil-derived proteases such as 
cathepsin G or elastase, has been demonstrated to increase IL-33-mediated 
ST2 activation.  
 
IL-33 is found in high levels in conditioned medium from necrotic structural, 
but not haematopoietic, cells [232]; this led to the proposal that IL-33 was 
released from necrotic or damaged cells as an “alarmin”, a warning that 
barriers had been breached and that an inflammatory response is required. 
Full length IL-33 appears to be localised and stored within the nucleus, from 
where it can be released after necrosis and cell damage [224]. Recently, 
however, the release of IL-33 from fibroblasts has been associated with 
mechanical stress rather than necrosis, indicating that living cells can also 
secrete IL-33: this mechanism involves export via nuclear pore complexes and 
trafficking through the cytoplasm in vesicles prior to being released from a 
viable cell [233] and appears to be preceded by signaling to increase calcium 
mobilisation.  
 
 
4.1.2 IL-33 and Disease 
IL-33 interacts with many cells of the immune system, including Th2 cells, 
eosinophils, basophils, DCs, macrophages, NK cells and mast cells [64, 234] 
but due to the nature of its release from damaged cells, IL-33 can initiate 
proinflammatory responses, inducing cytokine release from innate cells such 
as MC, which express ST2, as evidenced by this response being dramatically 
reduced in ST2-/- mice [232]. Consistent with this, in mucosal inflammation, 
IL-33 plays a dominant role in the initial response prior to the involvement of 
the adaptive immune response [235].  
 
Thus, in situations where epithelial barriers are breached by pathogens, the 
release of IL-33 from damaged cells may be one of the first signals in 
mobilisation of immune responses. Indeed, IL-33 release from damaged 
epithelia is involved in the clearance of parasites, including helminths, as 
such IL-33 can act on nuocytes [236] and mast cells to induce the production 
of IL-13, crucial for activating smooth muscle hypercontractability and mucus 
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production from goblet cells allowing physical expulsion of the parasite [237]. 
This role is seen with Trichuris muris where IL-33 administration in a model 
of the intestinal parasite infection induces worm expulsion and prevents a 
Th1 response, reducing pathology [238]. In a non-mucosal setting, IL-33-ST2 
signaling has also been shown to be important for protection against 
Toxoplasma gondii-induced encephalitis [239].  
 
Although IL-33 function can be beneficial to the host in parasite responses, 
the enrichment of IL-33 at epithelial surfaces can exacerbate pathology at 
these sites as evidenced by increased eosinophil recruitment and induction of 
IL-13 (mRNA) that promotes remodelling of the epithelium and development 
of cutaneous fibrosis following subcutaneous administration of IL-33 [240]. 
Consistent with this, levels of IL-33 are found to be increased in human 
psoriatic plaques and administration of IL-33 induces skin lesions in murine 
models, and these are characterised by the presence of mast cells, 
neutrophils and increase serum levels of IL-5, IL-13, SCF and MCP-1 [241]. 
Moreover, in terms of lung pathology, in vivo administration of IL-33 to 
C57BL/6 mice induced eosinophilia, IgE and IgA accumulation, epithelial 
hyperplasia and mucus hypersecretion [220] and reflected the well 
documented role of IL-33 in a variety of different experimental models of 
asthma, allergy and lung inflammation [64, 220, 221, 242-252]. Interestingly, 
therefore, IL-33 has also been implicated in the initiation and development of 
autoimmune disease where it has been reported to exacerbate pathology in 
models of arthritis, ulcerative colitis, Crohns disease and SLE [61, 64, 234, 
253-255]. 
 
As indicated by its role in parasite expulsion, expression of IL-33 can also be 
protective and this has recently been seen in inflammatory disease, where its 
ability to reduce adipose tissue development and tissue inflammation 
demonstrated a cardio-protective function of IL-33 in atherosclerosis. 
Similarly the fatal hyper-activation of the immune response associated with 
sepsis is reduced by IL-33 [64, 234, 253]. Relating to this latter effect in 
sepsis, IL-33 has been shown to be protective with respect to infection with a 
range of diverse pathogens [256-258] and consistent with this, ST2 -/- mice 
are more susceptible to polymicrobial sepsis via reduced bactericidal activity 
of macrophages and neutrophils [259, 260]. 
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4.1.3 IL-33 and Mast cells 
Mouse mast cells express ST2 [220, 261-263] at higher levels than other 
leukocytes [261]. ST2 is expressed on mouse mast cells throughout 
development from the earliest stages and preceding FcεRI expression [6]: 
however, it is thought that ST2 signaling is unlikely to be involved in 
transducing differentiation of mast cells, rather it most likely has a role in 
enhancing survival and modulating function [261]. By contrast, in humans, 
ST2 does not appear to be expressed on mast cells throughout their 
development [62].  
 
There are several potential splice variants of ST2, including membrane bound 
and soluble forms (sST2): normally, mast cells express ST2 at their surface 
but upon stimulation with calcium ionophore, to mimic IgE crosslinking, 
production is switched to the soluble form [42, 262, 264, 265]. Soluble ST2 
acts as an antagonist decoy receptor by preventing IL-33-mediated ligation of 
surface ST2 [266] and hence this process is proposed to limit mast cell 
activation via a negative-feedback loop mechanism. In contrast, when mast 
cells are stimulated with IL-33, surface expression of ST2 is upregulated 
[267], creating a positive feedback loop to amplify the signal and thus the 
response. 
 
There is increasing evidence that IL-33 activates mast cells with reports of 
induction of IL-6, IL-13, IL-1β, GM-CSF, MCP-1 and MIP1α release from BMMC 
[42] in the absence of IgE sensitization and degranulation [42, 61, 62, 268]. 
IL-33 is also able to induce MCP6 release, the murine homologue of tryptase, 
an important mediator in many mast cell processes [269]. These responses 
promote inflammation by inducing leukocyte infiltration and activation [61]. 
Interestingly, IgE sensitization appears to enhance IL-33-mediated survival 
[62], eicosanoid and cytokine production of human mast cells, perhaps 
reflecting that IgE sensitization increases ST2 expression[268]. However, as 
with murine mast cells treated with IL-33 in vitro [42, 60, 268] or in vivo 
[155], no degranulation has been observed in human mast cells treated with 
IL-33 [62].  
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4.1.3.1 IL-33 signaling in mast cells 
IL-33 mediates its effects by binding to, and signaling through the receptor 
ST2 [220]. Initiation of signaling after IL-33 ligation of ST2 is dependent on 
the recruitment of IL-1RAcP [267, 270-272] which forms a complex with ST2 
via their TIR domains [272], allowing signal propagation from the plasma 
membrane (Figure 4.1). The importance of this coreceptor is seen in vivo 
when the effects of IL-33 on cytokine expression are reduced by the 
expression of a dominant negative form of IL-1RAcP. Recently in human and 
mouse mast cells, ST2 has also been found to associate with cKIT, the SCF 
receptor, and it has been proposed that IL-1RAcP and cKIT are constitutively 
associated and complex with ST2 after its ligation by IL-33 [273]. Although 
the forming of this complex is not essential for IL-33 to induce a reaction 
from mast cells, it allows a full response. In this way IL-33 can synergize with 
SCF to amplify chemokine and cytokine production and perhaps increase 
survival [261, 273, 274].  
 
In vitro studies using BMMC demonstrated that MyD88 is essential for IL-33 
signaling [268] and results in coupling, via IRAK1 and IRAK4 and TRAF6/TAK1, 
to the subsequent activation of NFκB and ERK, JNK and p38 MAPKs [60, 220, 
273] (Figure 4.1). Similarly, it has been reported that, in human mast cells, 
IL-33 activates ERK, JNK and p38 MAPKs as well as protein kinase B (PKB) and 
NFκB [62, 273, 274].  
 
 
4.1.4 IL-33 and IgE sensitization  
It has been reported that although MC can be directly activated by IL-33, 
such responses are enhanced by sensitization with IgE [42, 61, 62, 268].  
 
Classical FcεRI-mediated activation of mast cells involves antigen-mediated 
crosslinking of IgE-bound FcεRI, resulting in receptor aggregation and 
initiation of signaling cascades, required for production of cytokines and 
eicosanoids, as well as degranulation [156]. The initial binding of IgE to FcεRI 
has traditionally been thought to be a “silent” interaction with no 
biochemical outcome for the MC. This idea has been increasingly challenged 
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by data suggesting that the interaction between IgE and its receptor increase 
development and survival of mast cells as well as triggering induction of 
cytokine production in the absence of receptor crosslinking [275-278].  
 
The precise mechanism of this IgE-mediated activation, which appears to 
involve components of classical FcεRI signaling such as Lyn and Syk [279], is 
unclear with three potential mechanisms described; (1), FcεRI signaling after 
ligation by IgE; (2), low levels of FcεRI aggregation within the membrane 
triggered by binding of IgE initiates signaling [17, 277]; (3) signaling by an as 
yet undefined receptor that binds IgE, either via the Fab portion of IgE or a 
non-specific interaction [276]. The low-affinity IgE receptor FcεRII (or CD23) 
is not expressed in BMMC [164]. Interestingly, therefore, whilst treatment of 
BMMC with monomeric IgE stimulates production of IL-4, IL-13, IL-6 and TNFα 
mRNA, this induction is not mirrored by cytokine secretion [277], suggesting 
that IgE may prime mast cells but that antigen-induced crosslinking is 
required to provide signals for release of mediators from the cell. Relating to 
this, In vivo experiments demonstrated IgE binding to FcεRI increases IL-6, 
MCP-1 and IL-1β mRNA [171], irrespective of the specificity of the IgE. It has 
been proposed [171] that this low level of IgE sensitization is crucial for 
normal immune function by priming mast cells for the subsequent antigen 
response, with repeated low level sensitizations such as in allergic responses 
or parasite infections perhaps further altering the subsequent MC response.  
 
 
4.2 Aims 
To investigate the role of IgE sensitization in IL-33-ST2 responses in murine 
mast cells 
To identify further potential key signaling components, including PLD and 
SphK involved in IgE sensitization and priming of mast cells as well as their 
potential roles in FcεRI- and ST2-mediated activation of murine mast cells. 
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4.3 Results and Discussion 
4.3.1 Murine mast cells respond to IL-33 to produce cytokine; 
signaling is ST2-dependent and increased by IgE 
sensitization. 
It has been widely demonstrated that mast cells express ST2; PDMC, BMMC 
and CTMC all demonstrate ST2 expression as shown earlier (Figure 3.1) with 
PDMC exhibiting the greatest expression, perhaps reflecting their increased 
maturation. Consistent with their expression of ST2, all subtypes 
demonstrated a dose-dependent increase in cytokine production, either IL-6 
or MCP-1, in response to IL-33 treatment that plateaus at 50-100 ng/ml 
(Figure 4.2). This response is dependent on ST2 expression as IL-33-
stimulated cytokine production is abrogated in both ST2 -/- PDMC (Figure 4.3 
A) and BMMC (Figure 4.3 B), findings expected as no other receptor has been 
identified for IL-33 [220, 267].  
 
 
4.3.1.1 Sensitization affects IL-33-induced cytokine production. 
The cytokine responses reported above were assayed from mast cells 
sensitized with IgE to reflect the physiologically relevant state of mast cell 
activity. To determine whether IgE sensitisation modulates the functional 
responses of IL-33 signaling, the effects of such priming on IL-33-mediated 
degranulation and cytokine production were investigated.  
 
Although IL-33 is able to induce cytokine production in the absence of IgE 
sensitization, sensitization increases this production, particularly at higher 
concentrations of IL-33. For example, for IL-33 at 100 ng/ml (Figure 4.4 B), 
the addition of IgE significantly increases IL-6 and IL-13 production after IL-33 
stimulation compared to that from non-sensitized cells.  
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4.3.1.2 Sensitization does not license IL-33-induced degranulation. 
As different phenotypes of mast cells exhibit differential degranulation 
responses (Chapter 3), both PDMC (Figure 4.5 A, C) and BMMC (Figure 4.5 B, 
D) were analysed for their ability to degranulate in response to IL-33, with. 
PMA/Ionomycin treatment used as a positive control as it induces strong 
degranulation responses and is not affected by pre-treatment with IgE. As 
expected sensitization is essential for degranulation triggered by FcεRI-XL, 
however in both murine mast cell phenotypes IL-33 does not induce any 
discernible β-hexosaminidase release regardless of cell type or priming by IgE 
(Figure 4.5 A-D).  
 
In order to confirm these data, an alternative method of quantifying 
degranulation based on the Lamp1 expression method developed for CD8+ T-
cells [162] was adapted for mast cells. The method is described previously 
(2.9.2). Graphic representation of GMFI analysis of the right peak, 
demonstrates that as expected, PMA/Ionomycin and XL induce increased 
surface Lamp1 expression, and thus degranulation.  
 
As IL-33-induced degranulation could not be recorded using β-hexosaminidase 
release (Figure 4.5 A-D), this more sensitive method was employed for all 3 
subtypes of murine mast cells.  PDMC (Figure 4.5 E), BMMC (Figure 4.5 F) and 
CTMC (Figure 4.5 G) all exhibit a strong response to PMA/Ionomycin and 
measureable responses to XL. Interestingly in the BMMC and CTMC there also 
is a low level of LPS-induced degranulation. Although this was not statistically 
significance, it could indicate LPS induces exocytosis in mast cells at a level 
not previously detected by the conventional method of β-hexosaminidase 
release. Alternatively LPS could stimulate exocytosis of vesicles that do not 
contain β-hexosaminidase but are labelled by Lamp1. However, even using 
this technique there is again no evidence for any exocytotic response induced 
by IL-33 with no change in % cells expressing Lamp1 (not shown) or the GMFI. 
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4.3.1.3 IgE sensitization increases ST2 expression 
Interestingly, it was found that whilst IgE sensitization does not modulate 
expression of CD117 (Figure 4.6 A) or TLR4 (Figure 4.6 E), and decreases that 
of FcεRI (Figure 4.6 B), it slightly increases the surface expression of ST2 by 
PDMC (Figure 4.6 D). Using geometric mean fluorescence intensity (GMFI) 
there is an average increase in ST2 expression of 18% after sensitization and 
an apparent reduction of 35% of FcεRI expression (Figure 4.6 F). The effect on 
cytokine production in sensitized MC at the higher concentration of IL-33 
(Figure 4.4) may reflect that IgE-mediated upregulation of ST2 allows a 
higher signal strength response at high concentrations of IL-33. 
 
Such downregulation of FcεRI expression by IgE is controversial as some 
groups have reported that exposure to monomeric IgE may increase FcεRI 
expression [275] whilst others note that rather than upregulating FcεRI, IgE 
stabilises its expression on the surface [280].  It is therefore important to 
note that FACS analysis of FcεRI expression on sensitized cells should be 
approached with caution as the antibody used interacts with the α-subunit of 
the receptor, the IgE-binding subunit lacking signal-transducing ability, and 
hence the apparent downregulation observed here could be due to the 
reduced availability of binding sites for the anti-FcεRI antibody caused by the 
binding of IgE to FcεRI during sensitization. To further explore the effects of 
sensitization on these mast cell receptors, their expression over a 42 h period 
of sensitisation was analysed. This revealed that by 42 h, the increase in ST2 
appears to resolve and its surface expression returns to that of non-sensitized 
cells (Figure 4.7 A). By contrast, FcεRI expression is progressively reduced 
with sensitization (Figure 4.7 B) whereas expression of CD117 is increased 
after 42 h of sensitization (Figure 4.7 C). 
 
As the upregulation of ST2 is rapid and reversible, this could potentially 
reflect recycling from internal stores, a suggestion supported by the finding 
that the total cellular pool of ST2 expression is greater than that on the 
surface (Figure 4.7 D). Thus, ST2 signaling may involve a cycling trafficking 
mechanism similar to that reported for TLR4 in macrophages and DCs [281, 
282] to ensure sustained signaling. Perhaps surprisingly, the profiles of TLR4 
expression did not mirror that of ST2 as the total expression of TLR4 
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appeared to be similar to that on the surface of mast cells (Figure 4.7 E). 
However, this may reflect reports that TLR4 appears to only signal via the 
MyD88 pathway in mast cells and so may not undergo internalisation of TLR4 
after LPS signaling, as required during TRIF-dependent, MyD88-independent 
TLR4 signaling [28, 48, 51, 283]. 
 
 
4.3.2  IL-33 signaling involves mobilisation of calcium in 
murine mast cells. 
 
4.3.2.1 IL-33 induced calcium mobilisation in murine mast cells requires 
IgE sensitization, extracellular calcium and ST2 expression. 
Mast cells in tissues are primed by binding of IgE and this sensitization is 
essential for mast cell activation via cross-linking of FcεRI (XL). However, 
mast cells respond to a wide range of stimuli including LPS and IL-33 and the 
effect of sensitization on these other methods of mast cell activation is not 
well defined. It is widely established that Ca2+ mobilisation is crucial to 
normal mast cell responses to crosslinking of FcεRI (Figure 1.5) and indeed, 
the importance of sensitization in the activation of MC by XL, LPS and IL-33 is 
seen in Figure 4.8 A. IL-33, like LPS, induces a slow calcium mobilisation that 
is almost entirely dependent on prior IgE sensitisation of PDMC. As this low 
profile of calcium mobilisation was suggestive of calcium influx, the role of 
extracellular calcium on the responses induced by IL-33 was investigated by 
repeating the experiments using buffer depleted in Ca2+. This resulted in an 
initial small peak in intracellular calcium mobilisation resulting from release 
from internal stores followed by a return to basal levels due to the lack of 
extracellular calcium (Figure 4.8 B). PDMC (Figure 4.8 C) and BMMC (Figure 
4.8 D) derived from ST2 -/- mice exhibited significantly reduced calcium 
responses after IL-33 treatment. As with previous experiments with other 
stimuli, including LPS and FcεRI crosslinking (Figure 3.9), IL-33-stimulated 
PDMC again displayed reduced calcium responses when compared to those of 
BMMC.  
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4.3.3 IL-33-mediated activation of NFκB and ERK requires IgE 
sensitization and ST2 expression. 
As sensitization is crucial for XL and IL-33-mediated activation of calcium 
signaling, it was important to determine if these effects were maintained 
downstream with the activation of ERK and NFκB, as determined by Western 
Blotting analysis of dual phosphorylation of ERK and degradation of IκBα 
respectively (2.10). After the addition of the cross-linking agent DNP to mast 
cells in the absence of prior IgE sensitization, NFκB is not activated as 
determined by the maintenance and even increase in IκBα expression (Figure 
4.9 A). By contrast, when cells are sensitised with IgE over night prior to DNP 
addition, FcεRI is crosslinked (XL) and IκBα expression is decreased and 
maintained at lower levels. Interestingly, given the calcium data, in the 
absence of sensitization IL-33 stimulates a rapid degradation of IκBα at 20 
min that returns almost to basal levels by 30 min (Figure 4.9 B). When the 
cells are sensitized prior to IL-33 stimulation expression of IκB does not 
return towards basal levels until about 60 min, an effect dependent on ST2 
expression (Figure 4.9 C). This lengthened period of reduced IκBα expression 
allows a more prolonged NFκB signal from IL-33. 
 
ERK activation is almost absent in non-sensitized cells after addition of Ag 
(Figure 4.10 A), the slight increase in activity seen at 60 minutes is preserved 
in repeat experiments, presumably reflecting some basal cycling activity or 
alternatively that the Ag (DNP) induced some signaling in the cells 
independently of IgE-sensitisation of FcεRI. However, there is a bi-phasic 
profile of DNP-mediated ERK activation seen in sensitized cells representing 
cyclic activation of ERK in mast cells at 10 and 30 mins. By contrast, but 
reflecting the NFκB data, without IgE sensitization, IL-33 is able to induce 
ERK phosphorylation that peaks at 30 min after which it returns to basal 
levels (Figure 4.10 B). Sensitized mast cell also display a similar peak of ERK 
activation at 30 min, although this is exhibited at a higher signal strength and 
reflects a higher basal ERK phosphorylation. This enhanced basal ERK 
activation suggests that MAPK may be involved in the “priming” process 
occurring during sensitization of mast cells. ERK activation in ST2 -/- MC is 
essentially absent after IL-33 stimulation in BMMC (Figure 4.11 B). The PDMC 
results  (Figure 4.11 A) are puzzling and suggest possible stimulation 
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contamination, indicted by the high ERK phosphorylation at 0 min in ST2 -/-. 
A further IL-33-induced signal is not apparent above this increased basal ERK 
signal, an effect preserved in two experiments. 
 
 
4.3.4 Role of phospholipase D in IL-33 signaling  
PLD-mediated hydrolysis of phosphatidylcholine (PtdCho) produces 
phosphatidic acid (PA) which can be further converted to DAG or 
lysophosphatidic acid (LPA), all products being second messengers important 
in both GPCR and RTK signaling, secretion, trafficking, cytoskeletal 
reorganisation and cell survival [284]. There are two mammalian PtdCho-
specific PLD isoforms identified, which can occur as multiple splice variants 
and require PIP2 for activation [285]. 
 
Phospholipase D signaling has been reported to be crucial for mast cell 
responses to cross-linking of FcεRI [286-288] and has been suggested to play 
an important role in IL-33 signaling [126] potentially upstream of the IL-33-
induced calcium mobilisation reported above (Figure 4.12). 
Traditionally, roles for PLD signaling have been investigated using primary 
alcohols like Butan-1-ol that by trapping PLD-products, block functional 
responses, but this approach does not allow for analysis of individual PLD 
isoforms. However, several biochemical PLD inhibitors have been recently 
developed, including pan PLD, PLD 1 and 2 inhibitors that potentially act by 
an allosteric mechanism rather than by direct interaction with the catalytic 
domain [289, 290]. The pan-PLD inhibitor, 5WO, inhibits both PtdCho-PLD 
isoforms, and whilst the PLD 1 inhibitor, 809, exhibits > 100 fold selectivity 
for this isoform, the PLD 2 inhibitor, APV, is less selective, losing its 
specificity for PLD 2 at higher concentrations (>20 µM) [284]. Since 
performing the experiments in this thesis a more specific PLD 2 has been 
developed [291]. 
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4.3.4.1 PLD inhibition affects murine mast cell viability.  
As PLD is important in many mast cell processes it was important to check 
their toxicity before employing the inhibitors in any experiments. With both 
PDMC (Figure 4.13 A) and BMMC (Figure 4.13 B) the inhibitors showed little 
induction of cell death, as evidenced by the change in 7AAD staining, at 
lower concentrations (1 µM) but by 5 µM, there were obvious increases in cell 
death. Although administration of IL-33 helped to increase the basal level of 
cell survival, it did not rescue cell viability after treatment with any of the 
inhibitors, especially after APV treatment.  
 
4.3.4.2 PLD signaling is involved in mast cell degranulation responses 
Previous studies had reported that PLD activity is essential for the full 
degranulation response to FcεRI crosslinking in mast cells [286-288]. IL-33 
does not induce degranulation in PDMC (Figure 4.5) but the role of PLD in 
FcεRI- and PMA/Ionomycin-stimulated degranulation was investigated.  
Analysis of the dose dependent effects of the inhibitors revealed that in the 
presence of the individual isoform inhibitors FcεRI-mediated degranulation 
(XL) was not significantly different from basal levels up to an inhibitor 
concentration of 5 µM (Figure 4.14 A). The pan-isoform inhibitor was more 
potent, with significant inhibition seen at 1 µM, suggesting that both PLD 
isoforms played a role in such degranulation. 
PMA/Ionomycin potently induces degranulation in mast cells by directly 
activating PKC, an activator of PLD [292, 293]. When pre-treated with the 
PLD 2 Inhibitor and the PLD 1/2 inhibitor at 5µM, degranulation is 
significantly reduced compared to that of control cells but this effect is not 
seen in the presence of PLD 1 inhibition (Figure 4.14 B). As the inhibitors 
appeared to slightly increase basal levels of degranulation, the data are also 
presented as the “stimulated” degranulation values corrected for their 
respective basals (Figure 4.14 C).  These data suggest that PLD 1 does not 
play a role in the regulation of degranulation in PMA/Ionomycin treated mast 
cells, an interesting finding as PLD 1 has been reported to be activated by 
PMA in fibroblast-like cell lines [292, 293].  
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4.3.4.3 PLD signaling is involved in mast cell cytokine responses 
The cytokine response induced by FcεRI-XL in IgE sensitized mast cells is 
strongly inhibited by both of the individual PLD isoform inhibitors, again 
indicating a role for both PLD 1 and PLD 2 signaling in XL responses (Figure 
4.16 A). In non-sensitized cells (PBS) PLD inhibition also reduced basal 
cytokine levels. Although IL-33 does not induce degranulation, it stimulates 
cytokine production that is augmented by prior IgE sensitisation of mast cells. 
The role of PLD in such enhancement was thus analysed (Figure 4.16 B).  IL-
13 production from both IgE sensitized and non-sensitized MC treated with IL-
33 and potently inhibited by pan-PLD and PLD 2-specific inhibitors whereas 
PLD 1 inhibition produces a plateau response that preserves some IL-13 
production. 
Further investigation of the role of PLD in IL-33-stimulated cytokine 
production by IgE-sensitised mast cells was then performed to determine 
whether it applied to both PDMC MCP-1 and IL-13 production (Figure 4.17 A) 
and BMMC MCP-1 and IL-6 production (Figure 4.17 B). Low levels of MCP-1 are 
produced constitutively by sensitised mast cells and inhibition of PLD 1 or PLD 
2 reduces such basal cytokine production by both PDMC and BMMC. Whilst 
inhibition of PLD 1 (809) only partially reduces IL-33-induced MCP-1 
production by PDMC and BMMC, release of this chemokine is essentially 
completely abrogated by the inhibitor of the PLD 2 isoform (APV) in both cell 
types and by the pan-PLD inhibitor in BMMC. A similar pattern is observed 
with IL-13 production by PDMC and IL-6 release by BMMC and suggests that 
PLD 2 is indispensible for IL-33-induced cytokine production in mast cells 
whereas PLD 1 plays a role but may be redundant to PLD 2.  
 
 
4.3.4.4 PLD inhibition suppresses calcium mobilisation in murine mast 
cells. 
FcεRI-XL-mediated degranulation and FcεRI-XL- and IL-33-induced cytokine 
production are both modulated by inhibition of PLD (Figure 2.12). It was 
therefore investigated whether this reflected suppression of calcium signaling 
as this has been shown to be key to both functional responses. Indeed, PLD-
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mediated activation of degranulation has been proposed to involve calcium 
signaling, either via PA- and DAG-mediated PKC or PA-mediated SphK 
activation [286-288]. 
 
All three PLD inhibitors were found to be effective in reducing calcium 
mobilisation resulting from FcεRI crosslinking (Figure 4.18 A) and IL-33 
stimulation (Figure 4.18 B), when used at 5 µM to ensure inhibition of PLD 
activity.  Rather surprisingly, given the above cytokine responses, the PLD 2 
inhibitor appeared to be least effective in modulating IL-33-mediated calcium 
mobilisation, albeit there was no significant difference between the three 
inhibitors. This modulation appeared to reflect suppression of intracellular 
calcium release rather than influx of extracellular calcium as the second 
slower phase of calcium movement appeared still to be present. This was 
further investigated by performing the experiments with FcεR1-XL in the 
absence of extracellular calcium and EGTA to prevent the calcium influx 
phase and this revealed that indeed the PLD inhibitors were targeting the 
intracellular mobilisation phase (Figure 4.18 C). 
 
As mentioned before, PLD 2 inhibition by APV needs to be interpreted with 
caution especially at higher concentrations where it loses selectivity. 
Moreover, calcium movement is very sensitive to environmental influences 
such as inhibitors [161] thus to further explore the role of PLD 2-specific 
responses, inhibitor dose response experiments were performed. Using 
decreasing doses of APV (Figure 4.18 A), there is still inhibition of calcium 
mobilisation in response to FcεRI-XL evident even at a dose of 0.5 µM (Figure 
4.18 D), 10X less than the initial dose and at concentrations where no effect 
is detected in terms of degranulation. These dose effects were similarly 
reflected in the analysis of FcεRI-mediated calcium mobilisation in the 
absence of extracellular calcium (Figure 4.18 E). Collectively, therefore, 
these data suggest that APV is targeting PLD 2 and hence PLD 1 and PLD 2 
both appear to play important but, as no further inhibition is obtained with 
the pan-PLD inhibitor, possibly redundant roles in FcεRI- and IL-33-stimulated 
calcium mobilisation.  
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4.3.4.5 PLD inhibition modulates FcεRI- and IL-33-stimulated NFκB and 
ERK activation.  
As the PLD 1 and PLD 2 inhibitors inhibited calcium mobilisation, cytokine 
production and degranulation, their effect on signals potentially downstream 
of calcium mobilisation, namely ERK and NFκB activation were analysed by 
Western blotting.  
 
The activation of NFκB, as evidenced by a decrease in IκB expression, was 
determined after FcεRI-cross-linking (XL) and as expected, this revealed a 
time-dependent decrease in IκB expression over 60 min to a level lower than 
that in unstimulated cells (Figure 4.19). However, in cells treated with the 
pan-PLD (1/2) inhibitor, IκBα expression was not decreased but rather, since 
exposure to the inhibitor alone appeared to visually slightly decrease IκB 
expression relative to that observed in control cells, was if anything slightly 
increased, suggesting that blocking PLD activation not only prevented NF-κB 
activation but that the feedback mechanisms that regulate such responses 
resulted in an increase of IκBα levels to above basal levels. Interestingly 
therefore, inhibition of PLD 1 had no apparent effect on such NF-KB 
activation whilst inhibition of PLD 2 resulted in similar modulation to that 
observed with the pan-PLD inhibitor, suggesting that PLD 2 may be important 
for efficient NF-κB activation.  
 
By contrast, when similar experiments were performed using IL-33 as a 
stimulus, the overall results were quite different (Figure 4.20). Thus, IL-33 
stimulates the transient degradation of IκB within the first 20 min, before 
expression of IκB recovers towards basal levels by 60 min. Whilst the pan-PLD 
inhibitor appeared to have no effect, when the cells are stimulated with IL-33 
in the presence of the PLD 1 inhibitor, there appears to a reproducible 
faster/stronger recovery of IκB levels whilst inhibition of PLD 2 appeared to 
antagonise the recovery of IκB levels. Collectively, these data suggested that 
PLD 1 and PLD 2 could counter-regulate IL-33 mediated NF-κB activation, 
with PLD 2 acting to terminate signaling. Moreover, whereas for FcεRI-
signaling the pan-PLD and PLD 2 inhibitors appeared to target the activation 
phase with both inhibitors preventing degradation of IκB, for IL-33, PLD 
activation was associated with regulation of maintenance of NF-κB activation 
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as whilst neither of the PLD 1 or PLD 2 inhibitors modulated the initial 
degradation phase, they promoted or antagonised the subsequent up-
regulatory, negative feedback phase, respectively.  
 
FcεRI-mediated activation of p42 and p44 ERK follows a biphasic pattern with 
peaks at 10 and 30 min post stimulation, with both isoforms being activated 
to a similar degree. In the presence of the pan-PLD inhibitor such activation, 
although still biphasic, was reduced after the initial peak at 10 min. Rather 
surprisingly therefore, exposure to the selective PLD 1 and PLD 2 Inhibitors 
essentially suppressed all ERK activation from 20 min post stimulation (Figure 
4.21 A). Interestingly pre-treatment with the selective inhibitors, particularly 
that targeting PLD 2, increased basal levels of pERK and this may impact on 
the cell in terms of a “stimulation index”-type of sensing of responses and is 
also reflected by an increase in the first peak of ERK activation, particularly 
by the PLD 1 inhibitor.  As inhibition of either of the individual PLD isoforms 
completely ablates the second peak of phosphorylation, it implies not only 
that PLD activity is required for this signal but also that a distinct, PLD-
independent pathway is required for the initial phase of ERK activation. 
 
ERK activation by IL-33 differs considerably from that induced by FcεRI-XL, 
with a slower, weaker monophasic response peaking at 30 min and activation 
predominantly representing the p42 isoform. Inhibition of the individual PLD 
isoforms again increases the basal levels of dually phosphorylated ERK, again 
indicating a role for PLD in regulating basal ERK activity. However, in the 
case of IL-33 inhibition of either PLD 1 or PLD 2 results in enhancement of 
both the duration and extent of ERK activation; in particular, especially 
following inhibition of PLD 2, an early phase of ERK activation is revealed and 
this could perhaps reflect relief of suppression of early PLD-independent peak 
observed following stimulation via FcεRI, which was also observed to be 
increased in the presence of PLD inhibitors (Figure 4.21 B).  
 
 
4.3.4.6 Analysis of PLD activity in murine mast cells. 
To validate the role of PLD in the above mast cell processes, PLD activity was 
directly quantified by the transphosphatidylation assay. Such analysis showed 
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that whilst no PMA or FcεRI-mediated accumulation of PtdEtOH could be 
detected within 10 min of stimulation, significant levels were detected for 
both stimuli within 60 min relative to the basal levels in IgE-sensitised PDMC 
(Figure 4.22 A). As expected, IgE sensitization was required for FcεRI-
stimulated activity and interestingly, IL-33-stimulated activity (Figure 4.22 
B). Moreover, although the selective PLD inhibitors tended to suppress both 
FcεRI- and PMA-stimulated PLD activities, these could only be blocked 
significantly by the pan PLD inhibitor suggesting that both PLD 1 and PLD 2 
signaling contribute to these responses (Figure 4.22 C). By contrast, and 
rather surprisingly given the effects of PLD inhibitors on IL-33 signaling and 
functional responses, no IL-33-coupled PLD activity could be detected within 
60 min. Indeed, no IL-33-stimulated PLD activation could be detected over a 
period of 18h stimulation (Figure 4.22 D). However, what this analysis clearly 
showed was that there is significantly increased “basal” PLD activity in IgE-
sensitised mast cells over this 18 h period. To determine the source of this 
constitutive activity and to investigate whether this reflected sensitization, 
the ability of IgE-sensitisation to induce PLD activation was determined; this 
revealed that although there was a significant constitutive basal PLD activity, 
this was increased by exposure to IgE with significant effects observed within 
the 18 h sensitisation period. As IL-33 only induced calcium mobilisation in 
IgE-sensitised cells, this would explain the observed PLD-dependence of IL-
33-associated calcium signaling. 
 
In order to determine which isoforms are involved in the basal and IgE-
sensitised responses, the PLD inhibitors were employed at a low 
concentration of 1 µM to prevent any potential loss of specificity by the PLD 2 
inhibitor. Whilst, and consistent with data in the literature, basal PLD activity 
was significantly inhibited by the PLD 2, but not PLD 1, inhibitor, IgE-
sensitised PLD activation was only significantly inhibited by the pan-PLD 
inhibitor suggesting that both PLD 1 and PLD 2 are involved (Figure 4.22 F).  
 
These data strongly imply that sensitization does increase the basal 
homeostatic PLD activity in mast cells and confers the PLD-sensitivity of IL-33 
responses in mast cells. By contrast, although sensitisation contributes to the 
overall FcεRI-mediated PLD response, comparison of the “sensitised” and 
“sensitised and XL” FcεRI-mediated responses with those occurring in the 
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absence of IgE show a substantial additional component resulting from XL 
that is more sensitive to PLD inhibition, particularly that of PLD 1, than IL-33 
signaling, perhaps reflecting the faster, stronger calcium responses as well 
perhaps as the differential degranulation responses via FcεRI and IL-33 
signaling in murine mast cells.  
 
 
4.3.5 The role of sphingosine kinase in IL-33 signaling.  
Many immunoregulatory receptors including FcR, couple to sphingosine kinase 
(SphK) activation downstream of PLD [126, 294, 295]. Mast cells express both 
sphingosine kinase (SphK) 1 and SphK 2 isoforms, although the relative role of 
each in FcεRI signaling is still under debate as anti-sense studies with RBL 
cells suggested that FcεRI was coupled to SphK1 for degranulation [296] 
whereas analysis of Sphk1, SphK 2 and double knockout models have 
indicated that whilst FcεRI is coupled to both SphK1 and 2, SphK2 is key and 
non-redundant in FcεRI signaling [195, 297]. However recent evidence also 
suggests a crucial role for SphK1 in mast cell-dependent allergic inflammation 
[298]. To determine if SphK activity plays a role in IL-33 signaling in murine 
mast cells, a series of experiments were performed using the SphK inhibitors 
DMS and 5c. DMS is isoform non-selective inhibitor of SphK that has also been 
reported to inhibit PKC activation [299], while 5c has been reported to 
selectively target SphK1 [300]. Consistent with a role for one or more SphK 
activities in IL-33 functional responses, in IgE-sensitised PDMC (Figure 4.23 C) 
and BMMC (Figure 4.23 D), increasing concentrations of DMS inhibit cytokine 
production. However, at 25 µM DMS, where there is essentially no cytokine 
production observed, this most likely reflects the loss of cell viability in both 
PDMC (Figure 4.23 A) and BMMC (Figure 4.23 B). Nevertheless, in PDMC there 
is substantial inhibition of cytokine production at 10 µM DMS, a concentration 
that is not toxic to the cells.  
 
As SphK activity has been reported to regulate calcium signaling (Figure 3.8), 
it was important to determine if inhibition would affect calcium mobilisation 
and hence place SphK upstream of this important signal. Consistent with 
previous published data, DMS (10 µM) was able to significantly inhibit calcium 
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mobilisation induced by FcεRI cross-linking (XL), (Figure 4.23 E), apparently 
by modulating both mobilisation of intracellular stores and influx of 
extracellular calcium. Similarly, calcium mobilisation following stimulation 
with LPS is reduced by inhibition of SphK (Figure 4.23 F) but analysis in 
calcium-free buffer suggests that for this stimulus, this predominantly 
reflects inhibition of influx, consistent with the results reported above 
suggesting LPS stimulates little or no mobilisation of intracellular calcium 
(Chapter 3). Interestingly therefore, DMS-induced inhibition of IL-33-induced 
calcium mobilisation (Figure 4.23 G) mimics the IL-33 signal observed when 
extracellular calcium is absent and only intracellular calcium movement 
occurs. This suggests an alternative mechanism of mobilising intracellular 
calcium during IL-33 signaling compared to FcεRI-XL whereas, and as 
observed for LPS, DMS prevents influx of extracellular calcium influx.   
 
To explore this further, the effect of the selective SphK1 isoform inhibitor, 5c  
was examined. This inhibitor does not substantially increase cell death of 
either PDMC (Figure 4.24 A) or BMMC (Figure 4.24 B), allowing use of a high 
concentration (30 µM) to ensure inhibition of SphK1. Consistent with what has 
previously been reported, the calcium response induced by crosslinking FcεRI 
(XL) is weakly but significantly reduced by 5c (Figure 4.24 C) and it appears 
that this effect is due to a reduction in intracellular store mobilisation. By 
contrast, the SphK1 inhibitor has no effect on the calcium profile after IL-33 
stimulation (Figure 4.24 D) perhaps indicating that SphK2 is the more 
dominant isoform in IL-33 signaling and consistent with previous reports that 
this isoform is important for extracellular influx [195]. 
 
Consistent with the above findings, 5c generally only weakly inhibits IL-33-
stimulated cytokine production by PDMC (Figure 4.24 E) and BMMC (Figure 
4.24 F), although MCP-1 production in PDMC is reduced almost to the (high) 
basal levels observed in these cells, perhaps reflecting the poor ability of 
these cells to release this chemokine in response to receptor stimulation and 
also suggesting that the distinct cytokine responses to IL-33 may be 
differentially regulated. Basal cytokine production appears mainly 
unaffected. Collectively, these findings indicate that Sphk1 activation is 
unlikely to be critical for IL-33-stimulated cytokine production, although the 
DMS data may implicate an important role for SphK 2 in these responses.  
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To validate these studies, the activity of SphK was directly determined in cell 
lysates from FcεRI- or IL-33-stimulated cells. Following FcεRI-XL, there is an 
initial slight increase in SphK activity at 30 seconds followed by a sharp 
decrease to levels below that of basal (Figure 4.25 A). By contrast, in 
response to IL-33 stimulation, SphK activity steadily increases over time 
(Figure 4.25 B), again reflecting the slow and steady signaling induced by IL-
33 compared to XL. As with previous signaling studies the mast cells were 
sensitized and although this may have modulated basal levels of SphK, as 
seen with PLD, this was not quantified. SphK produces S1P, an important 
second messenger in cell signaling. S1P may act both intracellularly and 
extracellularly in mast cells either directly as a second messenger in signal 
transduction and calcium mobilisation or by interaction with cell surface 
receptors S1P1 and S1P2. [301-303]. To corroborate the SphK data, it was 
important to determine the levels of S1P produced after IL-33 stimulation of 
mast cells. Using conditioned medium and cell lysates of IL-33-treated PDMC 
as sources of extracellular and intracellular pools of S1P respectively, the 
production of S1P was quantified by ELISA. Intracellular S1P expression in cell 
lysates (Figure 2.34 C) was found to increase, peaking by 30 min then 
diminishing towards basal levels with kinetics consistent with the SphK assay 
(Figure 4.25 B). Analysis of S1P released from the cell (supernatant) displayed 
faster kinetics, with release maintained throughout the timecourse and were 
reminiscent of those recorded previously after Ag-mediated crosslinking of 
FcεRI in BMMC [304].  
 
Extracellular S1P can act via the receptors, S1P1 and S1P2 to induce 
migration, degranulation and trigger hyper-responsiveness in FcεRI-stimulated 
cells [296, 305] to amplify the responses of mast cells both in vitro (human 
cord blood) and in vivo, the latter in a model of mouse anaphylaxis [195, 
306]. S1P activation of mast cells also plays an important role in an OVA 
model of allergic asthma [298]. To investigate this, the serum and 
broncheoalveolar lavage fluid (BALf) from individual mice treated with PBS or 
OVA plus Alum in a murine model of acute asthma were tested for the 
production of SIP and hence SphK activity during development of asthma 
(Figure 4.25 D) and this revealed that whilst there was an increase in the 
 118 
levels of S1P in the serum, but not the BALf, after the induction of airway 
hyper-responsiveness by OVA and Alum in this model. 
 
 
4.4 Conclusions 
It is well established that sensitisation by IgE is required for signaling via 
FcεRI in mast cells but the results presented here confirm the suggestion 
[171, 277] that this also primes/licenses the cells for full signaling, in this 
case, via IL-33/ST2 and LPS/TLR4. As ST2 is the only one of these receptors 
that is directly upregulated on the surface of mast cells by IgE-sensitisation, 
potentially via trafficking of internal pools, it is likely that these priming 
effects reflect cooperative signaling occurring amongst downstream 
pathways. 
 
Thus, although IL-33 can induce cytokine production by MC, this is enhanced 
by IgE-sensitization that reflects more prolonged NFκB activation and 
increased ERK signaling, potentially resulting from the IgE-mediated licensing 
of the resulting IL-33-stimulated extracellular calcium mobilisation, data 
consistent with previous studies reporting calcium mobilisation during 
sensitization in BMMC and RBL-2H3 cells [277, 278, 307, 308]. Calcium 
mobilisation in response to IgE-FceR1 ligation was not directly analysed, but 
as IgE sensitization appears to increase PLD activity and prime PLD-dependent 
calcium signaling in response to IL-33, PLD appears to be a key priming signal 
associated with IgE-sensitisation as previously reported for FcεRI responses in 
BMMC [308].  
 
Consistent with a key role for PLD signaling in IgE-sensitisation of mast cell 
responses, basal cell viability, proliferation and cytokine production is 
suppressed by inhibitors of PLD. In terms of receptor-signaling, however, the 
role of PLD appears to depend on the stimulus and the cell type. Thus, for 
FcεRI-signaling, both PLD 1 and 2 isoforms are involved in calcium, ERK 
activation and degranulation responses, an effect confirmed by direct 
analysis of PLD activity. Previous reports, investigating the role of PLD in 
degranulation [309], found PLD 1 may be the more dominant isoform in FcεRI 
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signaling [288]. However, recent evidence suggests that PLD 2, previously 
thought to be restricted to basal constitutively active homeostatic role, can 
be stimulated by XL [310, 311]. PLD 2, similar to PLD 1, can be stimulated by 
PKCα and DAG, resulting from increased PIP2 - PLCγ signaling following FcεRI 
crosslinking [285]. Furthermore, KO models and siRNA studies have suggested 
that PLD 2 functions to regulate cell morphology and compartmentalisation of 
the cytosol [312-315], ensuring the correct location and morphology of the 
Golgi complex, secretory granules and lysosomes. Of particular interest to 
this study, it appears that such signals and important for determining FcεRI 
localisation within the cell surface lipid microdomains, crucial for signaling 
[287, 316] and that fusion of mast cell granules with the plasma membrane 
may also be regulated by PLD 2 in a calcium-dependent manner [317].  
 
The relative roles of the PLD isoforms in IL-33-ST2 signaling has been more 
difficult to determine but appears that in MC, PLD 2 is the more important 
activity. Thus, whilst inhibition of either PLD prevented IL-33-induced 
calcium mobilisation, downstream cytokine responses were more reliant on 
PLD 2 activity. This was initially surprising considering it is generally 
considered that PLD 1 is the important isoform in agonist responses, but 
presumably reflects that the PLD-dependence of IL-33 effects is dependent 
on the IgE-licensing of PLD 1 and PLD 2 activity. Furthermore, as it has been 
reported that PLD requires extracellular as well as intracellular calcium for 
full activation [318, 319], it may be that the calcium and PLD assays, 
performed over a shorter time-course in vitro, do not reflect the status of 
these signals elicited by IL-33 in IgE-sensitised mast cells over the 24 h period 
of the cytokine assay.  Nevertheless, as PLD 1 activity is associated with 
vesicular membranes, regulation of translocation and secretion of granules, it 
is more dominant in driving exocytosis/degranulation following FcεRI 
crosslinking [314, 317, 320]. The predominant role of PLD 2 may go some way 
to explaining the absence of degranulation induced by IL-33 as reported here 
and previously [42, 60, 268, 321]. Similarly MC degranulation is dependent on 
intracellular calcium release [190, 202, 203, 322], a response not initiated by 
IL-33. These results suggest a link between PLD 1 activity and calcium release 
from the ER in murine mast cell degranulation. Interestingly as some IL-33-
induced cytokine production was preserved despite PLD inhibition after IgE 
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sensitisation, there is a suggestion that another co-factor, other than IgE, 
may be promoting PLD activity. 
 
Unfortunately due to the crucial role for PLD signaling in a variety of 
homeostatic and protective cell processes, inhibition of PLD is likely to be a 
difficult route for therapeutic intervention. However, PLD-dependent 
regulation of hyper-inflammatory IL-33-mediated mast cell induced by IgE-
sensitization suggests this could be more safely targeted by therapeutics, 
such as omalizumab, which have been designed to prevent inhibit IgE ligation 
to FcεRI [323, 324] and could therefore be exploited to limit IL-33-stimulated 
pathology. 
Previously, it was demonstrated that IL-33 failed to stimulate calcium 
mobilisation in BMMC [60, 321]. These data are confirmed here but are 
extended by the finding that IgE-sensitisation of mast cells licenses IL-33-
mediated calcium mobilisation, predominantly via influx of extracellular 
calcium influx but with some evidence of a low level of mobilisation of 
intracellular stores in BMMC but not in PDMC. Both PLD and SphK signaling 
appear to be involved in such IL-33-mediated calcium mobilisation and whilst 
inhibitor studies suggested both PLD isoforms could mediate this response, 
they supported a role for SphK2 but not SphK1 in IL-33-induced calcium 
influx. 
Activation of both SphK isoforms was reported to be involved in FcεRI and SCF 
responses in BMMC [304] and the data presented here suggested that both 
SphK1 and 2 were likely involved in FcεRI-mediated calcium mobilisation in 
PDMC. However, and consistent with the findings of functional plasticity of 
mast cell subtypes presented in this thesis, recent evidence suggests that 
SphK isoform usage depends on species of origin and culture 
method/maturation state of the cells [325]. Thus, in BMMC and PDMC, SphK 2 
was found to be required for FcεRI-mediated calcium mobilisation, 
degranulation, cytokine and leukotriene production, whereas only SphK 1 was 
employed by human BMMC for FcεRI-induced cytokine production [325]. Thus, 
our studies using the SphK 1 inhibitor, suggesting that SphK 2 is the 
predominant isoform involved in IL-33 responses, is consistent with these 
findings although further studies with recently developed, better SphK 
 121 
isoform inhibitors would allow more detailed analysis of isoform dependence 
in MC function [326].  
As both PLD isoforms reduce intracellular calcium mobilisation, the rise in 
intracellular calcium concentration could be mediated by PA stimulated S1P-
SphK release from ER, however as PLD inhibition does not completely ablate 
the intracellular calcium concentration there may also be a further 
mechanism of IL-33- induced calcium mobilisation. The recent association of 
PI3K p100δ in IL-33-ST2 signaling in Th2 cells [327], a molecule that can 
directly promote influx of calcium via membrane bound SOCs or promote 
PLCy-mediated IP3 production [328] may provide an alternative mechanism 
and an interesting focus for future studies. 
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Figure 4.1 IL-33 signaling  
 
IL-33 signaling in mast cells requires the recruitment of the receptor ST2 and 
the co-receptor IL-1RAcP.  TIR domains then recruit MyD88, to activate IRAK1 
and IRAK4 using TRAF6 and TAK1. Further signal propagation leads to activation 
of ERK, JNK and p38 MAPK alongside the degradation of IκB resulting in 
activation of NFκB. 
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Figure 4.2 Murine mast cells express the IL-33 receptor, ST2 and respond 
to IL-33 stimulation. 
 
IgE-sensitized PDMC, BMMC and CTMC were treated with the indicated dose of 
IL-33 for 24 h at 37oC before analysis of IL-6 and IL-13 levels in culture 
supernatants by ELISA. Data are presented as the mean of duplicate samples 
from a single experiment with error bars representing SD.  
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Figure 4.3 IL-33-induced cytokine production requires ST2 expression by 
murine mast cells. 
 
PDMC obtained from WT or ST2 -/- (BALB/c) mice were sensitized with murine 
anti-DNP IgE (0.5 µg/ml) overnight then stimulated with IL-33 (100 ng/ml) for 
24 h at 37oC before release of IL-13 and IL-6 was measured by ELISA. Data are 
presented as the mean values of triplicate samples ± SD and are from a single 
experiment representative of 3 independent experiments. Statistical analysis 
using one-way ANOVA with Tukey’s multiple comparison test. *** p< 0.001. 
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Figure 4.4 IgE sensitization modulates IL-33-induced cytokine production 
from PDMC. 
 
PDMC sensitized or not with murine anti-DNP IgE (0.5 µg/ml) overnight were 
stimulated with IL-33 at 10 ng/ml (A) or 100 ng/ml (B) for 24 h at 37oC before 
release of IL-13, IL-6 and MCP-1 was measured by ELISA. Data are presented as 
the mean values of triplicate samples ± SD and are from a single experiment 
representative of 2 independent experiments. Statistical analysis using one-
way ANOVA with Tukey’s multiple comparison test. *** p< 0.001.  
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Figure 4.5   IL-33 does not induce degranulation of murine mast cells. 
 
PDMC (A, C, E,), BMMC (B, D, F) and CTMC (G), were sensitized with murine 
anti-DNP IgE (0.5 µg/ml) then stimulated with DNP (0.5 µg/ml) to induce cross-
linking (XL), IL-33 (10 ng/ml), LPS (0.5 µg/ml) or PMA (1 µM) plus Ionomycin (1 
µM) for 30 mins at 37oC. Degranulation was determined as the % β-
hexosaminidase released relative to the total activity of the cells (A-D) Data 
are presented as single samples from a single experiment (A, B) or the 
combined results of 5 (C) or 2 (D) independent experiments where error bars 
represent SEM. Statistical analysis using one-way ANOVA with Tukey’s multiple 
comparison test. Alternatively (E-G), degranulation was determined by flow 
cytometric analysis of cell surface Lamp1 expression by 7AAD-FcεRI+CD117+ 
mast cells. Geometric mean fluorescence (GMFI) of positive gate of Lamp1 
expression was determined relative to the isotype control as described (2.9.2). 
Data are presented as triplicate samples ± SD and are from a single experiment 
representative of a single (F, G) or 2 (E) independent experiments. Statistical 
analysis using one-way ANOVA with Tukey’s multiple comparison test. * p< 
0.05, ** p< 0.01, *** p< 0.001.  
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Figure 4.6 Effect of IgE sensitization on expression of mast cell surface 
phenotypic markers. 
 
Flow cytometric analysis of PDMC sensitized, or not, with murine anti-DNP IgE 
overnight were gated for live 7AAD- cells then analysed for CD117 (A), FcεRI 
(B), ST2 (D) and TLR4 (E) expression. The single stain for FcεRI is shown in (C) 
to demonstrate that the reduction in staining is not a result of interference by 
other stains. The geometric mean fluorescence (GMFI) of cells positively 
expressing each marker was determined relative to gating against the relevant 
isotype control obtained with non-sensitised cells  (F). CD117 data is 
represented as a ratio of non-sensitized CD117 expression. Results are 
combined data of at least 3 independent experiments where error bars 
represent SEM and statistical analysis is by unpaired, two-tailed t-test. * p< 
0.05, *** p< 0.001 
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Figure 4.7 Effect of IgE sensitization on mast cell surface markers at 18 h 
and 42 h and the comparison of surface and total expression of 
ST2 and TLR4. 
 
Flow cytometric analysis of PDMC sensitized, or not, with murine anti-DNP IgE 
for 18 h or 48 h were gated for live 7AAD- cells then analysed for CD117 (A), 
FcεRI (B), ST2 (D) and TLR4 (E) expression. Non-sensitized, 7AAD-, FcεRI+, 
CD117+ cells were analysed for surface and total (surface and intracellular) ST2 
(D) and TLR4 (E) expression. The geometric mean fluorescence (GMFI) of cells 
positively expressing each marker was determined relative to gating against 
the relevant isotype control obtained with non-sensitised cells.  Results are 
representative of a single experiments performed in triplicate where error bars 
represent SD and statistical analysis is by unpaired, two-tailed t-test. **** p< 
0.0001. 
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Figure 4.8 IL-33 stimulated calcium mobilisation is dependent on IgE 
sensitization, extracellular calcium and ST2 expression. 
 
WT or ST2 -/- PDMC (A, B, C) and BMMC (D) sensitised (A-D) or not (A) with 
murine anti-DNP IgE (0.5 µg/ml) and loaded with Fura-2/AM were stimulated at 
50s in serum-free HBSS with DNP (0.5 µg/ml) to induce cross-linking (XL) of 
FcεRI (A), 0.5 µg/ml LPS (A)  or 100 ng/ml IL-33 (A-D). Intracellular calcium 
mobilisation and influx were recorded in real-time using excitation-emission 
ratios of 340/380 nm. For the analysis of intracellular mobilisation alone, the 
cells were stimulated in calcium-free buffer supplemented with 100 µM EGTA 
to remove all extracellular calcium (EGTA) (B). Calcium levels were calculated 
from Rmax and Rmin values and the data presented as the mean calcium 
values of triplicate samples  ± SD (baseline calcium values subtracted) from a 
single experiment representative of at least 3 independent experiments. 
Statistical analysis using a two-tailed, paired t-test. **** p< 0.0001. 
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Figure 4.9 Effect of sensitization and ST2 expression on NFκB activation 
by FcεRI and IL-33. 
 
WT (A-C) or ST2 -/- (C) PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) 
overnight (IgE) or not (PBS) were cultured with DNP (0.5 µg/ml) to induce 
cross-linking (XL) of FcεRI (A) or IL-33 (10 ng/ml) (B, C) for the indicated times 
and expression of IκBα analysed by Western blotting. “0 min” represents zero 
timepoint control. β-actin was used as a loading control. Graphical 
presentation of densitometric analysis was performed using Image J to 
determine the relative intensity of IκBα compared to β-actin for each 
timepoint. Data are from a single experiment representative of at least 2 
independent experiments. 
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Figure 4.10 Effect of sensitization on ERK activation by FcεRI and IL-33. 
 
PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight (IgE) or non 
sensitized (PBS) were cultured with DNP (0.5 µg/ml) to induce cross-linking 
(XL) of FcεRI (A) or IL-33 (10 ng/ml) (B) for the indicated times and expression 
of Pp44/p42 (pERK) analysed by Western blotting. “0 min” represents zero 
timepoint control. p44/42 (ERK) was used as a loading control. Graphical 
presentation of densitometric analysis was performed using Image J to 
determine the relative intensity of Pp44/42 compared to p44/42 for each 
timepoint. Data are from a single experiment representative of at least 2 
independent experiments. 
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Figure 4.11 IL-33 mediated ERK activation is dependent on ST2 expression. 
 
WT or ST2 -/- PDMC (A) or BMMC (B) sensitized with murine anti-DNP IgE (0.5 
µg/ml) overnight (IgE) were cultured with IL-33 (10 ng/ml) for the indicated 
times and expression of Pp44/p42 (pERK) analysed by Western blotting. “0 
min” represents zero timepoint control. p44/42 (ERK) was used as a loading 
control. Graphical presentation of densitometric analysis was performed using 
Image J to determine the relative intensity of Pp44/42 compared to p44/42 for 
each timepoint. Data are from a single experiment representative of at least 2 
independent experiments. 
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Figure 4.12 Proposed involvement of PLD and SphK in IL-33 signaling. 
 
Phospholipase D signaling has been reported to be crucial for mast cell 
responses to cross-linking of FcεRI  [286-288] and has been suggested to play an 
important role in IL-33 signaling [126]. Although the mechanism of PLD 
coupling to ST2 is unknown, PLD-derived PA potentially induces calcium 
mobilisation via SphK-produced S1P production. 
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Figure 4.13 Effect of PLD inhibition on murine mast cell viability.   
 
PDMC (A) or BMMC (B) were pre-treated with the indicated concentrations of 
PC-PLD inhibitors 5WO (pan PLD 1/2), 809 (PLD 1) or APV (PLD 2) for 30 min at 
37oC before stimulation with IL-33 (10 ng/ml) for 24 h before cell death was 
assessed by 7AAD uptake by flow cytometry and is presented as % change in 
7AAD+ cells compared to untreated cells. Data represents are from a single 
experiment.  
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Figure 4.14 FcεRI-induced mast cell degranulation requires PLD signaling. 
 
PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight were pre-
treated with the indicated dose (A) or 1 µM (B, C) of the inhibitors 5WO (pan 
PLD 1/2), 809 (PLD 1) or APV (PLD 2) for 30 mins prior to stimulation with DNP 
(0.5 µg/ml) to induce cross-linking (XL) of FcεRI (A) or PMA (1 µM) plus 
Ionomycin (1 µM) (B, C) for a further 30 mins at 37oC. Degranulation was 
determined as the % β-hexosaminidase released relative to the total activity of 
the cells and was then adjusted to represent increase in β-hexosaminidase 
release over unstimulated cells (basal) (C). Data represents the combined 
results of 3 independent experiments where error bars show SEM. Statistical 
analysis using two-way ANOVA with Bonferroni multiple comparison test. * 
p<0.05 and ** p< 0.01. 
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Figure 4.15 PLD signaling plays a role in IL-33-induced IL-13 production.  
 
PDMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight (IgE) or 
not (PBS) then pre-treated with the indicated dose of PC-PLD inhibitors 5WO 
(pan PLD 1/2), 809 (PLD 1) or APV (PLD 2) for 30 mins at 37oC before 
stimulation with DNP (0.5 µg/ml) to induce FcεRI cross-linking (XL) (A) or IL-33 
(10 ng/ml) (B) for 24 h at 37oC. Release of IL-13 was measured by ELISA from 
supernatants. Results from a single experiment performed in duplicate where 
error bars show SD.  
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Figure 4.16 IL-33-induced cytokine production is dependent on PLD 2 but 
not PLD 1. 
 
PDMC (A) and BMMC (B) were sensitized with murine anti-DNP IgE (0.5 µg/ml) 
overnight then pre-treated with the described dose of PC-PLD inhibitors, 5WO 
(pan PLD 1/2), 809 (PLD 1) or APV (PLD 2) for 30 mins at 37oC before 
stimulation with IL-33 (10 ng/ml) for 24 h at 37oC. Release of IL-13 and MCP-1 
was measured by ELISA from supernatants. Results from a single experiment, 
where error bars represent SD, and are representative of at least 2 
independent experiments.  
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Figure 4.17 Calcium mobilisation in murine mast cells requires PLD 
signaling. 
 
WT PDMC sensitised with murine anti-DNP IgE (0.5 µg/ml) were simultaneously 
loaded with the described dose (D, E) or 5 µM (A- C) of PC–PLD inhibitors and 
Fura-2/AM before stimulation in serum-free HBSS at 50s with DNP (0.5 µg/ml) 
to induce cross-linking (XL) of FcεRI (A, C-E)) or IL-33 (100 ng/ml) (B). 
Intracellular calcium mobilisation and influx were recorded in real-time using 
excitation-emission ratios of 340/380 nm. For the analysis of intracellular 
mobilisation alone, the cells were stimulated in calcium-free buffer 
supplemented with 100 µM EGTA to remove all extracellular calcium (EGTA) (C, 
E). Calcium levels were calculated from Rmax and Rmin values and the data 
presented as the mean calcium values of triplicate samples  ± SD (baseline 
calcium values subtracted) from a single experiment representative of at least 
3 independent experiments. Statistical analysis using a two-tailed, paired t-
test. *** p< 0.001. 
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Figure 4.18 FcεRI-induced NFκB activation is downstream of PLD signaling.  
 
PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight then pre-
treated with 1 µM of PC–PLD inhibitors for 30 mins at 37oC were treated with 
DNP (0.5 µg/ml) to induce cross-linking (XL) of FcεRI for the indicated times or 
left unstimulated for 60 mins as a control and expression of IκBα analysed by 
Western blotting (A). β-actin was used as a loading control. Graphical 
presentation of densitometric analysis was performed using Image J to 
determine the relative intensity of IκB to β-actin for each timepoint. Data are 
from a single experiment representative of at least 2 independent 
experiments.  
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Figure 4.19 IL-33-induced NFκB activation is downstream of PLD signaling.  
 
PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight then pre-
treated with 1 µM of PC–PLD inhibitors for 30 mins at 37oC were treated with 
IL-33 (10 ng/ml) for the indicated times and expression of IκBα analysed by 
Western blotting (A). “0 min” represents zero timepoint control. β-actin was 
used as a loading control. Graphical presentation of densitometric analysis was 
performed using Image J to determine the relative intensity of IκB to β-actin 
for each timepoint. Data are from a single experiment representative of at 
least 2 independent experiments. 
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Figure 4.20 Basal, FcεRI- and IL-33- induced ERK phosphorylation in murine 
mast cells is downstream of PLD signaling. 
 
PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight then pre-
treated with 1 µM of PC–PLD inhibitors for 30 mins at 37oC were treated with 
DNP (0.5 µg/ml) to induce cross-linking (XL) of FcεRI (A) or IL-33 (10 ng/ml) (B) 
for the indicated times or left unstimulated for 60 mins as a control (A). For IL-
33 treatment “0 min” represents zero timepoint control (B). Expression of P-
p44/42 was analysed by Western blotting with p44/42 used as a loading 
control. Graphical presentation of densitometric analysis was performed using 
Image J to determine the relative intensity of P-p44/42 to p44/42 for each 
timepoint. Data are from a single experiment representative of at least 2 
independent experiments.  
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Figure 4.21 Determining the direct PLD activity in mast cells induced by IgE 
sensitization, FcεRI, IL-33 and PMA. 
 
PDMC were cultured in the presence of  5 µCi [3H]Palmitate and murine anti-
DNP IgE (0.5 µg/ml) overnight (A-E). Cells were then washed and resuspended 
in serum-free HBSS before being loaded with 1% ethanol and, where 
appropriate, pre-treated with 1 µM of the indicated PC–PLD inhibitor for 20 
mins at 37oC. Where indicated, a sample was taken and the reaction 
terminated (Control (E). Alternatively, cells were then stimulated with DNP 
(0.5 µg/ml) to induce cross-linking (XL) of FcεRI (A-C), IL-33 (100 ng/ml) (B, E), 
PMA (1 µM) (A, D) or murine anti-DNP IgE (0.5 µg/ml) (F, G) for 60 mins (B, C, 
D, G) or the indicated time course. Data are presented as mean value of 
[3H]PtdEtOH (cpm) expressed as a % of the total incorporation of [3H]palmitate 
± SD of triplicate cultures from a single experiment representative of at least 2 
independent experiments. Statistical analysis using one-way ANOVA with 
Tukey’s multiple comparison test (A), two-way ANOVA with Bonferroni multiple 
comparison test (B-D) or unpaired, one-tailed t-test (E- H). * p< 0.05 and ** p< 
0.01. 
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Figure 4.22 IL-33 signaling in murine mast cells involves SphK. 
 
PDMC (A, C, E-G) or BMMC (B, D) sensitized overnight with murine anti-DNP IgE 
(0.5 µg/ml) and pre-treated with the indicated concentrations (A-D) or 10 µM 
(E-G) of the SphK inhibitor, DMS for 30 min were then stimulated with IL-33 (10 
ng/ml) for 24 h at 37oC. Cell death was assessed by 7AAD uptake using flow 
cytometry as described (2.6) (A, B) and is presented as % change in 7AAD+ cells 
compared to untreated cells. Release of IL-6 and MCP-1 was measured by ELISA 
from supernatants. Viability and ELISA results are matched and are 
representative of 2 independent experiments (A, C) or a single experiment (B, 
D) where error bars show SD.  
For calcium results PDMC were simultaneously loaded with 10 µM DMS and 
Fura-2/AM. Cells were stimulated at 50s in serum-free HBSS with DNP (0.5 
µg/ml) to induce cross-linking (XL) of FcεRI (E), LPS (0.5 µg/ml) (F) or IL-33 
(100 ng/ml) (G). The intracellular calcium mobilisation and influx were 
recorded in real-time using excitation-emission ratios of 340/380 nm. For the 
analysis of intracellular mobilisation alone, the cells were stimulated in 
calcium-free buffer supplemented with 100 µM EGTA to remove all 
extracellular calcium (EGTA) (E-G). Calcium levels were calculated from Rmax 
and Rmin values and the data presented as the mean calcium values of 
triplicate samples  ± SD (baseline calcium values subtracted) from a single 
experiment representative of at least 2 independent experiments. Statistical 
analysis using a two-tailed, paired t-test. **** p< 0.0001. 
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Figure 4.23 IL-33 signaling in murine mast cells involves the SphK 2 
isoform. 
 
PDMC (A, C-E) or BMMC (B, F) sensitized overnight with murine anti-DNP IgE 
(0.5 µg/ml) and pre-treated with the indicated concentrations or 30 µM (E, F) 
of the SphK 1 isoform specific inhibitor, 5c for 30 min were then stimulated 
with IL-33 (10 ng/ml) for 24 h at 37oC. Cell death was assessed by 7AAD uptake 
using flow cytometry as described (2.6) (A, B) and is presented as % change in 
7AAD+ cells compared to untreated cells. Release of IL-6 and MCP-1 was 
measured by ELISA from supernatants. Viability and ELISA results are matched 
and are representative of 2 independent experiments (A, E) or a single 
experiment (B, F) where error bars show SD.  
For calcium results PDMC were simultaneously loaded with 30 µM 5c and Fura-
2/AM. Cells were stimulated at 50s in serum-free HBSS with DNP (0.5 µg/ml) to 
induce cross-linking (XL) of FcεRI (E) or IL-33 (100 ng/ml) (F). The intracellular 
calcium mobilisation and influx were recorded in real-time using excitation-
emission ratios of 340/380 nm. Calcium levels were calculated from Rmax and 
Rmin values and the data presented as the mean calcium values of triplicate 
samples  ± SD (baseline calcium values subtracted) from a single experiment. 
Statistical analysis using a two-tailed, paired t-test. **** p< 0.0001. 
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Figure 4.24 FcεRI and IL-33 treatment directly stimulates SphK activity in 
mast cells to produce S1P found in the serum of a murine 
model of asthma  
 
IgE-sensitised PDMC were treated with DNP (0.5 µg/ml) (A) or IL-33 (100 ng/ml) 
(B) for the indicated times before measurement of SphK as described (2.12). 
The results were analysed to determine fold difference to 0 min baseline, 
assigned the value “1” Data is combined from 2 (A) or 3 (B) independent 
experiments. Values are represented as mean ± SEM.   
S1P concentration from IgE-sensitised PDMC were treated with IL-33 (10 ng/ml) 
for the indicated times and then S1P levels in culture supernatants or cell 
lysates were determined by ELISA (C). Data are presented as a single value. 
Serum and BALf samples obtained from mice treated with PBS (control) or 
OVA/ALUM in a model of OVA-induced airway hyper-responsiveness as 
described (2.14) was analysed for S1P expression by ELISA (D). Data presented 
as a single value from a single experiment. 
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Figure 4.25 Proposed revision of IL-33 signaling. 
 
IL-33-ST2 can signal independently of IgE sensitization however, IgE ligation of 
FcεRI, without the need for crosslinking, can augment IL-33 signaling 
potentially via increased PLD 1 and PLD 2 activity. This increased PLD platform, 
especially PLD 2, allows further signal propagation by IL-33-ST2 and Sphk2 
activation to allow calcium mobilisation and increase NFκB activation. 
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5 FcεRI, ST2 and TLR4 crosstalk in murine mast 
cells; potential for modulation by ES-62. 
 
5.1 Introduction 
5.1.1 ST2 and FcεRI crosstalk 
Data presented in the previous chapter highlighted the cooperative 
interactions between IgE sensitization and IL-33 signaling in murine mast 
cells. To further explore these interactions and their potential role in vivo, 
the potential crosstalk occurring during antigen-mediated activation of IgE 
sensitized mast cells in the presence of IL-33 was investigated, as both of 
these signals are likely to be present in abundance under pathological 
conditions such as those pertaining in asthma. Indeed, previous data in 
human primary mast cells have demonstrated increased degranulation [274] 
and cytokine production [62] following co-stimulation via IL-33/ST2 and 
FcεRI-XL. Likewise, FcεRI-mediated induction of cytokines, including MCP-1, 
TNFα and IL-13 from murine BMMC is increased by simultaneous treatment 
with IL-33- treatment [268] although the degranulation responses of BMMC 
and RBL-2H3 were largely unaffected [60].  Consistent with a physiological 
role for such crosstalk, in a model of passive cutaneous anaphylaxis, 
prevention of IL-33-ST2 ligation limits the response to IgE administration 
[329], whilst in a model of antibody-induced arthritis, exposure to IL-33 
increases mast cell activation to exacerbate disease.  
 
Although the signaling mechanisms involved have not been defined, such 
cooperation leading to IL-33-mediated augmentation of FcεRI responses was 
lost in MyD88-/- BMMC, reflecting loss of IL-33, but not FcεRI, signaling. 
Neither IRAK1 nor ERK activation appeared to be increased during crosstalk 
whereas TAK1, p38, JNK and NFκB activation was augmented in studies using 
RBL-2H3 mast cells and to a lesser extent in BMMC. Such increases in signaling 
activity were only apparent during simultaneous administration of IL-33 with 
the FcεRI crosslinking agent, and not following IL-33 pre-treatment [60]. IL-33 
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has been similarly shown to promote mast cell activation in response to 
signaling via other Fc receptors including the IgG receptor, FcγRIII resulting in 
increased IL-1 production in early inflammation [330]. Interestingly, long-
term exposure (>72 h) to IL-33 has been reported to suppress FcεRI-mediated 
calcium signaling in mast cells potentially via downregulation of PLCγ [321], 
indicating alternative roles for IL-33 in acute and chronic antibody-mediated 
inflammatory conditions. 
 
 
5.1.2 ST2 and TLR4 crosstalk. 
The ability of LPS, a lipopolysaccharide on the surface of Gram-negative 
bacteria, to augment immune responses is well documented.  Consistent with 
this, LPS has been reported to increase FcεRI-mediated mast cell responses in 
terms of cytokine production [32, 49, 58, 59] and, when co-administered with 
OVA, to increase AHR, eosinophil infiltration, cytokine production and 
degranulation of histamine in a murine model of asthma [49].  
 
The potential interaction between LPS and IL-33 signaling is therefore of 
great interest due to their combined presence during infection [253] as well 
as the close relationship between their receptors, TLR4 and ST2, and 
consequent similarity in their signaling pathways (Figure 5.1) Not only does 
the physical presence of bacteria simulate IL-33 release after tissue damage 
but LPS signals, via TLR4, induce IL-33 production from macrophages [223], 
human mucosal epithelial cells [331], murine monocytes [332] and DC [333, 
334]. Moreover, this LPS-induced IL-33 release from macrophages further 
augments anti-bacterial responses via TNFα production [335, 336]. 
 
Although crosstalk mechanisms between the receptors for LPS (TLR4) and IL-
33 (ST2) have not been defined, there are clear opportunities for this to 
occur as ST2 exhibits some structural homology with TLRs  [337] with both 
types of receptors possessing TIR domains that utilise MyD88-dependent 
signaling machinery. Rather surprisingly therefore, despite the seemingly 
positive relationship between IL-33 and LPS, it has generally been reported 
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that ST2 negatively regulates MyD88-dependent TLR responses by 
sequestering MyD88 and Mal using its TIR domain [178, 179]. More recently, 
structural and protein-protein docking analysis has supported this negative 
regulatory role by demonstrating that membrane bound ST2-TIR domains can 
prevent Mal and MyD88 from associating with TLR4 [338]. Furthermore and 
consistent with this, mutations in its TIR domain resulted in a failure of ST2 
to inhibit LPS-induced NFκB activation [179]. As LPS upregulates ST2 on 
macrophages and monocytes, this suggested that ST2 acts to signal in a 
feedback mechanism to limit TLR4 signaling [179, 339]. Moreover, it has also 
been suggested, that in macrophages, ST2 signaling inhibits LPS responses by 
downregulating TLR4 expression [340]. Conversely, recent evidence suggests 
that IL-33 signaling has no effect on TLR4 or MyD88 expression but rather 
instead, ST2 inhibits LPS-TLR4 signaling by inducing degradation of IRAK1 that 
is essential for TLR4 signaling in mast cells [341]. 
 
These molecular studies provided evidence that the ST2 receptor can 
negatively modulate TLR4 signaling however only one of these studies were 
performed under conditions of IL-33-ST2 signaling [341], perhaps going some 
way to explaining the contradictory reports in the literature where IL-33 acts 
to increase LPS responses [335, 336]. In these studies, IL-33 upregulates 
expression of TLR4, MD-2, CD14 and MyD88, findings corroborated by their 
reduced expression in cells from ST2-/- mice. Moreover, IL-33-deficient mice 
have been reported to exhibit reduced responses to LPS [235] and 
additionally, soluble ST2, an inhibitor of IL-33 signaling, has been found to 
inhibit cytokine production in response to LPS in a murine model of LPS-
induced acute lung injury [342]. Although it is not clear what switches ST2 
between a positive and negative regulator of TLR4 signaling, it is well 
established that TLRs are able to associate with other innate receptors, for 
example C-type lectins [343]. 
 
 
5.1.3 Potential modulation of IL-33 responses by ES-62.  
ES-62 can inhibit FcεRI-induced responses in human mast cells[126]) where 
this inhibition is due to TLR4-mediated PKCα degradation, preventing 
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subsequent coupling of FcεRI-mediated coupling to PLD/SphK-driven calcium 
mobilisation and consequent NFκB activation. Data presented in this thesis 
(Chapter 3) has shown that ES-62 can similarly target FcεRI responses in 
murine PDMC, BMMC and CTMC and in addition to suppressing calcium 
mobilisation and inducing degradation of PKCα, in all three subtypes. ES-62 
has also been reported to inhibit FcεRI and TLR4 signaling in murine BMMC via 
targeted degradation of PKCα, PKCδ and MyD88 [134] and perhaps consistent 
with the latter finding identifying a commonality of action, ES-62 has also 
been shown to downregulate MyD88 in Th17 cells [135], macrophages and DC 
(Eason, McGrath, Rodgers and Harnett unpublished). Interestingly, therefore 
IL-33 signals via MyD88 and is associated with promoting pathology in several 
diseases in which ES-62 has demonstrated therapeutic potential, including 
rheumatoid arthritis and asthma. Moreover, mast cells have been reported to 
play an increasingly dominant role in the pathology of Th17-mediated 
disease, especially in those associated with chronic infection and/or 
inflammation where a Th17 response prolongs pathology. In particular, mast 
cells stimulated with IL-33 have been found to drive Th17 development in a 
model of allergic asthma [244] and chronic intestinal inflammation [344]. As 
ES-62 exhibits protection against autoimmune and allergic inflammatory 
disease by suppressing IL-17-mediated inflammation [135, 345], it was 
possible that ES-62 was acting, at least in part, by suppressing IL-33-mediated 
induction of such responses.  
 
 
5.1.4  ST2 deficient mast cells 
ST2-deficient mice were created to study the role of ST2 in immune 
responses [158] and since the identification of IL-33 as its ligand, the role of 
ST2 in IL-33 signaling. Although ST2 is expressed early in mast cell 
development, ST2 -/- mice have equivalent mast cell numbers in the skin as 
WT mice and these mast cells appear to degranulate normally. Moreover, 
BMMC can be derived from ST2-/- bone marrow, confirming that ST2 is not 
essential for mast cell development [346]. 
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5.2 Aims 
The availability of ST2-/- mice allowed the validation of the dependence of IL-
33 signaling on ST2 expression in various mast cell responses (Chapter 4). 
However, as there are contradictory reports that whilst IL-33 augments LPS 
responses, ST2 signaling can inhibit LPS responses [179, 340], it was planned 
to exploit this resource to further examine the relationship between ST2 and 
TLR4 in terms of crosstalk between IL-33 signaling and the classical pro-
inflammatory ligand, LPS. Moreover, in earlier studies showing ES-62-
mediated desensitisation of pro-inflammatory TLR4-signaling it was suggested 
that ES-62 could perhaps signal directly via ST2, and although this did not 
seem to be the case in macrophages [132], it was also decided to test the 
effect of ST2 deficiency on the anti-inflammatory effects of the non-
canonical TLR4 ligand, ES-62 in mast cells.  
 
 
5.3 Results and Discussion 
5.3.1.1 IL-33 signaling modulates FcεRI-mediated cytokine production in 
murine mast cells.  
Whilst FcεRI-XL induces little or no production of IL-6 or IL-13 by PDMC or 
BMMC from WT or ST2-/- BALB/c mice, IL-33 generally induces low levels of 
these cytokines by WT mast cells, although there is a relatively strong 
production of IL-6 by BMMC.  All of these IL-33 responses, as were the 
negligible FcεRI, were completely abrogated in cells from ST2-/- mice. In 
terms of co-stimulation, with PDMC there was no reproducible effect on 
production of IL-6 however that of IL-13 was increased, but not significantly, 
in 2/3 experiments (Figure 5.2 A). By contrast, following such co-stimulation 
of BMMC, IL-13 is consistently increased (Figure 5.2 B) whilst IL-6 production 
is significantly reduced (2/3 experiments), potentially reflecting the different 
signaling responses to FcεRI-XL seen amongst PDMC, BMMC and CTMC 
(Chapter 3). 
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5.3.1.2 The availability of ST2 affects FcεRI-induced calcium mobilisation 
and downstream signaling in murine mast cells. 
To address whether ST2 expression modulated FcεRI-signaling in an IL-33-
independent manner analogous to that reported for LPS/TLR4 signaling the 
effects of ST2 deficiency on FcεRI-induced calcium mobilisation, NF-κB and 
ERK activation were assessed. Although FcεRI-XL induced little or no cytokine 
production from either WT PDMC or BMMC, any such production appeared to 
be lost in ST2-deficient cells (Figure 5.2) and perhaps consistent with this, 
PDMC (Figure 5.3 A) and BMMC (Figure 5.3 B) generated from ST2 -/- mice 
exhibited significantly reduced calcium responses after XL which appeared 
predominantly to be a as a result of reduced influx of extracellular calcium 
(Figure 5.3 C, D).  
 
Likewise, IκB expression is not reduced to the same extent and recovers 
faster in ST2-/- BMMC relative to that observed in WT cells, indicating weaker 
NFκB activation in response to FcεRI-XL (Figure 5.3 E). Moreover, FcεRI-
mediated ERK activation is similarly reduced in both PDMC (Figure 5.4 A) and 
BMMC (Figure 5.4 B) from ST2-/- compared to WT mice. These data suggest 
that rather than the negative feedback role proposed for ST2 in LPS/TLR4 
signaling, FcεRI requires ST2 expression for full signaling.  
 
 
5.3.2 ST2 negatively regulates LPS signaling in mast cells.   
As LPS responses are reportedly increased in mast cells deficient in ST2, the 
interaction between IL-33-ST2 and LPS-TLR4 signaling was further examined. 
When IL-33 and LPS are co-administered there is a significantly increased 
effect on IL-6 and IL-13 production in both PDMC (Figure 5.5 A) and BMMC 
(Figure 5.5 B) relative to either single stimuli alone, supportive of previous 
results [335, 336] and in conjunction with their cooperative role in infection. 
Although in this experiment the stimulation of IL-13 production in PDMC 
appears synergistic, over several experiments all of these enhanced responses 
are less than additive responses of the single stimuli perhaps suggesting they 
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are signaling via a shared pathway or both utilising core elements. In the 
absence of ST2 signaling, LPS-induced IL-6 and IL-13 cytokine production in 
PDMC and IL-6 in BMMC is consistently, significantly increased and to higher 
levels than that resulting from co-stimulation with LPS and IL-33. This could 
perhaps suggest that by functionally signaling via ST2, IL-33 is relieving its 
negative regulation on TLR4 and therefore these findings could some way to 
resolving the contradictory data relating to the regulation of TLR4 signaling 
by IL-33/ST2 in the literature. In contrast BMMC IL-13 is significantly reduced 
in ST2 -/- in 3/3 experiments. Interesting, although as expected the IL-33 
response is lost in the ST2-deficient cells, ST2 -/- PDMC and BMMC co-
stimulated with LPS and IL-33 exhibited reduced rather than equivalent 
cytokine responses compared to those treated with LPS (IL-6; 2/3, IL-13; 
3/3). This surprising finding perhaps suggests that although ST2 is essential 
for its signaling, IL-33 can interact with another (undefined) receptor, 
possibly as part of the normal active IL-33-ST2/IL-1RAcP complex, that is not 
sufficient to transduce IL-33 functional responses in the absence of ST2 but 
can still sequester signaling elements shared with TLR4, or act otherwise, to 
negatively modulate TLR4 responses in the presence of IL-33. IL-1RAcP, 
bearing TIR domains, assists in MyD88 recruitment within the ST2 complex. It 
has been proposed that IL-1RAcP may also bind IL-33, although to a lesser 
extent than ST2 [347], so perhaps IL-1RAcP expression is maintained on ST2 -
/- cells, allowing the observed effects. 
 
These findings support previous data suggesting ST2 inhibits TLR4 signaling 
but perhaps instead of true inhibition, the interaction is more of regulatory 
signal, to tune the phenotype of immune response and/or prevent hyper-
responses resulting from the high levels of LPS and/or IL-33 potentially 
observed under conditions of pathological inflammation. Thus, the absence of 
ST2 allows TLR4 to signal to its full potential. In the case of BMMC, this would 
suggest that TLR4 signaling would act to suppress IL-13 production, possibly 
reflecting the role for LPS in driving Th1-type responses and limiting Th2-
promoting signals by IL-33 stimulated BMMC, cells expected to play roles in 
Th2-driven allergy in the mucosa. Although this latter proposal is somewhat 
at odds with reports that LPS augments airway-hyperresponsiveness [49, 348], 
evidence in the literature also demonstrated that LPS inhibits Th2 cytokine 
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responses in the BALF and AHR [349] as well as the perinatal exposure to LPS 
inducing protection against asthma [350].  
 
 
5.3.2.1 Expression of ST2 and TLR4-MD2 on mast cells is linked  
To begin to identify the mechanisms of crosstalk between ST2 and TLR4 
signaling, their relationships in terms of their surface expression was 
investigated. LPS has been shown previously to upregulate ST2 expression on 
macrophages and monocyte [179, 339] and here flow cytometric analysis of 
CD117+ FcεRI+ cells demonstrated that whilst ST2 was strongly expressed on 
all WT PDMC (Figure 5.6 A, C, E, G) and BMMC (Figure 5.6 B, D, F, H) but not 
on ST2-/- mast cells, it was further up-regulated following exposure to LPS, 
indicating that LPS may induce either positive or negative feedback responses 
by upregulating the IL-33 receptor. To address the mechanisms involved, the 
effects of LPS on surface and total (permeabilised cells) ST2 expression were 
investigated and this revealed a general upregulation of ST2 expression 
indicating this this did not simply involve trafficking of intracellular pools of 
ST2 to the surface (Figure 5.7 G, H).  
 
In these experiments on BALB/c mice, TLR4 staining was relatively weak and 
hence was only detected on about 60% of PDMC (Figure 5.7 A, C, E, G) and 
BMMC (Figure 5.7 B, D, F, H). Although not significant, and surprisingly given 
that LPS responses tended to be increased, there appeared to be a decrease 
in the proportion of cells (Figure 5.7 C, D) and expression levels (Figure 5.7 E, 
F) of TLR4 in ST2 -/- mast cells. Analysis of permeabilised cells showed a 
similar reduction in expression indicating that this was not as a result of a 
defect in trafficking TLR4 to the surface (Figure 5.7 G, H). These data suggest 
that ST2 and TLR4 expression may be linked and as we have found TLR4 to be 
expressed only relatively late (4 weeks) in their development in vitro, these 
findings may suggest that ST2 -/- cells may be slightly more immature than 
those derived from WT mice.  
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5.3.2.2 The availability of ST2 affects LPS-induced calcium mobilisation 
and downstream signaling murine mast cells. 
Analysis of LPS-stimulated calcium mobilisation in WT and ST2-/- PDMC 
(Figure 5.8 A) and BMMC (Figure 5.8 B) revealed, consistent with the reduced 
levels of TLR4 expression, that in BMMC the calcium response was suppressed 
and that this reflected reduced intracellular calcium mobilisation (Figure 5.8 
B, D). It should be noted however, that in these experiments, the LPS 
response in WT PDMC is very low (Figure 5.8 A). In BMMC although data 
reflects a lower TLR4 expression and IL-13 production by ST2 -/- cells, they 
are rather at odds with the increased levels of IL-6, suggesting that IL-13 and 
IL-6 production by such cells is differentially regulated, with IL-13 production 
perhaps being more dependent on calcium mobilisation signals.   
 
To address this ST2-TLR4 crosstalk further, activation of NFκB was assessed 
and this showed that as with WT cells, IκB is downregulated in ST2 -/- PDMC 
treated with LPS (Figure 5.9 A), however, quantitation of the data indicated 
that ST2 -/- PDMC exhibited a delay in the degradation of IκB, although a 
slightly enhanced level of IκB (relative to β-actin) was found in PDMC from 
ST2-deficient mice. The increase in this negative regulator was strongly 
pronounced in the equivalent BMMC but this was almost completely ablated 
in response to LPS, indicating a strong NF-KB activation. Moreover, in WT but 
not ST2-/- BMMC, IκB expression is beginning to recover by 60 min (Figure 5.9 
B). Interestingly, LPS-induced ERK phosphorylation in increased in PDMC 
(Figure 5.10 A) and BMMC (Figure 5.10 B) from ST2 -/- mice both in terms of 
faster kinetics and also stronger activation.  
 
Collectively, these data indicate that whilst ST2 expression acts to promote 
LPS/TLR4 coupling to calcium signaling in BMMC, it limits LPS-stimulated NF-
KB and ERK responses in PDMC. This suggests that whilst the stronger 
production of IL-13 observed in BMMC may be dependent on the ST2-
mediated enhancement of calcium mobilisation in WT cells, that of IL-6 is 
more dependent on NFκB and ERK signaling. Recent evidence suggests that 
alternate IL-13 production from IL-33 stimulated MC, may arise from differing 
requirements for co-stimulation with IL-3, provided in BMMC culture 
conditions, to activate STAT5 [351]. 
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5.3.3 ES-62 can modulate IL-33 signaling in murine mast cells. 
It has previously been shown that ES-62 can desensitise FcεRI and LPS-induced 
mast cell responses [126, 134] and consistent with this, suppress OVA-induced 
AHR by resetting Th17/Th2 polarised responses [345]. Thus, due to the 
emerging role for IL-33 and mast cells in these responses [220, 221, 243-246], 
the effects of ES-62 on IL-33-stimulated production of a range of pro-
inflammatory cytokines (IL-6, IL-13, IL-17, IL-22 and IL-23) and chemokines 
(MCP-1), implicated in promoting the Th17/Th2 polarised responses observed 
in allergic inflammation, were investigated.  This revealed that in IgE-
sensitised PDMC, pre-treatment with ES-62 (2 µg/ml) for 18 h suppressed 
production of all these cytokines, albeit this did not reach significance in all 
experiments (Figure 5.11 A). Interestingly, pre-treatment with ES-62 for only 
2 h was sufficient to inhibit IL-13, IL-17 and MCP-1 and under these 
conditions, also inhibited production of IL-17 and MCP-1 by non-sensitised 
cells, even at concentrations lower than the “standard” dose of 2 µg/ml 
(Figure 5.11 B).  
 
That such ES-62 immunomodulation was not mediated by receptor 
downregulation was evidenced by the flow cytometric analysis of surface 
expression of FcεRI, CD117 and ST2 (Figure 3.7) that showed that pre-
treatment with the parasite product had negligible effect on expression of 
any of these markers on either resting or IgE-sensitised mast cells. By 
contrast, as described for its effects on FcεRI- and LPS-stimulated pro-
inflammatory responses (Figure 3.9), ES-62-mediated inhibition of cytokine 
responses was reflected by inhibition of IL-33-stimulated calcium 
mobilisation, with both the extent and kinetics of calcium mobilisation 
reduced (Figure 3.12 A). The mechanisms involved in such desensitisation of 
calcium mobilisation are not clear but it has been proposed ES-62 may signal 
abortively during its initial interaction with TLR4 on macrophages as 
evidenced by production of a low level of cytokines [184]. Thus, in order to 
determine if ES-62 could potentially induce signaling upon initial binding to 
TLR4 on mast cells its ability to activate calcium mobilisation was 
determined. This revealed that ES-62 induces a very slight immediate calcium 
response in mast cells  (Figure 5.12 B) that may contribute to the, as yet 
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unknown, signals that promote degradation of PKCα, δ and/or MyD88 
expression in order to uncouple TLR4, FcεRI and potentially, ST2 signaling in 
mast cells.  
 
 
5.3.4 ES-62 modulates FcεRI and LPS-induced cytokine 
responses from mast cells derived from ST2 -/- mice. 
As shown previously, ES-62 significantly inhibits IL-6 and IL-13 production 
induced by IL-33 from PDMC (Figure 5.13 A) and as expected, this is 
dependent on ST2 expression, although in this experiment there was residual 
IL-33-stimulated IL-13 production that was also inhibited by ES-62 in ST2 -/- 
PDMC, a finding that was not observed in repeat experiments. Such ES-62-
mediated inhibition of IL-33-mediated, ST2-dependent cytokine responses 
were also observed in BMMC (Figure 5.13 B).  
 
As shown in Chapter 3, ES-62 inhibits LPS-induced IL-6 and IL-13 production 
from both PDMC and BMMC derived from WT mice (Figure 5.14 A). Such ES-62 
activity in BMMC does not require ST2 expression as demonstrated by the 
maintenance of inhibition of LPS-induced cytokines from ST2 -/- BMMC 
(Figure 5.14 B). Interestingly in ST2 -/- PDMC, LPS-induced cytokines are not 
significantly inhibited by ES-62 (3/3 experiments for IL-13 and IL-6). 
Consistent with this, the ES-62-mediated suppression of IL-6 produced by 
PDMC (Figure 5.15 A) but not BMMC (Figure 5.15 B) in response to co-
stimulation with IL-33 and LPS is also lost in ST2-deficient cells. IL-13 
responses mirrored this trend, although for this cytokine these effects were 
not statistically significant.  
 
IL-33 stimulation generally enhanced FcεRI-mediated cytokine responses 
although the precise effect depended on the MC subtype and the cytokine 
analysed (Figure 5.2).  ES-62 is able to significantly inhibit this increased 
cytokine production in both PDMC (Figure 5.16 A) and BMMC (Figure 5.16 B). 
In ST2 -/- cells, cytokine production is significantly and dramatically 
decreased, coinciding with the loss of IL-33 signaling but is still significantly 
modulated by ES-62 in the case of BMMC IL-13 production.  
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Collectively, these data again highlight signaling differences between the 
PDMC and BMMC subtypes and their subsequent response to ES-62 modulation, 
which may reflect differential negative regulatory mechanisms of action of 
ES-62 in PDMC and BMMC. 
 
 
5.4 Conclusion  
ST2 has been reported to be non-essential for the generation of mast cells 
[346] and our ability to generate expanded PDMC and in vitro differentiated 
BMMC corroborate this proposal.  Although ST2-deficiency does not prevent 
MC generation it may, however, affect their maturation or activation 
capacity as the reduced calcium, NFκB and ERK activation and subsequent 
cytokine responses observed in response to FcεRI-XL in PDMC and BMMC from 
ST2 -/- mice, indicates an important role for ST2 in the activation of MC by 
antigen-mediated IgE crosslinking (Table 5.1). This may suggest that IL-33 
signaling is important for the maturation of murine mast cells and indeed 
their lower expression of TLR4 suggests ST2 -/- MC may not reach full 
maturity, or alternatively take longer to mature, with their altered responses 
to stimuli reflecting this. As IgE sensitization of FcεRI appears to be required 
for optimal IL-33-ST2 responses, these new findings further support crosstalk 
between FcεRI and ST2 receptors. The requirement of ST2 (independently of 
IL-33 ligation) for full FcεRI function suggests an involvement of ST2 in 
formation or stabilization of signaling clusters during the early stages of 
FcεRI-mediated activation, perhaps to prevent abortive signaling. 
 
Similarly, our data provide further support to the proposal that ST2 may 
interact with TLR4 to modulate mast cell responses. There is conflicting 
evidence in the literature relating to the role of ST2 in regulating LPS/TLR4 
signaling with IL-33 reported to increase LPS responses whilst ST2 expression 
has been shown to inhibit LPS signaling. The differential effects of ST2 
expression on IL-13 production observed between the PDMC and BMMC may 
therefore go part of the way to resolve such discrepancies reported, as given 
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their differential signaling, the precise subtype of mast cell and/or receptor 
targeted may influence the observed response. For example, although ST2-
deficiency results in reduced FcεRI- and LPS-mediated calcium mobilisation 
(the latter only significant in BMMC), whilst FcεR1-coupling to NF-κB and ERK 
activation is also suppressed, that of TLR4 is enhanced. Moreover, whilst ST2 
expression is important for ES-62-mediated inhibition of PDMC, it is 
dispensable in BMMC.  
 
Regulation of TLR4 signaling is important to prevent unnecessary pathology 
due to hyper-inflammation during immune responses and reflecting this, 
failure to regulate TLR4-mediated responses has been implicated in several 
diseases [352]. Although exposure to LPS can directly downregulate TLR4 
surface expression resulting in "LPS tolerance" [353], regulation of LPS-
responses is commonly controlled by heterologous receptor signaling, which 
may be constitutive or upregulated following TLR4 stimulation and functions 
to downregulate surface expression and promote degradation of TLR4 as well 
as suppressing TLR4 gene induction. TLR4 expression on macrophages has 
been reported to be decreased by ST2-deficiency [340] and consistent with 
this, it was found here that there is also decreased TLR4 expression in ST2-/- 
MC. TLR4 expression is constantly cycled in macrophages allowing 
environmental sampling, and it has been suggested that ST2, the expression 
of which appears to be linked to that of TLR4, behaves in a similar manner by 
cycling though early endosomes alongside TLR4 [281, 282].  
 
LPS upregulates ST2 levels in PDMC and BMMC indicating a negative feedback 
response perhaps analogous to that described for macrophages where MyD88 
sequestration by ST2 via TIR domains has previously been reported [178, 
179]. Perhaps consistent with this, a recent study suggested IL-33-ST2 
signaling induced proteasome-dependent degradation of IRAK1, a signaling 
element that is recruited to activated MyD88 and non-redundant for TLR4 
signaling in murine mast cells [341], In addition, it has also been reported 
that TLR4 signaling can be inhibited by sustained interaction of the p85 
regulatory subunit of PI3K with MyD88 [57, 354] and ES-62 targets MyD88 in 
mast cells and T cells to prevent IL-1R/TLR signaling suggesting this is a key 
intersecting point in ST2 and TLR4 signaling (Figure 5.17), the latter both for 
canonical pro-inflammatory signaling (eg LPS) and also subversion to an anti-
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inflammatory phenotype (ES-62). Regardless of the mechanism, however, IL-
33 modulation of TLR4-induced mast cell activation is important in both 
inflammation and homeostasis as aberrant responses to commensal bacteria 
may be limited by low level, constitutive exposure to IL-33 at epithelial 
surfaces [341]. 
 
Although LPS is well established to drive Th1 immune responses, ST2-
modulation of LPS responses in MC provides a mechanism whereby IL-33 may 
drive the development of a strong Th2 phenotype or alternatively, a 
mechanism whereby LPS can limit Th2 responses.  IL-33 has been shown here 
to have the capacity to induce IL-17, IL-22 and IL-23 generation by MC, 
cytokines associated with a Th17 phenotype. The ability of Th17 cells to 
master regulate polarisation towards a Th1 or Th2 phenotype in autoimmune 
(role in type 1 diabetes reviewed in [355]) or allergic (role in asthma 
reviewed in [356, 357]) disease respectively, conditions in which IL-33 has 
been proposed to play a pathogenic role [221, 358, 359], may therefore 
suggest an important role for ST2-TLR4 crosstalk in mast cells in regulating 
such responses. Indeed, MC have previously been demonstrated to promote 
Th17 T cell differentiation via their effect on DC [93] and abundant IL-6 
production [360]. The IL-33 stimulated production of IL-17, IL-22 and IL-23 by 
MC shown here now supports previous work reporting direct stimulation of 
Th17 differentiation by IL-33-stimulated mast cells in vitro and IL-33-
mediated exacerbation of Th17-pathogenesis in OVA-induced allergic asthma 
in mice [244]. This regulatory mechanism may also provide a means whereby 
IL-33 and MC can exhibit both protective and pathological roles in disease, 
depending on the tissue involved and the surrounding inflammatory situation.  
 
The ES-62-mediated inhibition of Th17-related cytokines from MC reflects the 
ability of the parasite product to ameliorate Th17/Th1 [135] and Th17/Th2 
[345] biased inflammatory situations and may suggest that mast cells may be 
targeted under these conditions. Indeed, ES-62 is able to significantly reduce 
mast cell cytokine production in response to all of the key immunoregulatory 
stimuli tested as evidenced by its inhibition of LPS/TLR4, IL-33/ST2 and FcεRI 
signaling, either independently or in combination. The mechanisms involved 
have not been fully defined but with respect to FcεRI and LPS/TLR4 (Chapter 
3), this appears to involve targeted degradation of PKCα, PKCδ and MyD88 
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[126, 134]. The mechanism underpinning its action against IL-33 signaling is 
much less understood but preliminary studies presented here again indicate 
suppression of calcium mobilisation.  
 
Interestingly, it was proposed previously [132] that ES-62 might exploit the 
ability of ST2 to sequester MyD88 [179, 340] to modulate TLR signaling in 
monocytes, however, this did not appear to be the case as ES-62 was still 
able to inhibit IL-12 production in response to LPS stimulation in cells from 
ST2-deficient mice [132]. The finding that FcεRI and LPS responses in BMMC 
can still be inhibited by ES-62 in the absence of ST2 expression, supports and 
extends these previous data. Interestingly, therefore, the preliminary data 
presented here also suggest that ST2 is required for inhibition of PDMC 
responses by ES-62. It was previously reported that whilst ES-62 
downregulated expression of PKCα in each of PDMC, BMMC and CTMC it 
potentially mediated it's suppressive effects on the strong, TLR-biased 
cytokine responses of BMMC, but not PDMC, at least in part by downregulating 
MyD88 [134].  These new data may suggest that as PDMC only make weak 
cytokine responses, even in response to LPS/TLR4, that exploiting the ability 
of ST2 to sequester MyD88, rather than directly inducing its degradation is 
sufficient to enable ES-62-mediated suppression of such responses (5.18). 
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Figure 5.1 IL-33/ST2 and LPS/TLR4 share common signaling molecules. 
 
Members of the IL-1R family and TLR family of receptors such as ST2 and TLR4 
have similarities in signaling pathways.  Using TIR domains, ST2 and TLR4 
recruit MyD88 to initiate signaling using IRAK1, IRAK4 and TRAF6, resulting in 
canonical NFκB, ERK, JNK and p38 activation. 
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Figure 5.2 IL-33 increases cytokine production induced by FcεRI, an effect 
dependent on ST2 expression. 
 
IgE-sensitized PDMC (A) and BMMC (B) obtained from WT or ST2 -/- BALB/c 
mice were treated simultaneously with DNP (0.5 µg/ml) to induce cross-linking 
(XL) of FcεRI and IL-33 (10 ng/ml) for 24 h at 37oC before analysis of IL-6 and 
IL-13 levels in culture supernatants by ELISA. Data are presented as the mean 
of triplicate samples ± SD from a single experiment representing 3 independent 
experiments. Statistical analysis using unpaired, two-tailed t-test. *** p< 0.001. 
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Figure 5.3 FcεRI-stimulated calcium mobilisation and NFκB activation is 
dependent on ST2 expression. 
 
WT or ST2 -/- PDMC (A, C) and BMMC (B, D) sensitised with murine anti-DNP IgE 
(0.5 µg/ml) and loaded with Fura-2/AM were stimulated at 50s in serum-free 
HBSS with DNP (0.5 µg/ml) to induce cross-linking (XL) of FcεRI. Intracellular 
calcium mobilisation and influx were recorded in real-time using excitation-
emission ratios of 340/380 nm. For the analysis of intracellular mobilisation 
alone, the cells were stimulated in calcium-free buffer supplemented with 100 
µM EGTA to remove all extracellular calcium (EGTA) (C, D). Calcium levels 
were calculated from Rmax and Rmin values and the data presented as the 
mean calcium values of triplicate samples  ± SD (baseline calcium values 
subtracted) from a single experiment representative of at least 3 independent 
experiments. Statistical analysis using a two-tailed, paired t-test. *** p< 0.001. 
WT or ST2 -/- BMMC (E) sensitized with murine anti-DNP IgE (0.5 µg/ml) 
overnight were cultured with DNP (0.5 µg/ml) to induce cross-linking (XL) of 
FcεRI for the indicated times and expression of IκBα analysed by Western 
blotting. “0 min” represents zero timepoint control. β-actin was used as a 
loading control. Graphical presentation of densitometric analysis was 
performed using Image J to determine the relative intensity of IκBα compared 
to β-actin for each timepoint. Data are from a single experiment.  
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Figure 5.4 FcεRI induced ERK phosphorylation is decreased in ST2 -/- 
murine mast cells. 
 
WT or ST2 -/- PDMC (A) or BMMC (B) sensitized with murine anti-DNP IgE (0.5 
µg/ml) overnight were cultured with DNP (0.5 µg/ml) to induce cross-linking 
(XL) of FcεRI for the indicated times and expression of Pp44/p42 (pERK) 
analysed by Western blotting. “0 min” represents zero timepoint control. 
p44/42 (ERK) was used as a loading control. Graphical presentation of 
densitometric analysis was performed using Image J to determine the relative 
intensity of Pp44/42 compared to p44/42 for each timepoint. Data are from a 
single experiment representative of at least 2 independent experiments. 
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Figure 5.5 Co-administration of IL-33 and LPS increases cytokine 
production from murine mast cells and is increased further in 
the absence of ST2 expression. 
 
IgE-sensitized PDMC (A) and BMMC (B) obtained from WT or ST2 -/- BALB/c 
mice were treated simultaneously with LPS (0.5 µg/ml) and IL-33 (10 ng/ml) 
for 24 h at 37oC before analysis of IL-6 and IL-13 levels in culture supernatants 
by ELISA. Data are presented as the mean of triplicate samples ± SD from a 
single experiment representing 3 independent experiments. Statistical analysis 
using unpaired, two-tailed t-test. ** p< 0.01 and *** p< 0.001. 
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Figure 5.6  LPS upregulates frequency and expression of ST2 on murine 
mast cells. 
 
Flow cytometric analysis of PDMC (A, C, E, G) or BMMC (B, D, F, H) sensitized 
with murine anti-DNP IgE and treated with LPS (0.5 µg/ml) overnight. Cells 
were gated for live 7AAD- , CD117+ and FcεRI+ cells then analysed for surface 
(A-H) and total (surface and intracellular) (G-H) ST2 expression. The gating 
plots relative to WT isotype (A, B) were used to determine % frequency (C, D) 
and the geometric mean fluorescence (GMFI) (E-H) of ST2+ cells. Data 
represents the combined results of two independent experiments performed in 
duplicate where error bars represent SEM. Statistical analysis is by unpaired, 
one-tailed t-test. * p< 0.05 and *** p< 0.001. 
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Figure 5.7 Absence of ST2 reduces the TLR4 expression of murine mast 
cells. 
 
Flow cytometric analysis of PDMC (A, C, E, G) or BMMC (B, D, F, H) sensitized 
with murine anti-DNP IgE and treated with LPS (0.5 µg/ml) overnight. Cells 
were gated for live 7AAD-, CD117+ and FcεRI+ cells then analysed for surface 
(A-F) and total (surface and intracellular) (G-H) TLR4 expression. The % 
frequency (C, D) and the geometric mean fluorescence (GMFI) (E, H) was 
determined relative to gating against the relevant WT isotype control. Data 
represents the combined results of two independent experiments performed in 
duplicate where error bars represent SEM. Statistical analysis is by unpaired, 
one-tailed t-test.  
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Figure 5.8 LPS-stimulated calcium mobilisation is dependent on ST2 
expression. 
 
WT or ST2 -/- PDMC (A, C) and BMMC (B, D) sensitised with murine anti-DNP IgE 
(0.5 µg/ml) and loaded with Fura-2/AM were stimulated at 50s in serum-free 
HBSS with LPS (0.5 µg/ml). Intracellular calcium mobilisation and influx were 
recorded in real-time using excitation-emission ratios of 340/380 nm. For the 
analysis of intracellular mobilisation alone, the cells were stimulated in 
calcium-free buffer supplemented with 100 µM EGTA to remove all 
extracellular calcium (EGTA) (C, D). Calcium levels were calculated from Rmax 
and Rmin values and the data presented as the mean calcium values of 
triplicate samples  ± SD (baseline calcium values subtracted) from a single 
experiment representative of at least 3 independent experiments. Statistical 
analysis using a two-tailed, paired t-test.* p<0.05 and *** p< 0.001. 
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Figure 5.9 LPS-stimulated NFκB activation is dependent on ST2 
expression. 
 
WT or ST2 -/- PDMC (A) and BMMC (B) sensitized with murine anti-DNP IgE (0.5 
µg/ml) overnight were cultured with LPS (0.5 µg/ml) for the indicated times 
and expression of IκBα analysed by Western blotting. “0 min” represents zero 
timepoint control. β-actin was used as a loading control. Graphical 
presentation of densitometric analysis was performed using Image J to 
determine the relative intensity of IκBα compared to β-actin for each 
timepoint. Data are from a single experiment representative of a single (A) or 2 
independent experiments (B).  
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Figure 5.10 LPS- induced ERK phosphorylation is increased in ST2 -/- 
murine mast cells. 
 
WT or ST2 -/- PDMC (A) or BMMC (B) sensitized with murine anti-DNP IgE (0.5 
µg/ml) overnight were cultured with LPS (0.5 µg/ml) for the indicated times 
and expression of Pp44/p42 (pERK) analysed by Western blotting. “0 min” 
represents zero timepoint control. p44/42 (ERK) was used as a loading control. 
Graphical presentation of densitometric analysis was performed using Image J 
to determine the relative intensity of Pp44/42 compared to p44/42 for each 
timepoint. Data are from a single experiment representative of at least 2 
independent experiments. 
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Figure 5.11 ES-62 modulates IL-33-induced cytokine responses.  
 
 
PDMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight (A) or 
non-sensitized (B) in the presence of 2 µg/ml or the indicated dose (B) of ES-62 
or 2 h ES-62 (2 µg/ml) treatment prior to stimulation with IL-33 (10 ng/ml) for 
24 h at 37oC.Release of IL-13, IL-6, IL-17, IL-22, IL-23 and MCP-1 was measured 
by ELISA from culture supernatants (A). (B) presented as % change compared to 
uninhibited cytokine production. Results from a single experiment representing 
at least 2 independent experiments with the exception of the IL-17 ELISA. Error 
bars represent SD. Statistical analysis is by unpaired, one-tailed t-test. * p< 
0.05, ** p< 0.01 and *** p< 0.001. 
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Figure 5.12  ES-62 modulates calcium mobilisation induced by IL-33 and 
directly stimulates calcium mobilisation in mast cells. 
 
PDMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight in the 
presence (A) or absence of (B) ES-62 (2 µg/ml) then loaded with Fura-2/AM 
before stimulation at 50s in serum-free HBSS with IL-33 (100 ng/ml) (A) or ES-
62 (2 µg/ml) (B). Intracellular calcium mobilisation and influx were recorded in 
real-time using excitation-emission ratios of 340/380 nm. Calcium levels were 
calculated from Rmax and Rmin values and the data presented as the mean 
calcium values of triplicate samples  ± SD (baseline calcium values subtracted) 
from a single experiment representative of at least 2 (B) or 3 (A) independent 
experiments. Statistical analysis using a two-tailed, paired t-test. **** p< 
0.0001. 
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Figure 5.13 IL-33-induced cytokine production is modulated by ES-62. 
 
WT or ST2 -/- PDMC (A) and BMMC (B) sensitized with murine anti-DNP IgE (0.5 
µg/ml) overnight in the presence or absence of ES-62 (2 µg/ml) were 
stimulated with IL-33 (10ng/ml) for 24 h at 37oC before release of IL-13 and IL-
6 was measured by ELISA from culture supernatants. Data are presented as the 
mean of triplicate samples ± SD from a single experiment representing 3 
independent experiments. Statistical analysis using unpaired, two-tailed t-
test.* p< 0.05, ** p< 0.01 and *** p< 0.001. 
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Figure 5.14 LPS-induced cytokine production is increased in the absence of 
ST2 expression and is still modulated by ES-62. 
 
WT or ST2 -/- PDMC (A) and BMMC (B) sensitized with murine anti-DNP IgE (0.5 
µg/ml) overnight in the presence or absence of ES-62 (2 µg/ml) were 
stimulated with LPS (0.5 µg/ml) for 24 h at 37oC before release of IL-13 and IL-
6 was measured by ELISA from culture supernatants. Data are presented as the 
mean of triplicate samples ± SD from a single experiment representing 3 
independent experiments. Statistical analysis using unpaired, two-tailed t-
test.* p< 0.05, ** p< 0.01 and *** p< 0.001. 
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Figure 5.15  Cytokine production following co-administration of LPS and IL-
33 is altered in the absence of ST2 expression and is 
modulated by ES-62. 
 
WT or ST2 -/- PDMC (A) and BMMC (B) sensitized with murine anti-DNP IgE (0.5 
µg/ml) overnight in the presence or absence of ES-62 (2 µg/ml) were 
stimulated with LPS (0.5 µg/ml) and IL-33 (10 ng/ml) for 24 h at 37oC before 
release of IL-13 and IL-6 was measured by ELISA from culture supernatants. 
Data are presented as the mean of triplicate samples ± SD from a single 
experiment representing 3 independent experiments. Statistical analysis using 
unpaired, two-tailed t-test.* p< 0.05, ** p< 0.01 and *** p< 0.001. 
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Figure 5.16  Cytokine production following co-stimulation of FcεRI by IL-33 
is reduced in the absence of ST2 expression and is modulated 
by ES-62. 
 
WT or ST2 -/- PDMC (A) and BMMC (B) sensitized with murine anti-DNP IgE (0.5 
µg/ml) overnight in the presence or absence of ES-62 (2 µg/ml) were 
stimulated with DNP (0.5 µg/ml) to induce cross-linking (XL) of FcεRI and IL-33 
(100 ng/ml) for 24 h at 37oC before release of IL-13 and IL-6 was measured by 
ELISA from culture supernatants. Data are presented as the mean of triplicate 
samples ± SD from a single experiment representing 3 independent 
experiments. Statistical analysis using unpaired, two-tailed t-test.* p< 0.05, ** 
p< 0.01 and *** p< 0.001. 
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Table 5.1  Summary of the role of ST2 in FcεRI-XL and LPS/TLR4 signaling 
and responses in BMMC and PDMC. 
 
In the absence of ST2 expression, FcεRI-XL calcium signaling, NFκB and ERK 
activation and subsequent IL-6 and IL-13 cytokine responses are reduced in 
both BMMC and PDMC. LPS-induced responses in ST2-deficient MC vary based on 
murine MC subtype. In BMMC, LPS calcium mobilisation is inhibited but not in 
PDMC whereas NFκB and ERK activation is increased in both BMMC and PDMC. 
IL-6 production is increased in ST2-/- MC after LPS treatment but IL-13 is 
alternatively regulated in BMMC (decreased) and PDMC (increased). Co-
stimulation with IL-33 decreases LPS-induced IL-6 and IL-13 even in the 
absence of the IL-33 receptor, ST2. ES-62 does not require ST2 expression to 
inhibit FcεRI-XL cytokines, in both BMMC and PDMC and LPS responses in BMMC, 
however fails to modulated LPS responses in ST2 -/- PDMC. 
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Figure 5.17 Proposed method for ST2-TLR4 interaction and signaling 
modulation by ES-62. 
 
Previous data indicates that ST2 sequesters MyD88 from TLR4, limiting LPS 
signaling (ref) and reflects that MyD88 is shared between the receptors as it is 
required for both IL-33 and LPS to signal (A). With the absence of ST2, TLR4 
has greater access to MyD88 and so signaling propagation increases (B). ES-62 
does not need ST2 expression to signal (at least in BMMC) but is able to 
modulate ST2 signaling, most likely via TLR4-mediated MyD88 sequestration 
and degradation as seen previously in murine mast cells (C) [134]. 
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Figure 5.18  Model for alternate ES-62 modulation of BMMC and PDMC 
 
FcεRI, TLR4 and ST2 responses can be inhibited by ES-62 in both BMMC and 
PDMC, however the mechanism of suppression may vary in each mast cell type. 
Suggested methods of inhibition involve targeted degradation of PKCα and 
MyD88 to suppress calcium responses. In BMMC, but not PDMC, FcεRI and TLR4 
modulation does not require ST2 expression suggesting that the proposed 
mechanism of ST2-mediated MyD88 sequestration is not used by ES-62 in BMMC. 
However, with their requirement for ST2 expression, ES-62 may hijack ST2 to 
inhibit TLR4 signals via sequestration of MyD88 in PDMC, an ability made 
possible by the reduced cytokine responses from PDMC compared to BMMC. 
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6  ST2-cKIT crosstalk  
6.1 Introduction  
6.1.1 IL-33/ ST2 and SCF/ cKIT signaling 
SCF signaling has been reported to enhance responses via TLR4 [57] and FcεRI 
[55, 56] in mast cells (MC). For example, it appears that prolonged low levels 
of SCF stimulation allows MCs to be activated and degranulate in response to 
concentrations of Ag that would otherwise fail to induce activation; SCF 
appears to do this by increasing the basal phosphorylation levels of ERK, p38 
and LAT [55]. Recently, evidence has emerged to suggest that IL-33 and SCF 
signaling are similarly linked, with SCF priming of cKIT allowing IL-33 binding 
to ST2 to induce a physical association between the receptors, facilitating a 
broader and more enhanced signaling profile [273].  
 
Accordingly, in HMC-1, a human leukemic mast cell line, co-administration of 
IL-33 and SCF increases IL-6 and IL-13 production compared to that induced 
by IL-33 alone [361] and reflecting this, SCF increases ST2-mediated JNK and 
ERK phosphorylation in HMC-1 [361]. Indeed, in HMC-1 cells whilst ST2 
signaling was found to cross-activate cKIT, cKIT signaling was required for full 
IL-33 responses in mast cells [273] as evidenced by the finding that Imatinib, 
an inhibitor of cKIT signaling, suppressed IL-33-induced STAT3, ERK, PKB and 
JNK1 activation in HMC-1 cells, resulting in reduced IL-4, IL-6 and IL-8 
production. Although these data suggest that cKIT signaling is important for 
optimal IL-33 responses, the residual IL-33-mediated signaling observed in the 
presence of Imatinib indicates the activation of both cKIT-dependent and -
independent signaling processes [273]. Consistent with this proposal, whilst 
cKIT -/- BMMC exhibit reduced PKB and JNK1 activation and no ERK activation 
in response to IL-33, the kinetics and extent of JNK2, NFκB and p38 signaling 
are similar to those observed in WT BMMC. The mechanisms for such crosstalk 
are not clear but there is a physical association between cKIT, IL-1RAcP and 
ST2 and this association only occurs if cKIT has been activated, either 
constitutively in HMC-1 or following SCF pretreatment in BMMC. Nevertheless, 
in addition to the physical association between their receptors, crosstalk 
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between IL-33 and SCF signaling appears to be dependent on PI3K in murine 
MC [57]. It has therefore been proposed that SCF priming of cKIT is required 
to allow cells to respond to IL-33/ST2 signaling. 
 
6.1.2 SCF and cKIT signaling 
Many different cell types express SCF; for example in the lung, it is expressed 
by epithelial cells, fibroblasts, smooth muscle cells, endothelial cells, 
eosinophils and mast cells and in humans, SCF is produced in a range of 
tissues including thymus, spleen, testes and placenta [56]. SCF can be 
expressed in membrane-bound or soluble forms, with particular cell types 
exhibiting differential patterns of expression [362]. Similarly, the high 
affinity receptor for SCF, cKIT, is a transmembrane, type III receptor tyrosine 
kinase (RTK) [56] that is expressed on a variety of cells including 
haematopoietic progenitor cells (HPC), where it plays roles in self-renewal 
and differentiation of HPC into cells of the myeloid and lymphoid lineages. 
During haematopoiesis, cKIT is generally downregulated as cells mature, with 
the exception of mast cells where it remains essential for survival, 
differentiation, chemotaxis and activation [363, 364].  
 
Injection of recombinant SCF into patients induces skin hyperpigmentation 
and MC hyperplasia and hyperactivation, the latter as evidenced by 
degranulation and consequent increased levels of MC tryptase and histamine. 
SCF signaling creates chemotatic gradients for mast cell localization within 
tissues [56] and consistent with this, local SCF concentrations increase rapidly 
during early stages of wound healing then decline, mirroring the kinetics of 
mast cell recruitment and activation [362]. However, although in acute 
responses, SCF increases mast cell activation [41, 365], chronic exposure to 
SCF makes MC hyporesponsive to signals received by receptors coupled to 
tyrosine kinases, due to the induction of defective cytoskeletal 
reorganization [41].  
 
 
 183 
6.1.3 IL-33 and SCF in Disease 
6.1.3.1 IL-33 in cancer immunology 
Crosstalk between IL-33/ST2 and SCF/cKIT broadens the network of signaling 
components recruited, promoting greater functional responses from mast 
cells. Such cooperative signaling therefore has a potentially important role in 
pathologies where these two molecules are found in abundance, not only in 
cutaneous inflammation but also in cancer pathology, where they contribute 
to angiogenesis, cell growth and metastasis. Elevated serum IL-33 levels have 
been associated with several cancers including gastric cancer [366] and 
hepatocellular carcinoma [367, 368]. Indeed, as higher serum levels of IL-33 
correlate with increased metastasis, it has been proposed that they may be 
helpful in determining disease prognosis. 
 
Dissection of the role (s) of IL-33 in cancer, however, has been complicated 
by differing homeostatic roles played by the cytokine, depending on the local 
microenvironment. For example, although IL-33 is barely detectable in the 
vasculature around tumors in human, as its expression is most likely 
downregulated by the general inflammatory milieu present at the tumor site 
[369], it can drive angiogenesis as characterized by increased proliferation, 
migration and differentiation of human endothelial cells in vivo by inducing 
NO from endothelial cells [370]. Likewise, the ability of IL-33 to drive 
development of fibrosis and aberrant tissue growth, such as that seen in 
psoriasis [371], may also contribute to pathogenesis in cancer. Moreover, the 
ability of this cytokine to produce pro-inflammatory cytokines is also 
important as, for example, the IL-33 produced by myofibroblasts in the 
pancreas induces release of IL-6 and IL-8 from cells in the tumor 
microenvironment that are partly responsible for the progression of 
pancreatic cancer [372]. Consistent with this role for pro-inflammatory 
cytokines, prolonged NFκB activation by IL-33 has also been implicated in 
tumorogenesis [371]. 
 
Relating to the role of inflammation in cancer, IL-33 may also increase 
tumour growth and metastasis by its ability to influence DC phenotype and 
hence, the Th phenotype [373] of the immune response to tissue damage. 
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Thus, IL-33 release is an early danger signal for skin damage with UVB 
exposure upregulating IL-33 mRNA and protein in the epidermis of both mice 
and humans. Interestingly, therefore, UVB–induced squamous cell carcinomas 
that are not destroyed by immune responses express high levels of IL-33. 
Although IL-33 does not appear to promote tumour growth directly, its ability 
to reduce Th1 responses protects the tumour by limiting antigen presentation 
and cytotoxic cell activation [374]. This effect is also seen in a model of 
metastatic breast carcinoma where inhibition of ST2 signaling can increase 
anti-tumor responses characterized by reduced metastasis, slower tumor 
growth and increased levels of CD4+, CD8+ T cells and NK cells which have 
greater cytotoxic activity and IFNγ production [373]. These responses are 
proposed to be due to the inability of IL-33 to drive Th2 development under 
these conditions allowing a Th1/Th17 phenotype, that can combat tumor 
development, to dominate.  
 
It should be noted however, that IL-33-ST2 signaling in mast cell responses 
may also drive proinflammatory, anti-tumour responses as it has been 
proposed that mast cells responding to IL-33 released after cell injury and 
necrosis may invade necrotizing tumours [63]. The IL-33 released may not 
necessarily be produced by the tumor itself but could be generated by 
damaged cells surrounding the tumor [366, 372]. 
 
 
6.1.3.2 cKIT in cancer immunology 
Dysregulation of cKIT signaling appears to play two major roles in the 
development of cancers; initially, during the initial transformation of 
neoplastic cells, including mast cells, usually via gain-of function mutations 
or during progression and expansion of tumours, via increased angiogenesis 
and metastasis [375], with cKIT contributing to tumor growth via autocrine 
and paracrine stimulation in response to SCF produced by transformed cells 
[376], including mast cells [377]. In malignant cancers, cKIT plays multiple 
(contradictory) roles; whereas in melanomas decreased cKIT expression 
prevents apoptotic signaling and increases cell survival, upregulation of cKIT 
expression increases survival, proliferation and oncogenic transformation in 
myeloid and lymphoid proliferative diseases.  Similarly, in mastocytosis, high 
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cKIT expression can lead to poor prognosis and resistance to chemotherapy 
[376].  A number of potential oncogenic mutations of the cKIT receptor have 
been identified and the phenotype of disease can be determined by the type 
of mutation, the genetic background and the cell type affected, for example, 
mutations in the tyrosine kinase domain have been found to be particularly 
associated with mastocytosis [364] [376].  
 
 
6.1.3.3 Mast cells in cancer immunology 
Although their function in disease development and progression is not clear, 
mast cells have been implicated in playing a pathogenic role in a range of 
cancers including, skin [378], breast [379] [380], lung [381, 382] kidney [383], 
melanoma [384] and multiple myeloma [385]. Consistent with this, MC-
derived mediators, such as TNFα, VEGF, IL-8 and serine proteases promote 
angiogenesis, allowing increased tumor growth in the early stages and later, 
promotion of metastasis. Moreover, the levels and activity of mast cell 
chymase, tryptase and carboxypeptidase A are increased during progression 
of skin tumors and correlate with the induction and development of blood 
vessels within the skin tumor [386] whilst the ability of mast cells to drive 
inflammation towards a Th2 phenotype, promotes a more tumor-protective 
environment. Indeed, the precise function of mast cells in cancers may be 
determined by the differing tumour size, type and location, [11] (reviewed in 
[364]) as recruited immature mast cells can become “tuned” by the tumor to 
provide pro-metastatic signals [386]. 
 
 
6.1.3.4 HMC-1; an in vitro model of neoplastic mast cells 
Neoplastic mast cell diseases, termed mastocytosis can be divided into two 
categories, systemic and cutaneous with clinical symptoms depending on the 
location of mast cells and the release of specific mediators [387]. Although 
rare, systemic mastocytosis, is very aggressive and the pathology induced by 
the infiltrating mast cells generally results in a poor prognosis. Current 
treatments are limited to reducing total mast cell numbers, hence a more 
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neoplastic-specific therapy would allow the preservation of homeostatic and 
protective mast cell responses, reducing deleterious side-effects. Consistent 
with the role of SCF in mast cell survival and development, mastocytosis is 
frequently characterised by mutations in the cKIT receptor.  
 
HMC-1 cells are a human neoplastic mast cell line derived from a patient with 
mast cell leukemia [388]. HMC-1 cells actually comprise two distinct lines; 
HMC-1.1 identified by their V560G mutation on cKIT and HMC 1.2, bearing the 
D816V mutation. In humans, D816V is the most common mutation in systemic 
mastocytosis [364] and this allows ligand-independent autophosphorylation 
[56]. Although the mutation is found in haematopoietic progenitors and 
hence, subsequently in multiple cell lineages, pathogenesis is limited to mast 
cells [364]. Interestingly, therefore, mice with an equivalent mutation, D814V 
exhibit various acute leukemias and lymphomas, but not mast cell disease, 
suggesting that in mice this cKIT mutation is sufficient to trigger proliferative 
disease. By contrast, cKIT mutations are rarely found in human leukemias or 
lymphomas, suggesting the existence of differential pathogenic pathways for 
these diseases in humans and mice.   
 
HMC-1 represent immature mast cells that are independent of SCF for growth 
and survival and reflecting this maturation status, are characterised by their 
lack of well-formed granules, low tryptase and chymase expression as well as 
their lack of functional IgE receptors [389]. Reflecting their independence of 
SCF, HMC-1 exhibit constitutive cKIT signaling [390] and thus provide a good 
in vitro cell model to investigate SCF-cKIT signaling and its crosstalk with 
other signal transducers in cancer in order to identify potential novel 
therapeutic targets.  
 
 
6.2 Aims 
To investigate potential crosstalk between IL-33/ST2 and SCF/cKIT signaling 
in both primary (murine PDMC and BMMC) and transformed (HMC-1) mast 
cells, in particular to determine whether this involves PLD and SphK and can 
be modulated by ES-62 
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To investigate the role of mTOR signaling in such crosstalk in neoplastic 
human mast cells 
 
6.3 Results and Discussion 
6.3.1 Cooperation between SCF and IL-33 signaling in mast 
cells 
6.3.1.1 The effect of SCF on IL-33-induced responses in murine mast 
cells.  
Previous studies have reported increased cytokine responses following co-
stimulation of mast cells with SCF and IL-33 [273, 274]. Whilst IL-33 can 
stimulate release of MCP-1, IL-6 and IL-13, SCF can induce significant 
production of MCP-1, but not IL-6 or IL-13 from IgE-sensitized PDMC (Figure 
6.1 A). However, co-administration of IL-33 and SCF produced significantly 
increased responses of all of these cytokines, with synergistic responses being 
observed for both IL-6 and IL-13, where the resulting cytokine levels are 
greater than the sum of individual stimulation. MCP-1 production is less than 
additive, but as both IL-33 and SCF induce strong responses, this may reflect 
that a peak response has been reached.  
 
SCF, unlike IL-33, induces proliferation of both PDMC (Figure 6.1 B) and BMMC 
(Figure 6.1 C). Interestingly therefore, this SCF response is significantly 
enhanced by co-stimulation with IL-33, such crosstalk perhaps providing a 
rationale for the ability of IL-33 to stimulate human MC proliferation [62], but 
not PDMC or BMMC, as these data may suggest that murine MC may require 
greater levels of SCF than that found endogenously in serum during culture. 
 
The increased responses to IL-33 in the presence of SCF has potential 
implications for the role of mast cells in the development and progression of 
cancers, as for example mastocytosis, in which mutations generating 
constitutively active cKIT are observed, is characterised by MC 
hyperresponsiveness both in terms of cytokine production and proliferation 
(hyperplasia) [56, 391].  
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6.3.2  SCF enhances IL-33-induced calcium mobilisation. 
In IgE-sensitized PDMC, SCF was found to stimulate calcium mobilisation in a 
dose-dependent manner (Figure 6.2 A), with intracellular and extracellular 
mobilisation being detected at the highest dosage tested (100 ng/ml; Figure 
6.2 B). By contrast, at the lowest dose (1 ng/ml) the calcium profile has lost 
the rapid peak characteristic of intracellular mobilisation and appears to 
predominantly reflect influx of extracellular calcium (Figure 6.2 A), 
unfortunately this was not confirmed, perhaps suggesting that the intensity 
and phenotype of SCF calcium signaling may be regulated by levels of 
receptor ligation, in a similar manner to that described for FcεRI [392]. 
Interestingly, unlike IL-33, SCF does not require IgE-sensitization to mobilise 
calcium (Figure 6.2 C). 
 
Co-administration of IL-33 induces stronger calcium mobilisation than that 
observed with either IL-33 or SCF alone, with these effects appearing to be 
additive at both the lowest dose (1 ng/ml Figure 6.2 D) or highest dose (100 
ng/ml Figure 6.2 E) of SCF tested. Analysis of the responses observed in the 
absence of extracellular calcium (Figure 6.2 F) suggests that the additive 
effects in response to IL-33 at 100 ng/ml predominantly reflect enhancement 
of the influx of extracellular calcium as the mobilisation of intracellular 
calcium is not significantly modulated. These data indicate that IL-33- and 
SCF cooperate to increase calcium signaling although the additive nature of 
the response suggests that the enhanced influx of extracellular calcium 
appears to be autonomously controlled by each stimulus. This is similar to 
that reported for SCF amplification of FcεRI responses in BMMC, where SCF 
both induces calcium mobilisation and enhances FcεRI-mediated-calcium 
signaling. However, in this case it was concluded following baseline 
adjustment analysis that SCF acted to build a platform for further Ag-
stimulation of calcium mobilisation [55].  
 
After observing these amplifying effects of SCF on IL-33-mediated calcium 
mobilisation and cytokine production, it was hypothesized that when used in 
conjunction, IL-33 and SCF could overcome a threshold not reached by IL-33 
alone in PDMC to initiate the degranulation responses observed with human 
mast cells that may have been exposed to SCF during their culture conditions 
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[62]. However, stimulation with IL-33 plus SCF did not induce degranulation 
of PDMC (Figure 6.3 A). This failure of IL-33 and/or SCF to induce 
degranulation by PDMC, despite inducing strong calcium mobilisation might 
perhaps reflect an inability of these stimuli to downregulate an inhibitor of 
degranulation. A precedent for this has been provided by the finding that 
PDGF fails to induce degranulation despite stimulating a strong calcium 
response because it does not downregulate cAMP signaling that acts to inhibit 
degranulation [393]. 
 
 
6.3.2.1 The effect of SCF on IL-33-induced NFκB activation. 
As SCF augmented IL-33-ST2-mediated calcium signaling, it was investigated 
whether these effects were reflected in enhanced activation of NFκB. 
Interestingly, despite inducing strong calcium signaling, SCF was unable to 
activate NFκB signaling, at least of the canonical variety, as indicated by IκB 
degradation. However, when administered in combination with IL-33, IκB 
degradation appeared to occur slightly faster than observed following 
treatment with IL-33 alone (Figure 6.3 B). This inability of SCF to activate 
NFκB suggests that Ca2+ activation and NFκB are not directly associated in SCF 
signaling, although these experiments do not rule out the possibility that cKIT 
couples to NFκB activation via the non-canonical pathway, which does not 
require IκB degradation [394, 395]. 
 
 
6.3.2.2 IL-33 responses are modulated by serum factors in addition to 
SCF  
As SCF can enhance IL-33 responses, it is possible that differential levels of 
SCF present in FCS sources [396, 397], may contribute to the observed 
discrepancies in the functional responses of IL-33 presented in this thesis with 
those in the literature. To investigate this, the responses to IL-33 in the 
presence and absence of exogeneous were assessed under conditions of 
conventional (10%) and reduced (1%) serum. In addition, as prolonged (>48 h) 
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culture with SCF has been reported to inhibit FcεRI-mediated MC activation 
[41], similar effects on IL-33-mediated MC responses were also determined. 
 
Interestingly, the SCF-mediated amplification of IL-33-stimulated cytokine 
production is more pronounced in the presence of high (10%) levels of FCS, in 
PDMC (Figure 6.4 A) and, to a lesser extent, BMMC (Figure 6.4 B).  Indeed, in 
1% FCS, SCF can only restore IL-33 responses to the levels observed in 10% 
FCS with IL-33 alone, suggesting that as exogeneous SCF cannot compensate 
for the reduced level of serum, some additional serum factor(s) may be 
required for the optimal cooperative signaling between IL-33/ST2 and 
SCF/cKIT. 
 
 
6.3.2.3  HMC-1 cells, a model of human mastocytosis, respond to IL-33. 
To model the interaction of these cytokines in diseases such as mastocytosis 
the human leukemic mast cell line, HMC-1, was exploited to investigate IL-33 
and/or SCF signaling although unfortunately, in these experiments, the HMC-
1 subtype, HMC-1.1 or HMC-1.2 was not determined. Nevertheless, release of 
IL-6, MCP-1 and TNFα by HMC-1 cells was found to be significantly stimulated 
in response to an increasing dose of IL-33, despite the high levels of MCP-1 
produced constitutively by these cells (Figure 6.5 A).  
Interestingly, although, IL-33 induces cytokine responses by HMC-1 cells, it 
fails to induce calcium mobilisation, even in the presence of IgE (Figure 6.5 
B). These data provide further support that mast cells require to be 
sensitized in order to license IL-33-induced calcium signaling as, in 
combination with data obtained in the presence of DNP to mimic Ag-
mediated crosslinking of FcεRI, they confirm that HMC-1 cells do not express 
functional FcεRI receptors and hence, cannot be sensitized by IgE.  Moreover, 
and perhaps surprisingly given the important role of calcium signaling in 
promoting cytokine generation in primary mast cells [190, 193], these data 
indicate that calcium mobilisation is not required for IL-33-stimulated 
cytokine production by HMC-1 cells. However, as the calcium mobilisation 
experiments are performed in the absence of serum, they do not rule out the 
possibility that SCF or some other serum factor(s) either induce calcium 
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mobilisation or license IL-33 to do so, under the culture conditions pertaining 
in the cytokine assays. Given that cKIT is constitutively active in HMC-1 cells, 
and SCF induces strong calcium signals in PDMC, it is also rather surprising 
that no calcium responses are observed. However the rapid, eccentric signal 
observed may be a reflection of a continuous, dysregulated calcium signal as 
a result of endless cKIT stimulation. 
  
Perhaps consistent with the latter suggestion, IL-33 does not stimulate 
proliferation (as indicated by DNA synthesis) of HMC-1 cells either when 
administered alone or in the presence of exogenous SCF (Figure 6.5 C), 
findings conflicting with those in primary human MC [62].  However, the lack 
of effect of SCF may reflect the constitutive signaling induced by the cKIT 
mutation, although perhaps arguing against this, in reduced serum conditions, 
HMC-1 proliferation is reduced (Figure 6.5 D). Interestingly, therefore, there 
is evidence that although HMC-1 constitutively produce MCP-1, exposure to 
SCF is able to further increase this production [398, 399] via increased ERK 
activation [400]. MAPK signaling does not appear to be (fully) activated by 
the mutated cKIT [401] suggesting that cKIT activity can be further 
stimulated above that induced by the mutation or else, in addition to the 
kinase activity of cKIT, ligation by SCF is required to allow the "activated" 
receptor to interact with co-receptors and/or signal transducers in order to 
recruit the full repertoire of SCF-coupled signaling pathways. 
To further investigate the role of SCF, and other serum factors, in IL-33-
induced responses in HMC-1 cells, these cells were cultured in the presence 
of 1%, rather than 10%, FCS overnight prior to stimulation with IL-33. Basal 
MCP-1 production was found to be reduced under conditions of 1% FCS, and 
IL-33 failed to further stimulate MCP-1 (Figure 6.5 E). To address whether it 
is the SCF present in the serum that is required for IL-33-induced MCP-1 
production by these cells, rSCF was introduced in the presence of both low 
(1%) and high (10%) serum conditions but this did not affect the response, 
further suggesting that there is another component of serum besides SCF 
required for IL-33 signaling in MC. Indeed, the levels of SCF in FCS are 
reported to be less than 100 pg/ml which the investigators claim would be 
“insufficient to promote additive biologic effects”, although this was based 
on treatment of haematopoietic progenitor cells [396].  
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6.3.2.4 The effect of inhibition of cKIT signaling on IL-33 responses. 
To investigate SCF-independent IL-33 responses and probe for any other 
serum dependent effects, analysis was performed in the presence of 
inhibitors that have been reported to potently inhibit SCF-cKIT signaling. 
Imatinib is a tyrosine kinase inhibitor developed to block bcr-Abl signaling but 
that is known to also act on cKIT. It functions by binding to an inactive 
confirmation of the kinase at the site that binds ATP and perhaps reflecting 
this, cannot inhibit cKIT bearing the D816V mutation although it can inhibit 
the V560G variant [402], although this latter form is found in very few 
systemic mastocytosis cases. It has been proposed that resistance to Imatinib 
is most likely due to mutations preventing its binding [364] and to overcome 
this resistance a further cKIT inhibitor was developed. Dasatinib is a small 
molecule, ATP-competitive inhibitor of cKIT that can inhibit both of the 
D816V or V560G cKIT variants as well as Abl and the Src-related tyrosine 
kinases, Btk and Tec [56]. Dasatinib is structurally unrelated to Imatinib and 
can be used at much lower dose [403-405]. However, both inhibitors can also 
target PDGF-R and as this receptor is expressed by mast cells and PDGF is a 
potential candidate for the serum factor(s) [397] that can enhance IL-33 
signaling independently of SCF, it should be borne in mind that Imatinib and 
Dasatinib will also block such signaling. To perform these studies, the dosage 
of each cKIT inhibitor chosen was based on the range used therapeutically 
and although cell viability was reduced following overnight treatment at the 
higher doses of Imatinib, a working window (≤ 10 µM) to assess effects 
independent of toxicity was obtained for both PDMC and BMMC (Figure 6.6 A). 
As SCF-cKIT signaling is essential for mast cell survival this high dose toxicity 
is not surprising and interestingly, the addition of IL-33, a promoter of cell 
survival [62, 268], did not generally overcome the toxic effects of the 
inhibitors, although it tended to protect against cell death in BMMC.   
 
Analysis of cytokine release by PDMC and BMMC demonstrated a clear dose-
dependent inhibition of IL-33-induced MCP-1 (Figure 6.6 B) and IL-6 (Figure 
6.6 C) production following treatment with either Imatinib or Dasatinib. 
Unstimulated, “basal” MCP-1 production In the presence of 10% FCS was 
strongly inhibited by Imatinib and Dasatinib at non-toxic concentrations 
 193 
suggesting that some of the MCP-1 generated was in response to SCF/cKIT 
and/or serum growth factor signaling. BMMC appear to be more dependent on 
SCF/PDGF signaling than PDMC, as when they are treated with Imatinib or 
Dasatinib, basal MCP-1 production is completely ablated. This may represent 
a greater requirement of SCF for survival by the more immature BMMC. IL-6 
production is also sensitive to such inhibition with almost complete 
suppression of basal release. Although it is not possible to determine from 
this analysis how much of this reflects inhibition of cKIT signaling relative to 
that of PDGF, it suggests that the serum enhancer effects are predominantly 
Imatinib/Dasatinib-sensitive. Likewise, IL-33-stimulated MCP-1 and IL-6 
production could be essentially ablated by the inhibitors, particularly by 
Imatinib perhaps reflecting the higher toxicity of this inhibitor at the 
concentrations tested and the protective effects of IL-33 observed in the 
presence of Dasatinib.  
 
Dasatinib suppressed basal and SCF-induced MCP-1 production by PDMC and 
also reduced IL-33-induced MCP-1 (Figure 6.6 D) and IL-6 (Figure 6.6 E), but 
not as potently as it inhibited the SCF-MCP-1 response, perhaps suggesting 
that IL-33-induction of this cytokine can be independent of cKIT signaling. 
Moreover, the synergistic production of MCP-1 or IL-6 in response to the 
combination of IL-33 and SCF was reduced to about the level seen with IL-33 
or SCF alone. It is not clear whether this reflects inhibition of SCF/PDGF-
licensing of IL-33 signaling or direct targeting of downstream targets of ST2-
cKIT crosstalk such as Src-kinases [406] and/or c-Abl, as described for cKIT 
and PDGF-R  [407]. However, it was clear that irrespective of the culture 
conditions, inhibition of IL-33 responses by Dasatinib was not due to an effect 
on levels of surface ST2 (Figure 6.7 A) or cKIT (CD117) expression by PDMC 
(Figure 6.7 B).  
 
As Imatinib and Dasatinib induced negligible toxicity over their therapeutic 
range in HMC-1 cells (Figure 6.7 C, D), these inhibitor studies were next 
extended to HMC-1 cells to determine the effects of blocking cKIT activity on 
the observed IL-33 responses in these neoplastic human mast cells. Perhaps 
consistent with the constitutive activity of cKIT in these cells, raising serum 
levels from 1-10% did not substantially increase basal levels of MCP-1 or IL-6 
released by these cells. Interestingly, therefore, the IL-33 response was 
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completely ablated to the basal level by reduction of FCS to 1% suggesting 
that a non-SCF serum factor is also required for IL-33 responses in these cells 
(Figure 6.7 E). Nevertheless, in all cases, MCP-1 production was inhibited by 
Dasatinib, presumably via inhibition of cKIT. Interestingly, therefore 
Dasatinib (Figure 6.7 G) did not inhibit MC proliferation, although this was 
suppressed by Imatinib (Figure 6.7 F), suggesting that some factor other that 
the mutated cKIT activity was being targeted by Imatinib. 
 
 
6.3.2.5 Role of PLD in crosstalk between IL-33/ST2 and SCF/cKIT 
signaling 
PLD activation by IgE-sensitization was shown to license IL-33-ST2 signaling 
(Chapter 4). However, the cytokine responses to IL-33 in the absence of IgE-
sensitization were also suppressed by PLD inhibitors perhaps suggesting that 
SCF or some other serum factor not present under the conditions of assaying 
either PLD or calcium signaling was responsible for licensing of such IL-33-
functional responses. Thus, as cKIT signaling has been reported to activate 
PLD in a PI3K-dependent manner [408], the role of PLD in the cooperative 
signaling between IL-33 and SCF, and hence in the IL-33-stimulated cytokine 
responses observed in 10% FCS in the absence of IgE-sensitization, were 
investigated. 
 
Firstly, SCF-induced MCP-1 production by PDMC was found to be inhibited by 
the pan-PLD inhibitor (5WO), regardless of the sensitization status of the 
mast cells, reflecting previous reports that cKIT was coupled to PLD activity, 
(Figure 6.8).  Similarly, and as shown in Chapter 4, the IL-33-induced MCP-1 
response in both resting and IgE-sensitized PDMC, was also inhibited by the 
pan-PLD inhibitor (Figure 6.8 A). It was therefore not surprising that the 
synergistic MCP-1 and IL-13 responses to IL-33 + SCF, which could be further 
enhanced by IgE-sensitization, were also ablated by the inhibitor, presumably 
reflecting an ability of SCF- (and/or other serum-containing growth factors) 
associated PLD and calcium signaling to license optimal IL-33 signaling as 
discussed earlier for IgE sensitization. 
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Interestingly, therefore, SCF cytokine responses appeared refractory to 
inhibition of PLD 1 (809; Figure 6.9). Perhaps consistent with this, although 
the weak release of MCP-1 observed in response to IL-33 appeared to be 
inhibited, the synergistic MCP-1 response to IL-33 and SCF was generally 
unaffected in non-sensitized PDMC. However, IL-13 production following such 
co-stimulation was partially blocked, perhaps again suggesting involvement of 
an additional serum factor in the synergistic responses of SCF and IL-33 as 
well as highlighting differential regulation of MCP-1 and IL-13 production. By 
contrast, the synergistic production of both MCP-1 and IL-13 in IgE-sensitized 
PDMC was almost completely ablated by inhibition of PLD 1, presumably 
reflecting recruitment of this signal resulting from IgE-ligation of FcεRI. By 
contrast to the PLD 1 results, inhibition of PLD 2 (APV) ablates cytokine 
production in response to SCF or IL-33, either alone or in combination and 
regardless of sensitization status of the PDMC (Figure 6.10). These data 
further support a role for PLD, particularly PLD 2, in licensing optimal IL-33 
signaling, which in the absence of IgE-sensitization can be partially provided 
by SCF or perhaps some other serum factor.   
 
To determine whether PLD signaling also plays a role in IL-33/ST2 and 
SCF/cKIT crosstalk responses in human MC, the effect of inhibition of PLD 1 
and/or PLD 2 on basal and IL-33-stimulated HMC-1 responses was 
investigated. As HMC-1 cells express constitutive cKIT activation, this would 
allow analysis of ST2/cKIT crosstalk and performing the experiments in 1% 
and 10% serum would determine the need for SCF ligation of cKIT, or its 
interaction with other serum derived factors, to license the full signaling 
capacity of this receptor.  
 
Again, it can be seen that the IL-33-stimulated MCP-1 production observed in 
the presence of 10 % serum is lost when FCS levels in culture are reduced to 
1%, suggesting this serum enhancement is cKIT-independent and, perhaps 
consistent with this, this serum-licensing of IL-33 signaling is PLD 1-
dependent. By contrast, inhibition of "basal" ie cKIT-mediated responses is 
only inhibited by the PLD 2 or pan-PLD inhibitors, and this is similar in 1% 
(Figure 6.11 A) and 10% (Figure 6.11 B)  serum.  Interestingly inhibition of 
proliferation by the PLD 1 inhibitor is overcome by high levels of FCS (Figure 
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6.11 C), suggesting involvement of a non-PLD 1-coupled serum factor, such as 
SCF, in promoting this rescue of cell proliferation.  
 
 
6.3.2.6 Role of SphK in IL-33 plus SCF responses in mast cells.  
SphK activity has been shown to be crucial to cKIT-mediated tumor survival, 
growth and metastasis [409-411], This appears particularly to be the case in 
leukemias and lymphomas [412] where, for example, in chronic myeloid 
leukemia, Imatinib inhibits SphK1 activation [413]. Thus, using PDMC and 
HMC-1 cells, as a model for the cKIT-driven development of mast cell 
leukemia, the role of SphK in such SCF and IL-33 crosstalk was investigated. 
 
MCP-1 production induced by co-stimulation of PDMC with IL-33 and SCF was 
strongly inhibited by the SphK inhibitor, DMS (Figure 6.12 A) and the selective 
inhibitor of SphK1, 5C (Figure 6.12 B). Likewise, the proliferative response of 
HMC-1 induced by 10% serum was reduced to the level observed with 1% FCS 
by both DMS (Figure 6.12 C) and 5C (Figure 6.12 D).  It was rather surprising, 
given the results presented for IL-33 in Chapter 4, that neither of the SphK-
targeting reagents had much effect on the PDMC cytokine responses induced 
by either IL-33 or SCF alone (Figure 6.12 A, B). Nevertheless, as these data 
indicate that signaling induced by the co-administration of IL-33 and SCF is 
dependent on SphK1, and in the presence of 10% serum HMC-1 proliferation is 
also dependent on SphK1, these findings may suggest that SphK activation by 
some serum factor may be responsible for providing a platform for optimal 
SCF-IL-33 signaling in HMC-1 cells. 
 
To further investigate the role of SphK in responses of HMC-1 cells to IL-33 
and serum, the kinase activity of SphK was determined. Consistent with the 
proliferation data, culture of HMC-1 with 10 % FCS following serum starvation 
led to a significant increase in SphK activity within 30 min (Figure 6.13 A). 
Rather surprisingly given the cytokine data, treatment of HMC-1 cells with IL-
33 in 1% serum also stimulates SphK activity (Figure 6.13 B) and a similar, but 
enhanced, profile of activation is observed in response to co-stimulation with 
IL-33 plus 10% serum (Figure 6.13 C) perhaps suggesting that IL-33 (or some 
serum factor) may be stimulating SphK activation in 1% serum that is not 
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essential for cytokine production or proliferation. Future experiments should 
include a control of HMC-1 in 1% serum alone to determine whether this is not 
just a constitutive SphK activity of these transformed cells. Western Blot 
analysis of SphK1 expression (Figure 6.13 D) revealed that long-term culture 
(in the presence of 10% serum) had a negligible effect on the protein levels of 
this signal transducer and this was not substantially modulated by either of 
the cKIT inhibitors, Imatinib or Dasatinib (Figure 6.13 E), ruling out the 
possibility that chronic activation of cKIT downregulated this signal under 
conditions of "basal" HMC-1 signaling.  
 
 
6.3.2.7 Role of mTOR in IL-33 signaling. 
mTOR is a serine/threonine kinase that plays a key role in cell proliferation, 
metabolism and differentiation in response to growth factors and nutrient 
conditions [414-416] as evidenced by loss of mTOR function leading to arrest 
in the G1 phase of the cell cycle and suppression of protein synthesis [416]. 
Association with a number of distinct signaling molecules, including the 
scaffolding proteins RAPTOR and RICTOR, allows mTOR to form the mTORC1 
and mTORC2 complexes respectively (Figure 6.14). Based on studies with 
Rapamycin, which is a specific inhibitor of mTORC1 signaling, preventing 
mTOR and RAPTOR interaction, it is well established that a key function of 
the mTORC1 complex is to activate S6 kinase and and its downstream 
effector, 4E-BP1 to initiate RNA translation and protein synthesis [415, 416].  
 
Although it has been proposed that long-term treatment with Rapamycin may 
also inhibit mTORC2 formation by sequestering mTOR, and hence reducing its 
phosphorylation [414, 417, 418], it is generally believed that Rapamycin is 
not an inhibitor of mTORC2 function as this complex contains the Rapamycin-
insensitive transducer, RICTOR. Thus, due to the lack of mTORC2 inhibitors, 
function of this complex is less well-defined. Nevertheless, it is clear that 
mTORC2 phosphorylates and activates Akt at Ser473 [419, 420] allowing full 
activation of Akt by PI3K-dependent phosphorylation of Akt at Thr308 [419, 
420]. This activation of Akt occurs upstream of coupling to mTORC1 and 
hence acts to perpetuate mTOR signaling by linking the mTORC2 and mTORC1 
pathways and suppressing an inhibitor of mTORC1 formation [421]. The 
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signals required for activation of mTORC2 are unconfirmed but they may be 
initiated, either directly or indirectly, via growth factors [415]. 
 
In human and mouse mast cells, FcεRI and cKIT signaling activate mTORC1 via 
PI3K [414] and consequent PDK1-mediated phosphorylation of Akt Thr308 
[415, 416]. Although Rapamycin inhibits cKIT and FcεRI-induced cytokine 
production and cKIT-mediated survival in mast cells, it has no effect on 
FcεRI-mediated degranulation, presumably reflecting the "pre-formed" nature 
of this response. Likewise, in Th2 cells and innate lymphoid cells (ILC), IL-33 
requires PI3K-dependent activation of mTORC1 and S6K1 to produce IL-5 and 
IL-13 and consistent with this, in vivo, Rapamycin inhibited IL-33-induced 
airway inflammation [327]. Interestingly, as a consequence of the activating 
mutation of cKIT, HMC-1 cells express constitutively active mTOR and p70S6K 
[414] although such mTORC1 signaling remains sensitive to Rapamycin in both 
variants (D816V; HMC-1.2, V560G; HMC-1.1) of the cell line [422]. Thus, it 
was planned to investigate whether the synergism resulting from SCF and IL-
33 crosstalk could perhaps also reflect interactions of cKIT/ST2 modulating 
mTOR signaling. 
 
As mTOR signaling is important for mast cell growth and survival the potential 
toxic effects of Rapamycin on HMC-1 viability were first screened. As 
expected, the addition of serum or IL-33 reduces the cell death observed 
with serum starved (1% FCS; Control) HMC-1 cells (Figure 6.15 A). Perhaps 
counter-intuitively, treatment with Rapamycin also reduced the cell death 
triggered by nutrient withdrawal under conditions of serum starvation. 
However, this presumably reflects inhibition of mTORC1-driven apoptosis, 
resulting from S6K mediated inhibition of PI3K activity self-regulating the 
mTOR pathway to promote cell survival via phosphorylation of Akt at Thr308 
[423] and activation of the ERK/MAPK signaling pathway [424]. Rapamycin 
does not completely prevent cell death, as other pathways involved in 
nutrient withdrawal-induced cell death are unaffected. Nevertheless, these 
data rule out the possibility that any observed effects are due to Rapamycin 
toxicity.  
 
In the presence of 10% serum, MCP-1 is constitutively produced by HMC-1 
cells, presumably due to the activating mutation of the expressed cKIT. 
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Rather surprisingly, if anything, at low concentration (≤10 nM) Rapamycin 
tended to stimulate such cytokine production but this may reflect the ability 
of Rapamycin to promote cell survival by inhibiting the apoptosis-inducing 
effects of mTORC1 as discussed above. However, at higher concentrations 
cytokine production was somewhat inhibited by Rapamycin in a dose-
dependent manner (Figure 6.15 B), findings perhaps consistent with previous 
reports that cytokine production by HMC-1 cells requires mTORC1 signaling 
[414]. Similarly, Rapamycin also inhibits serum-stimulated proliferation of 
HMC-1, with significant reduction of DNA synthesis observed at the highest 
dose tested (Figure 6.15 C).  
 
As SCF/cKIT and IL-33/ST2 couple to PLD/SphK signaling and these elements 
contribute to functional responses in murine mast cells and HMC-1 cells, their 
potential role in SCF/serum and IL-33-stimulated mTOR activation was 
investigated. A precedent for this has been provided by studies showing that 
PLD signaling can activate mTOR pathways where PLD-generated phosphatidic 
acid (PA) promotes the association between mTOR and RAPTOR or RICTOR 
[425-427]. Moreover, further support is provided by studies showing that FCS-
stimulated S6K1 activation and phosphorylation of 4E-BP1 was prevented by 
using butan-1-ol to block PA formation [428, 429]. Thus, to determine 
whether serum- and/or IL-33-stimulated mTOR activation required PLD 
and/or SphK activation, the effects of Rapamycin and selective inhibitors of 
these lipid-directed signal transducers was assessed by Western blot analysis 
of the expression and phosphorylation/activation status of signaling 
components downstream of mTORC1, such as p70 S6K and RAPTOR whilst 
phosphorylation of AKT at Ser473 was exploited as a downstream readout of 
mTORC2 activation. 
 
Firstly, p70 S6 kinase is key to the regulation of protein synthesis and cell 
growth downstream of mTORC1 in mast cells [414] and consistent with this, 
phosphorylation of p70 S6 Kinase at Thr389 is rapamycin-sensitive and 
correlates with p70 S6 kinase activation in vivo [430, 431]. Thus, following 
serum withdrawal for 18 h (Unstimulated 60 min), p70 S6 kinase is found in a 
dephosphorylated and inactive state in HMC-1 cells (Figure 6.16 A). On 
replacement of serum (10% FCS) the cells undergo a rapid phosphorylation at 
Thr389 and activation of p70 S6 kinase that peaks at 10 minutes before 
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returning towards basal levels of phosphorylation within 60 min (Figure 6.16 
A), findings supporting previously reported data using SCF-treated HMC-1 
cells [414]. IL-33 does not alter the kinetics of the response induced by serum 
but amplifies the response. As predicted, Rapamycin completely inhibits 
phosphorylation of p70 S6K induced by both stimuli due to its inhibition of 
mTORC1 formation (Figure 6.16 B).  
 
Although IL-33 has been reported to activate mTOR using PI3K [327] and both 
IL-33 and SCF activate S6K, the role of PLD in the activation of this 
downstream signaling molecule by these stimuli has not been addressed. 
Interestingly, therefore, PA produced by PLD is crucial for mTORC1 and 
mTORC2 assembly [426], however the relative contributions of each PLD 
isoform in mTOR activation is controversial and may depend on subcellular 
localisation of the isoforms and/or the particular stimulus [427]. Thus, the 
relative contributions of PLD 1 and PLD 2 in SCF- and IL-33-mediated p70 S6K 
activation was addressed by the use of the selective inhibitors, 809 and APV 
respectively. This revealed that whilst neither inhibitor exhibited any 
substantial effect on the kinetics of S6K activation, inhibition of PLD 1 
increases the extent of p70 S6K phosphorylation both in response to serum 
and IL-33 (Figure 6.16 C), whereas inhibition of PLD 2 only appeared to 
promote the serum response (Figure 6.16 D). Similarly inhibition of SphK1 
(5C) increased the peak phosphorylation of p70 S6K induced by serum (Figure 
6.16 E).   These findings were rather unexpected given that S6K promotes 
protein synthesis and the Rapamycin data supported a role for mTORC1 in 
HMC-1 cytokine responses stimulated by serum. However, whilst the relative 
levels of Pp70 S6K were increased by the inhibitors, the finding that 
inhibition of PLD 2 appeared to dramatically suppress protein expression of 
p70 S6K, might suggest that it possibly acts in this way to reduce the overall 
activation of this mTORC1 effector and would be consistent with the 
observed PLD 2-dependence of serum-induced MCP-1 production in HMC-1 
(Figure 6.11).  
 
RAPTOR phosphorylation at Ser792 is shown to inhibit mTORC1 and prevent 
cell cycle progression during energy stress [432]. Corresponding to this we 
found that serum withdrawal induced RAPTOR phosphorylation (Unstimulated 
60 min) but after serum reintroduction this phosphorylation was dramatically 
 201 
reduced before recovering slightly (Figure 6.17 A). The addition of IL-33 
appears to increase the reduction in RAPTOR phosphorylation when compared 
to unstimulated levels, suggesting an enhanced mTORC1 activation in 
response to this stimulation, a suggestion supported by its ability to increase 
the extent of Pp70 S6K (Figure 6.16 A). Association of RAPTOR with mTOR can 
be inhibited by Rapamycin [417] and this investigation suggests that the 
inhibitory phosphorylation of RAPTOR is also increased by Rapamycin (Figure 
6.17 B). Pretreatment with PLD 1, PLD 2 and SphK1 inhibitors appeared to 
increase RAPTOR phosphorylation in unstimulated, serum and serum plus IL-
33 stimulated cells, suggesting greater mTORC1 inhibition and reduction in 
cell cycling, confirming the role for PLD in cell cycle progression [433] and for 
PLD 2 in cytokine production by serum-stimulated HMC-1 cells (Figure 6.11).  
 
Generally, serum withdrawal (Unstimulated) seems to reduce the levels of 
RAPTOR expression but this is rapidly upregulated by restoration of serum. 
This may indicate that during metabolic stress RAPTOR is downregulated as 
well as phosphorylated to regulate its activity and indeed, downregulation 
would amplify the relative level of phosphorylated element. Phosphorylation 
of RAPTOR targets the molecule to different subcellular compartments and it 
has been suggested that perhaps during nutrient stress, RAPTOR is located to 
the nucleus [434]. 
 
The inverse pattern of p70S6K and RAPTOR phosphorylation reflects mTORC1 
activation with the increase in an activatory signal and a reduction in an 
inhibitory signal. Although perhaps contradictory with the PLD 1 and SphK1 
p70S6K data (Figure 6.16), the Ser792 RAPTOR phosphorylation responses 
suggests that both PLD 1/2 and SphK1 signaling are involved in the activation 
of mTORC1 at least by serum.  
 
Akt phosphorylation at Ser473 is induced by mTORC2 and allows further Akt 
activation by PDK1 at Thr308  [419, 435].  Total levels of Akt remain constant 
regardless of the serum status whereas in the absence of serum, Akt 
phosphorylation at this site is elevated indicating greater mTORC2 activity 
(Figure 6.18 A). Replenishment of serum dramatically and rapidly reduces this 
phospho-Akt signal, which then returns towards the levels observed under 
serum starvation (Unstimulated 60) within 60 min, although this appears 
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delayed in the presence of IL-33. As would have been predicted, Rapamycin 
had no effect on either response, reflecting its inability to inhibit mTORC2 
activation (Figure 6.18 B).  Although the data are more difficult to interpret 
because of an apparent downregulation of Akt expression, inhibition of PLD 1 
(Figure 6.18 C) and PLD 2 (Figure 6.18 D) initially appears to further decrease 
the relative levels of p473 Akt induced by serum suggesting their inhibition 
also suppresses activation of mTORC2 as well as that of mTORC1 (Figure 6.18 
A). Conversely, at later timepoints, the recovery of Akt phosphorylation in 
the presence of serum is increased, indicating a role for PLD in the 
suppression of mTORC2, which is reduced in the presence of IL-33, potentially 
indicating that IL-33 can inhibit mTORC2 by another means other than PLD 
signaling. Likewise, inhibition of SphK1 also increases Akt phosphorylation, 
promoting mTORC2 activation (Figure 6.18 E). That these PLD and SphK 
inhibitors all appear to promote mTORC2 activity may therefore support the 
p70S6K data indicating that they can all inhibit mTORC1 formation.  
 
 
6.3.2.8 Effect of ES-62-mediated inhibition on IL-33 responses in HMC-1. 
Under conditions of reduced serum (1%) IL-33 does not further stimulate the 
high spontaneous release of MCP-1 from HMC-1 cells, reflecting its 
requirement of a serum factor to license its functional signaling. 
Nevertheless, ES-62 significantly inhibits such basal MCP-1 production from 
HMC-1 cells (Figure 6.19 A) irrespective of the presence of IL-33. By contrast, 
when the cells have been cultured in 10% serum, ES-62 does not inhibit the 
spontaneous release of either MCP-1 or TNFα but there is a reproducible 
trend for the parasite product to slightly inhibit IL-33-induced MCP-1 release 
(Figure 6.19 B) (Figure 6.19 C). 
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6.4 Conclusion 
6.4.1 SCF and serum factors enhance IL-33 responses 
Although serum is used as a source of SCF [396] when exogenous rSCF is used 
to replace serum there is only partial restoration of the cytokine response in 
murine MC and HMC-1 cells. Moreover, the amplified response to IL-33/SCF 
co-stimulation only occurs in the presence of 10% serum, suggesting a role for 
a further unidentified serum component(s), such as PDGF or EGF, in ST2-cKIT 
signaling. This finding may be important in vivo as microenvironments can be 
highly variable and hence, depending on the location and context of the 
interactions involved can have an influential impact on MC responses. For 
example, the microenvironment of tumors can be tailored by the tumor itself 
as well as the surrounding stromal cells [436, 437]. Thus an increase in co-
factors of IL-33 signaling could potentially modulate the immune response, 
particularly that of MC, to promote metastasis by increased angiogenesis, 
surrounding tissue destruction and release of growth factors [375].   
 
IL-33 and SCF crosstalk resulting in amplified functional responses appears to 
occur by signaling via converging pathways. Thus, previous studies found that 
the augmented responses to IL-33 and SCF observed in both MC and CD34+ 
progenitor cells [273, 438] were the result of synergistic activation of NFκB, 
ERK, PKB and JNK [273]. Here the involvement of calcium, PLD, SphK and 
mTOR in such augmented responses in PDMC (Table 6.1 A) and HMC-1 (Table 
6.1 B) were investigated and these studies revealed that, similarly to the IL-
33 cytokine responses in IgE-sensitized PDMC, although dependent on PLD 2, 
SCF-stimulated responses were not sensitive to inhibition of PLD 1 unless the 
MC were sensitized. Presumably reflecting this, cytokine responses to 
stimulation with IL-33 plus SCF were only partially reduced by inhibition of 
PLD 1, while inhibition of PLD 2 induces more robust dose-dependent effects. 
PLD 2 has generally been reported to exhibit high basal activity and hence 
reflect homeostatic responses whereas PLD 1 is considered to be more often 
involved in agonist responses. However, whilst the data in this thesis support 
the idea that PLD 2 is involved in regulating basal responses, they suggest 
that in mast cells, agonists elicit PLD 2 as well as PLD 1 with both isoforms 
involved in convergent IL-33 and SCF signaling. This may account for the 
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rather unusual patterns of PLD activation observed in response to IL-33/ST2 
signaling observed in mast cells. For example, it was reported in Chapter 4, 
and again above, that despite functional responses being susceptible to PLD 
inhibitors, IL-33 did not appear to directly stimulate PLD activity but rather 
that IgE sensitization licensed PLD activation and consequent IL-33-mediated 
calcium mobilisation.  However, this did not explain the ability of IL-33 to 
stimulate cytokine release in the absence of IgE sensitization, a response also 
involving PLD signaling. The data presented here relating to SCF (and/or 
serum) enhancement of IL-33 responses, similar to that of IgE sensitization, 
may now explain this as SCF/cKIT signaling appears to be PLD- and calcium-
dependent, as previously reported [408, 439] and these crosstalk effects 
would be masked in the assays measuring IL-33-mediated PLD activation and 
calcium mobilisation which are performed in the absence of serum.  Likewise, 
SphK signaling may also contribute to the SCF-induced signaling platform that 
allows and/or enhances IL-33 responses (Figure 6.20).  
 
The dual receptor (cKIT/ST2) and IgE-licensing requirement for full activation 
of IL-33-ST2 signaling potentially allows for both rigorous regulation and 
amplification of MC responses. Loss of (part of) this regulation, for example 
as exemplified by the constitutive cKIT signaling in HMC-1, could have 
important implications in the development of disease especially where both 
SCF and IL-33 are found in abundance such as asthma [440-442]. 
Interestingly, therefore, aberrant cKIT activation has been reported in non-
IgE dependent anaphylaxis [443] and “idiophathic” anaphylaxis [444], 
conditions associated with elevated levels of IL-33 expression [329].  
 
Thus, the ability of cKIT inhibitors such as Imatinib and Dasatinib to suppress 
IL-33/SCF cooperation and hence limit pro-inflammatory responses by MC 
could provide an attractive potential therapy in asthma. Indeed, Imatinib has 
been reported to prevent airway inflammation and remodeling in an OVA-
induced model of asthma [445], a disease where IL-33 contributes to 
pathology. Similarly in cancer, even if MC are not themselves transformed, 
they appear to play an important role promoting angiogenesis and 
remodelling of the tumour environment and hence, cKIT inhibitors, although 
not targeting the tumour directly, may exhibit some efficacy by restricting 
MC responses. Moreover, in mastocytosis, they may also be directly effective 
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by targeting the aberrant cKIT/ST2 and serum-driven survival and 
proliferative responses of such cells.  
 
 
6.4.2 mTOR signaling in HMC-1 is regulated by serum and PLD 
activity. 
During nutrient starvation, such as that observed experimentally after serum 
withdrawal or cKIT inhibition, cells undergo a complex set of events to avoid 
death, including the slowing or ceasing of proliferation, increased recycling 
of proteins and organelles and reduced biosynthesis. mTOR signaling plays an 
important role in sensing and interpreting such changes in the environment 
and initiating mechanisms to protect the cell [415]. Not surprisingly, 
therefore, dysregulated mTOR is implicated in oncogenesis particularly with 
respect to the growth of cancer cells due to aberrant activity of Akt, which 
drives proliferation, survival and nutrient absorption. Moreover, excessively 
high mTORC1 activity has been suggested to be responsible for 
transformation in several cancers [433, 446]. Perhaps reflecting this, 
proliferation of HMC-1 cells, which are leukemic MC, involves mTORC1 
signaling. Constitutive MCP-1 production also involves, in part, mTORC1 
signaling, perhaps reflecting the role for MCP-1 in recruiting and activating 
MC and other immune cells such as monocytes to promote angiogenesis, 
promoting cancer metastasis [447]. 
 
In the absence of serum, mTORC1 activity (as evidenced by p70 S6K 
phosphorylation) is reduced but mTORC2 activity (as evidenced by AKT, 
Ser473 and RAPTOR, Ser792 phosphorylation) is increased in HMC-1 cells, 
responses reversed by the reintroduction of serum (Figure 6.21) and which 
appear to be regulated, at least in part by PLD and SphK signaling. Although 
both pathways can act simultaneously [415], this may not be the case in HMC-
1 cells. Perhaps consistent with this, in human mast cells, there is evidence 
that each mTOR complex has a different role thus, whilst mTORC1 is crucial 
for survival, mTORC2 is important for proliferation, especially in neoplastic 
MC, with the relative predominance of particular mTOR complex varying 
depending on the maturation and nutrient status of the mast cells [448]. 
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Using this model our results are surprising where in reduced nutrient 
conditions there is a reduction in survival-promoting mTORC1 but an increase 
in mTORC2, driving proliferation, a counterproductive activity.  
 
As it has been reported that FcεRI and cKIT can activate mTORC1 in MC [414] 
and IL-33 stimulates mTORC1 and S6K1 in Th2 cells and innate lymphoid cells 
[327], it was proposed that ST2 could potentially activate mTOR signaling in 
mast cells. The data presented here for HMC-1 cells suggest this may be the 
case where IL-33 treatment increases p70 S6K phosphorylation and further 
decreases Akt Ser473 phosphorylation compared to serum alone (Figure 6.21). 
This effect is subtle and it would be interesting to determine the effect of IgE 
sensitization on mTOR activation by IL-33 in primary mast cells.  
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Figure 6.1 Co-administration of IL-33 and SCF increases cytokine 
production and proliferation. 
 
PDMC (A, B) or BMMC (C) sensitized with murine anti-DNP IgE (0.5 µg/ml) 
overnight were stimulated with IL-33 (10 ng/ml) ± SCF (100 ng/ml) for 24 h at 
37oC. Release of IL-13, IL-6 and MCP-1 was measured by ELISA from culture 
supernatants (A). Proliferation of was determined by the addition of [3H] 
thymidine for 12 h (B, C). Results represent mean counts per minute (cpm) of 
[3H] thymidine incorporation in newly synthesised DNA. Results represent the 
combined data from 2 independent experiments ± SEM (A) or a single (B-C) 
experiment ± SD.  Statistical analysis using one-way ANOVA with Tukey’s 
multiple comparison test. * p< 0.05, ** p< 0.01 and *** p< 0.001.  
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Figure 6.2 Calcium mobilisation induced by IL-33 is augmented by 
increasing SCF dose. 
 
PDMC sensitized (A-D) or not (C) with murine anti-DNP IgE (0.5 µg/ml) and 
loaded with Fura-2/AM were stimulated at 50s in serum-free HBSS with 100 
ng/ml IL-33 (D, E, F) ± the indicated dose (A, D) or 100 ng/ml SCF (B, C, E, F). 
Intracellular calcium mobilisation and influx were recorded in real-time using 
excitation-emission ratios of 340/380 nm. For the analysis of intracellular 
mobilisation alone, the cells were stimulated in calcium-free buffer 
supplemented with 100 µM EGTA to remove all extracellular calcium (EGTA) (B, 
F). Calcium levels were calculated from Rmax and Rmin values and the data 
presented as the mean calcium values of triplicate samples  ± SD (baseline 
calcium values subtracted) from a single experiment. Statistical analysis using 
a two-tailed, paired t-test. ** p< 0.01, *** p< 0.001 and **** p< 0.0001. 
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Figure 6.3 Co-administration of IL-33 and SCF increases NFκB activation. 
 
PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) then stimulated with 
DNP (0.5 µg/ml) to induce cross-linking (XL), IL-33 (10 ng/ml),  SCF (100 ng/ml) 
or PMA (1 µM) plus Ionomycin (1 µM) for 30 mins at 37oC. Degranulation was 
determined as the % β-hexosaminidase released relative to the total activity of 
the cells (A). Data are presented as the combined results of 4 independent 
experiments where error bars represent SEM. Statistical analysis using one-way 
ANOVA with Tukey’s multiple comparison test. *** p< 0.001. 
PDMC were sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight then 
cultured with IL-33 (10 ng/ml) ± SCF (100 ng/ml) for the indicated times and 
expression of IκBα analysed by Western blotting (B). “0 min” represents zero 
timepoint control. β-actin was used as a loading control. Graphical 
presentation of densitometric analysis was performed using Image J to 
determine the relative intensity of IκBα compared to β-actin for each 
timepoint. Data are from a single experiment. 
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Figure 6.4 IL-33 requires serum or SCF to stimulate cytokine production. 
 
PDMC (A) and BMMC (B) sensitized with murine anti-DNP IgE (0.5 µg/ml) 
overnight were stimulated with IL-33 (10 ng/ml) ± SCF (100 ng/ml) in 1% or 10% 
FCS supplemented RPMI for 24 h at 37oC. Release of IL-6 and MCP-1 was 
measured by ELISA from culture supernatant. Data is representative of a single 
experiment ± SD. Statistical analysis using two-way ANOVA with Bonferroni 
multiple comparison test. **** p< 0.0001. 
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Figure 6.5 IL-33 induces cytokine production but not proliferation or 
calcium mobilisation in HMC-1. 
 
HMC-1 incubated in 1% FCS-supplemented RPMI overnight were stimulated with 
IL-33 (10 ng/ml), SCF (100 ng/ml) or DNP (0.5 µg/ml) to induce cross-linking 
(XL) in 10% (A, C-E) or 1% FCS-supplemented RPMI (D, E) for 24 h (A, C-E) or the 
indicated time course at 37oC. Release of IL-6, MCP-1 and TNFα was measured 
by ELISA from culture supernatants. Data were obtained in a single experiment 
(A) or a single experiment representative of 2 independent experiments where 
error bars show SD (E). Proliferation was determined by the addition of [3H] 
thymidine for 12 h (C, D). Results represent mean counts per minute (cpm) of 
[3H] thymidine incorporation in newly synthesised DNA combined from 2 
independent experiments ± SEM.  
HMC-1 sensitized (IgE) or not (PBS) with murine anti-DNP IgE (0.5 µg/ml) in 1% 
FCS-supplemented RPMI and loaded with Fura-2/AM were stimulated at 50s in 
serum-free HBSS with 100 ng/ml IL-33 or DNP (0.5 µg/ml) to induce cross-
linking (XL) of FcεRI (B). Intracellular calcium mobilisation and influx were 
recorded in real-time using excitation-emission ratios of 340/380 nm. Calcium 
levels were calculated from Rmax and Rmin values and the data presented as 
the mean calcium values of triplicate samples  ± SD (baseline calcium values 
subtracted) from a single experiment representative of 3 independent 
experiments. Statistical analysis using a two-tailed, unpaired (D) or paired t-
test (B), one-way ANOVA with Tukey’s comparison test (A, C) or two-way 
ANOVA with a Bonferroni multiple comparison test (E). * p< 0.05, ** p< 0.01 and 
*** p< 0.001. 
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Figure 6.6 Inhibition of cKIT signaling reduces cell viability and cytokine 
production and prevents cooperative cytokine production 
induced by IL-33 and SCF in murine mast cells. 
 
PDMC (C, D) or BMMC sensitized with murine anti-DNP IgE (0.5 µg/ml) overnight 
were pre-treated with indicated concentrations of cKIT (CD117) inhibitors, 
Imatinib and Dasatinib (A-C), or 100 nM Dasatinib (D, E) for 30 min at 37oC then 
stimulated with IL-33 (10 ng/ml) (A-E) ± SCF (100 ng/ml) (D, E) for 24 h at 37oC 
before cell death was assessed by 7AAD uptake by flow cytometry. Results are 
presented as % 7AAD+ cells in total population (A). Release of IL-6 (C, E) and 
MCP-1 (B, D) was measured by ELISA from culture supernatants. Data is 
representative of a single experiment performed in duplicate where error bars 
show SD.  
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Figure 6.7 cKIT inhibition does not affect receptor expression of HMC-1 
but inhibits viability, cytokine production and proliferation. 
  
HMC-1 incubated in 1% (Starved) (A-G) or 10 % FCS-supplemented RPMI 
overnight (Unstarved) were pre-treated with indicated concentrations of cKIT 
(CD117) inhibitors Imatinib (C, F) and Dasatinib (D, E, G) or 100 nM Dasatinib 
(A, B) for 30 min at 37oC, followed by IL-33 (10 ng/ml) ± SCF (100 ng/ml) in 1% 
or 10% FCS supplemented RPMI (Serum) for 24 h at 37oC. Cell death was 
assessed by 7AAD uptake (C, D) and release of IL-6 and MCP-1 was measured by 
ELISA from culture supernatants in duplicate (E). Proliferation of was 
determined by the addition of [3H] thymidine for 12 h (F, G). Results, 
performed in duplicate, represent mean counts per minute (cpm) of [3H] 
thymidine incorporation in newly synthesised DNA. Surface CD117 (B) and ST2 
(A) expression on HMC-1 was determined by FACs. Graphs represent geometric 
mean fluorescence (GMFI) of positive expressing cells as defined by isotype 
controls (not shown). Data is representative of a single independent where 
error bars show SD.  
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Figure 6.8 PLD signaling is involved in individual and combined SCF and IL-
33-induced cytokine production in PDMC. 
 
Release of IL-13, MCP-1 was measured by ELISA in duplicate from culture 
supernatants of PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) (B) or 
not (A) overnight, pre-incubated with the indicated concentrations of pan-PLD 
isoform inhibitor, 5WO, for 30 min at 37oC, then stimulated with SCF (100 
ng/ml) ± IL-33 (10 ng/ml) for 24 h at 37oC. MCP-1 results represent combined 
data of 2 independent experiments ± SEM. IL-13 results represent a single 
experiment ± SD.  
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Figure 6.9 PLD 1 signaling is involved in SCF cytokine production in IgE 
sensitized PDMC. 
 
Release of IL-13, MCP-1 was measured by ELISA in duplicate from culture 
supernatants of PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) (B) or 
not (A) overnight, pre-incubated with the indicated concentrations of PLD 1 
isoform inhibitor, 809, for 30 min at 37oC, then stimulated with SCF (100 
ng/ml) ± IL-33 (10 ng/ml) for 24 h at 37oC. MCP-1 results represent combined 
data of 2 independent experiments ± SEM. IL-13 results represent a single 
experiment ± SD.  
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Figure 6.10 PLD 2 signaling is involved in SCF and IL-33-induced cytokine 
production in PDMC and is enhanced by IgE sensitization. 
 
Release of IL-13, MCP-1 was measured by ELISA in duplicate from culture 
supernatants of PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) (B) or 
not (A) overnight, pre-incubated with the indicated concentrations of PLD 2 
isoform inhibitor, APV, for 30 min at 37oC, then stimulated with SCF (100 
ng/ml) ± IL-33 (10 ng/ml) for 24 h at 37oC. MCP-1 results represent combined 
data of 2 independent experiments ± SEM. IL-13 results represent a single 
experiment ± SD.  
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Figure 6.11 PLD signaling is involved in IL-33-induced cytokine production 
and proliferation in HMC-1. 
 
HMC-1 incubated in 1% FCS-supplemented RPMI overnight were pre-incubated 
with the indicated concentrations of PLD inhibitors for 30 min at 37oC in 1% (A, 
C) or 10% FCS supplemented RPMI (B, C), then stimulated with IL-33 (10 ng/ml) 
(A, B) for 24 h at 37oC. Release of MCP-1 was measured by ELISA from culture 
supernatants (A, B). Proliferation of unstimulated HMC-1 was determined by 
the addition of [3H] thymidine for 12 h (C). Results represent mean counts per 
minute (cpm) of [3H] thymidine incorporation in newly synthesised DNA. Results 
represent a single experiment ± SD (C) or the combined data from 2 
independent experiments ± SEM (A, B).  
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Figure 6.12 IL-33 plus SCF responses in murine mast cells and serum-
induced proliferation in HMC-1 involve sphingosine kinase 
signaling. 
 
PDMC sensitized with murine anti-DNP IgE (0.5 µg/ml) (A, B) were pre-treated 
with the indicated concentrations of the non-isoform specific sphingosine 
kinase inhibitor, DMS (A) or the SphK1 specific inhibitor, 5C (B), for 30 min at 
37oC followed by IL-33 (10 ng/ml) ± SCF (100 ng/ml) for 24 h at 37oC. Release 
of MCP-1 was measured by ELISA in duplicate (A, B). Data from a single 
experiment ± SD, representative of 2 independent experiments.  
Unstimulated proliferation of HMC-1 incubated in 1% FCS-supplemented RPMI 
overnight (C, D) was determined by the addition of [3H] thymidine for 12 h 
after 24 h incubation with the indicated concentration of inhibitors DMS (C) or 
5C (D) in either 1% or 10% FCS-supplemented RPMI. Results represent mean 
counts per minute (cpm) of [3H] thymidine incorporation in newly synthesised 
DNA. Data obtained in triplicate from a single independent experiment where 
error bars show SD (C, D).  
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Figure 6.13 Sphingosine kinase activity is induced by serum and IL-33 in 
HMC-1. 
 
HMC-1 incubated in 1% FCS-supplemented RPMI overnight were treated with 
10% FCS (A, C) ± IL-33 (100 ng/ml) (B, C) for indicated time course. SphK 
activity was measured using a fluorimetric assay based on the increased 
fluorescence of the substrate JF02 following its phosphorylation by SphK as 
described (2.12). A representative experiment ± SD of at least 2 experiments is 
shown (left panel). The combined results were further analysed to more clearly 
display change in activity, where basal values “0 min” were subtracted from 
values at subsequent time points. Error bars show SEM. Statistical analysis 
using one-way ANOVA with Tukey’s multiple comparison test. * p< 0.05, ** p< 
0.01 and *** p< 0.001. 
Expression of SphK1 was analysed by Western blotting (D) of HMC-1 incubated 
in 1% FCS-supplemented RPMI overnight then pre-treated with Imatinib (10 µM) 
or Dasatinib (100 nM) before incubation in 10% FCS supplemented RPMI for 24 h 
or 48 h at 37oC. GAPDH was used as a loading control and SphK1 expression 
(42.5 kDa) was confirmed with a blocking peptide, pre-incubated with anti-
SphK1 antibody at 37oC from 20 mins. Graphical presentation of densitometric 
analysis was performed using Image J to determine the relative intensity of 
SphK1 compared to GAPDH for each timepoint. Data are from a single 
experiment.  
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Figure 6.14 mTOR signaling. 
 
mTOR is a serine/threonine kinase that plays a key role in cell proliferation, 
metabolism and differentiation in response to growth factors and nutrient 
conditions [414-416], with in particular, loss of mTOR function leading to arrest 
in the G1 phase of the cell cycle and loss of protein synthesis [416]. mTOR 
associates with multiple signaling molecules including the scaffolding proteins 
RAPTOR and RICTOR to form the mTORC1 and mTORC2 complexes respectively. 
mTORC1 complex activates S6 kinase and 4E-BP1 to initiate RNA translation 
and protein synthesis [415, 416]. Rapamycin is a specific inhibitor of mTORC1 
activation that prevents mTOR and RAPTOR interaction, preventing mTORC1 
formation. mTORC2 phosphorylates and activates Akt at Ser473 [419, 420] 
allowing full activation of Akt by PI3K-dependent phosphorylation of Akt at 
Thr308 [419, 420]. This activation of Akt is upstream of mTORC1 and 
perpetuates mTOR signaling by feeding into the mTORC1 pathway. The 
stimulus for activation of mTORC2 is unconfirmed but it may be directly or 
indirectly via growth factors [415]. 
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Figure 6.15 Rapamycin inhibits cytokine production and proliferation of 
HMC-1. 
 
HMC-1 incubated in 1% FCS-supplemented RPMI overnight were treated with 
the indicated concentrations of Rapamycin and microcystin LR (1 µM) for 30 
min at 37oC then IL-33 (10 ng/ml) or 10% FCS (Serum) for 24 h at 37oC before 
cell death was assessed by 7AAD uptake by flow cytometry. Data is presented 
as % 7AAD+ cells in the total population from a single experiment (A). Release 
of MCP-1 was measured by ELISA from culture supernatants in triplicate where 
error bars show SD (B). Unstimulated proliferation was determined by the 
addition of [3H] thymidine for 12 h after 24 h incubation with inhibitors. 
Results represent mean counts per minute (cpm) of [3H] thymidine 
incorporation in newly synthesised DNA ± SD (C). Results represent a single 
experiment. Statistical analysis using one-way ANOVA with Tukey’s multiple 
comparison test. * p< 0.05. 
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Figure 6.16 Serum and IL-33 stimulates p70 S6K Thr389 phosphorylation in 
HMC-1 
 
HMC-1 incubated in 1% FCS-supplemented RPMI overnight were treated with 
Rapamycin (100nM) (B), the SphK1 inhibitor, 5C (30 µM) (C), the PLD 1 
inhibitor, 809 (5µM) (D), or the PLD 2 inhibitor, APV (5µM) (E), for 30 min at 
37oC in 1% FCS supplemented RPMI then serum (10%) ± IL-33 (10 ng/ml) was 
added for the indicated time-course or left unstimulated for 60 mins as a 
control. Expression of phosphorylated p70S6K (Thr389) was analysed by 
Western blotting. Total p70S6K was used as a loading control. Graphical 
presentation of densitometric analysis was performed using Image J to 
determine the relative intensity of Pp70S6K (Thr389) to p70S6K for each 
timepoint. Data are from a single experiment representative.  
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Figure 6.17 Serum and IL-33 inhibits RAPTOR Ser792 phosphorylation in 
HMC-1. 
 
HMC-1 incubated in 1% FCS-supplemented RPMI overnight were treated with 
Rapamycin (100nM) (B), the SphK1 inhibitor, 5C (30 µM) (C), the PLD 1 
inhibitor, 809 (5µM) (D), or the PLD 2 inhibitor, APV (5µM) (E), for 30 min at 
37oC in 1% FCS supplemented RPMI then serum (10%) ± IL-33 (10 ng/ml) was 
added for the indicated time-course or left unstimulated for 60 mins as a 
control. Expression of phosphorylated RAPTOR (Ser792) was analysed by 
Western blotting. Total RAPTOR was used as a loading control. Graphical 
presentation of densitometric analysis was performed using Image J to 
determine the relative intensity of P-RAPTOR to RAPTOR for each timepoint. 
Data are from a single experiment representative.  
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Figure 6.18 Serum and IL-33 inhibits Akt Ser473 phosphorylation in HMC-1. 
 
HMC-1 incubated in 1% FCS-supplemented RPMI overnight were treated with 
Rapamycin (100nM) (B), the SphK1 inhibitor, 5C (30 µM) (C), the PLD 1 
inhibitor, 809 (5µM) (D), or the PLD 2 inhibitor, APV (5µM) (E), for 30 min at 
37oC in 1% FCS supplemented RPMI then serum (10%) ± IL-33 (10 ng/ml) was 
added for the indicated time-course or left unstimulated for 60 mins as a 
control. Expression of phosphorylated Akt (Ser473) was analysed by Western 
blotting. Total Akt was used as a loading control. Graphical presentation of 
densitometric analysis was performed using Image J to determine the relative 
intensity of P-Akt to Akt for each timepoint. Data are from a single experiment 
representative.  
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Figure 6.19 ES-62 modulates HMC-1 cytokine production. 
 
HMC-1 incubated in 1% FCS-supplemented RPMI overnight were treated with ES-
62 (2 µg/ml) in 1% (A) or 10% (B, C) FCS-supplemented RPMI overnight at 37oC 
then stimulated with IL-33 (10 ng/ml) for 24 h at 37oC. Release of MCP-1 (A, B) 
and TNFα (C) was determined by ELISA from culture supernatants. Results 
represent the combined data from 2 (C) experiments ± SEM or a single (A, B) 
independent experiment ± SD. Statistical analysis using one-tailed, unpaired t-
test. *** p< 0.001. 
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Table 6.1  Summary of SCF augmentation of IL-33 responses in PDMC and 
HMC-1. 
 
Additive effect of co-stimulation with IL-33 and SCF in PDMC (A) and HMC-1 (B). 
No degranulation was detected in PDMC regardless of stimulation and IL-33 
fails to induce proliferation independently however in combination with SCF, 
increases proliferation. MCP-1, IL-6 and IL-13 production in increased 
potentially as a result of PLD and SphK-mediated induction of cooperative 
calcium signaling and NFκB activation.  
IL-33-induced MCP-1 production is increased by SCF in HMC-1 potentially as a 
result of PLD and SphK cooperative signaling but HMC-1 do not display calcium 
mobilisation or proliferation following IL-33 treatment. SCF fails to induce 
proliferation however experiments were performed in 10% FCS-supplemented 
serum, which increases basal HMC-1 proliferation. 
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Figure 6.20  Proposed PLD and SphK signaling changes during co-
stimulation of ST2 and cKIT. 
 
IL-33 and SCF signal predominantly using the PLD 2 isoform. Sphingosine kinase 
isoforms are differentially used by SCF (SphK1) and IL-33 (Sphk2), potentially 
cooperating to increase calcium and NFκB signaling, allowing an increase in 
cytokine responses.  
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Figure 6.21 Proposed involvement on mTORC1 and mTORC2 in HMC-1 
under different serum and IL-33 conditions 
 
In HMC-1 cells, mTORC1 and mTORC2 activation is opposing. In reduced serum 
conditions mTORC2 dominates with reduced mTORC1 activation, a situation 
reversed in the presence of serum. Whether this inverse relationship is due to 
negative feedback or an alternative method has not been determined in this 
investigation. When HMC-1 are treated with serum and IL-33 simultaneously 
mTORC1 activation is increased. 
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7 General Discussion  
Mast cells have long been recognised as playing important roles in promoting 
immunity to infection and more recently in the resolution of inflammation 
and wound repair. Coupled with, their pathogenic roles in allergic and 
autoimmune inflammation, this	  has resulted in intense interest in their 
potential as therapeutic targets [14, 37, 75, 77, 142]. It is increasingly clear 
that such studies have been hampered by the gaps in our understanding of 
the multiple heterogeneous phenotypes of mast cells, their phenotypic and 
functional plasticity as well as the ability to respond to a diverse range of 
stimuli. The studies outlined in this thesis attempted to address these 
problems by characterising the pro-inflammatory responses of mucosal and 
connective tissue phenotypes of mast cells to a range of key 
immunomodulatory receptors. Moreover, and as a first step to identifying 
novel therapeutic targets, the signaling pathways involved in transducing 
such functional responses of mast cells were characterised, as well as their 
potential subversion by the helminth product, ES-62 as this has been used as 
a unique probe to identify targets of safe immunomodulation.  Interestingly, 
the modulatory effects of ES-62 were found to vary with each MC subtype 
(Table 3.3) highlighting the need to fully understand the mast cell biology of 
distinct phenotypic and functional subtypes in order to develop effective 
therapeutics.   
 
 
7.1 Mast cell phenotype can be modulated by in vitro 
culture conditions, resulting in diverse functional 
responses. 
Initial investigations were directed at determining the phenotypic and 
functional differences between mucosal and connective tissue mast cell 
subtypes, derived in vitro (Table 3.2).  Thus mast cells, or their precursors, 
were harvested from distinct locations (bone marrow and peritoneal cavity) 
and cultured in the presence of SCF, IL-3 and/or IL-4 to produce three 
phenotypes that may begin to reflect immature and mature versions of such 
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mast cells occurring in vivo. Consistent with this, mature PDMC (serosal) 
expanded with SCF in vitro, display greater degranulation responses to Ag-
mediated FcεRI crosslinking than the immature BMMC (mucosal) and CTMC 
(connective tissue), derived from bone-marrow precursors. Interestingly, 
however, the bone marrow-derived mast cells exhibit greater prostaglandin 
and cytokine responses suggesting a functional bias towards degranulation by 
mature cells. Culture with IL-3, rather than IL-4, also defines a functional 
response bias, with IL-3 plus SCF generating the mucosal-like cells, BMMC, 
which are reported to be in an immature state [11, 159]. This latter proposal 
is supported by the data presented here, as when compared to PDMC or CTMC 
(IL-4 plus SCF treated cells), BMMC have limited degranulation capability and 
reduced granule content (Figure 3.2). However, BMMC display greater 
cytokine responses to LPS and Ag-mediated FcεRI crosslinking than CTMC, but 
equivalent prostaglandin production. As CTMC responses display similarities 
to those of PDMC, namely poor cytokine production, whilst exhibiting a 
greater degranulation capacity than BMMC, one hypothesis is that CTMC 
represent an intermediate state between immature BMMC and fully mature 
PDMC. This would suggest that as mast cells mature, they pass through 
different response biases, from a predominance of cytokine production to a 
downregulation of cytokines in favour of increased degranulation responses. 
This proposal may be supported by the differential cytokine responses 
resulting from co-stimulation via TLR4/ST2 (Figure 5.5) and ST2/FcεRI (Figure 
5.2) in PDMC and BMMC. 
 
As CTMC are not functionally equivalent to the PDMC, this suggests that 
additional maturational factors present within the peritoneal cavity are 
required, highlighting the subtlety of mast cell maturation in vivo. Of course, 
at this stage, it is not possible to rule out that the BMMC and CTMC 
populations characterised here represent branching pathways of mast cell 
differentiation arising from a common precursor or even from distinct 
precursors within the bone marrow population as limited dilution and 
progenitor isolation studies were not performed prior to culture. 
 
Nevertheless, despite this functional plasticity, certain core signaling 
features appeared to be conserved. For example, despite the differential 
functional responses to FcεRI signaling in the three subtypes, the profiles of 
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calcium signaling were very similar across the mast cell subtypes, with 
involvement of both intracellular and extracellular calcium mobilisation 
(Figure 3.9). Interestingly, it was previously reported that LPS/TLR4 signaling 
did not involve calcium mobilisation [31, 188] in mast cells although it had 
been proposed that such signaling could promote FcεRI responses by 
enhancing calcium signaling via upregulation of SOC components [49]. Here, 
however, it was shown that following IgE-sensitization, LPS can indeed 
mobilize calcium, predominantly from extracellular sources, a finding in 
keeping with the ability of LPS to upregulate Orai1 in mast cells. More 
generally, BMMC were found to display the strongest calcium responses, 
typically utilizing calcium from both intracellular and extracellular sources, 
following stimulation with Ag, LPS or IL-33 whereas calcium signaling in CTMC 
and PDMC, appear to predominantly reflect influx of extracellular calcium. 
From this it is possible to create a tentative link between the strength of 
calcium mobilisation and volume of cytokine production. This link has 
previously been suggested for the rat RBL-2H3 "mast cell" line, where varying 
intracellular calcium availability was found to alter the levels of cytokine 
production [449]. This is perhaps not surprising as most functional responses 
of mast cells, including proliferation, gene expression, secretion, adhesion 
and migration [189-191] rely on calcium mobilisation to some extent. 
Regulation of these responses is likely to involve spatio-temporal regulation 
of calcium responses but, as yet, it is difficult to assign a type of calcium 
signal to a functional output as the data concerning the specific roles of 
influx versus ER release have been conflicting [190]. Nevertheless, calcium 
signaling is crucial for cytokine production [193] and likewise degranulation 
of mast cells is well established to be dependent on intracellular calcium 
release [190, 202, 203, 322]. 
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7.2 Mast cell responses are defined by complex 
interplay between multiple stimuli and receptor 
interactions. 
Mast cell responses are shaped by the interactions of a variety of stimuli and 
the studies in this thesis have focused on those implicated in driving allergic 
responses (FcεRI, IL-33/ST2 and LPS/TLR4) and cancer (SCF/cKIT) as a first 
step towards identifying key regulatory events in these pathways. Although 
there has been great interest in the emerging role of IL-33 in allergic 
inflammation, much of the data in the literature relating to mast cell 
responses to this cytokine are controversial. For example, there are 
conflicting reports as to whether IL-33 induces degranulation; however the 
data in this study show clearly that, even following IgE-sensitisation or 
SCF/serum co-stimulation, IL-33 does not stimulate degranulation by any of 
the subtypes of murine MC. The data presented here showing that IL-33 does 
not stimulate either PLD activation or calcium mobilisation in the absence of 
IgE –sensitization of the presence of SCF/serum may go some way to 
explaining this as degranulation of MC is dependent on intracellular calcium 
release [190, 202, 203, 322] and similarly, PLD 1, the predominant PLD 
isoform in FcεRI crosslinking [287, 288], is reported to be more dominant in 
driving exocytosis/degranulation [314]. The lack of degranulation even in 
responses to IL-33-stimulation of IgE-sensitised mast cells cultured in 10% 
FCS, may reflect the predominant PLD 2- and calcium influx-nature of this 
signaling. 
IL-33 does, however, stimulate cytokine production and this is associated 
with calcium mobilisation (via influx from extracellular sources) (4.3.2), NFκB 
and ERK activation (4.3.3). Moreover, although there is evidence for a role(s) 
of both PLD and SphK involvement in such IL-33-ST2 signaling, the former 
appears to require licensing by IgE-sensitisation and/or perhaps co-
stimulation with SCF or other serum-derived growth factors such as PDGF 
(Figure 7.1) and provides a rationale for the PLD-dependency of IL-33-
stimulated calcium mobilisation in IgE-primed mast cells. 
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SCF is an important growth factor for MC [363, 364] and consistent with this, 
in addition to its amplification of IL-33-stimulated MCP-1, IL-13 and IL-6 
responses shown here, it has been shown to increase FcεR1-mediated 
degranulation, cytokine and chemokine responses in MC [365, 440, 450]. 
Interestingly, therefore, long-term culture with SCF has been reported to 
inhibit FcεRI-mediated MC activation, suggesting “older” or chronically-
activated MC are less sensitive to stimulation [41]. Acute SCF treatment has 
been shown to increase FcεRI responses through augmentation of calcium 
mobilisation using DAG and IP3 [365] and although its ability to induce 
calcium mobilisation (6.3.2) would explain its ability to augment IL-33 
signaling, there is also evidence for alternative mechanisms underpinning 
SCF-IL-33 interactions, including cooperative PLD and SphK signaling (6.3.2.5-
6). As such cooperative signaling could be inhibited with pharmacological 
inhibitors of cKIT signaling, namely Imatinib and Dasatinib (6.3.2.4), these 
inhibitors could provide a mechanism to limit pathology under conditions 
where IL-33 and SCF are found in abundance, such as asthma [64, 242, 450] 
or cancer. Likewise, evidence of IL-33-mediated augmentation of serum 
(SCF)-induced mTORC1 activation (6.3.2.7), which is crucial for cell survival 
[448], was found in the human mast cell line, HMC-1, potentially providing a 
mechanism whereby IL-33 might increase (potentially aberrant) survival in 
human mast cells in tumour pathogenesis [62].  
Interestingly there appears to be a cKIT-independent activity in serum that 
enhances IL-33 functional responses, as evidenced by the incomplete 
suppression of cytokine production by Dasatinib. Further support is provided 
by the failure of exogenous rSCF to completely reconstitute IL-33 –induced 
cytokine responses following serum withdrawal. Collectively, these data 
suggest the presence of an additional co-stimulator of IL-33 in serum.  
Although PDGF, also found in serum [397], would be a potential candidate to 
fit this model, it is also robustly inhibited by Dasatinib [56]. 
Similarly to the enhancement of IL-33-ST2 responses by SCF-cKIT signaling, 
IgE sensitization of FcεRI also increases IL-33-stimulated cytokine responses 
(4.3.1), possibly as a result of increased ST2 receptor levels and by a 
mechanism whereby IgE-stimulated PLD activity licenses IL-33-mediated 
calcium mobilisation and increases NFκB and ERK activation. Consistent with 
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this, data from both PDMC and BMMC demonstrate cooperative cytokine 
production following mast cell co-stimulation via IL-33/ST2 and IgE-FcεRI-
signaling (Figure 5.2), mirroring previously reported studies [268] that also 
attributed such enhanced responses to increased calcium influx, NFκB and 
ERK activation.  Consistent with these findings, TAK1, a downstream effector 
of TRAF6 has been proposed to be the point of convergence to increase NFκB 
activation following co-stimulation via IL-33/ST2 and FcεRI [60]. IL-33 and 
SCF crosstalk has been reported to be dependent on PI3K signaling [57]; 
however, although this mechanism was not investigated here, PLD activation, 
which is downstream of PI3K signaling by many immunoreceptors, including 
FcR, appears to be a common element of the crosstalk between IL-33 and 
either SCF or IgE sensitization. 
In terms of PLD signaling, the data presented in this thesis suggest a rather 
more dominant role for PLD 2 in immunoreceptor signaling (Figure 7.1) than 
previously thought, as whilst generally PLD 2 has been proposed to be 
responsible for constitutive, basal signaling, PLD 1 has been defined as the 
dominant isoform in agonist activation of mast cells [288]. However, this 
apparent contradiction may be easily reconciled as the use of the isoform-
selective inhibitors suggested that sensitization of mast cells resulting from 
FcεRI binding of monomeric IgE or by exposure to SCF, involves the 
contribution of PLD 2 signaling to bring about "priming" of murine MC to allow 
IL-33-signaling. IL-33 alone does not appear to stimulate PLD activity or 
calcium mobilisation presumably reflecting the fact that the assays used to 
determine these activities were performed in serum-free conditions, 
effectively removing the SCF-mediated starting platform for IL-33-mediated 
PLD activation. This “basal” PLD 2 signal, especially induced by IgE 
sensitization, allows for increased PLD 1 and PLD 2 signaling following 
stimulation with IL-33 or SCF and may be responsible for the IL-33-induced 
calcium response, only observed in IgE sensitized cells (Figure 4.8) and 
potentially identifies the role for PLD in maintaining NFκB, and subsequent 
cell activation. Interestingly this calcium signaling is not completely ablated 
by PLD inhibition, indicating an alternative method of calcium mobilisation 
used by IL-33 suggesting future experiments should investigate any role for 
PLCγ-dependent production of IP3 in IL-33-induced MC signaling. In addition 
to its role in calcium signaling, the ability of IL-33 to rescue cell viability [62, 
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268] is lost following inhibition of PLD inhibition, suggesting a pro-survival 
role for PLD which may similarly provide a mechanism for IgE-induced MC 
survival [276, 279, 451]. The increased PLD response produced by cooperative 
IL-33 and SCF signal may also be reflected in serum-mediated activation of 
mTORC1, as in HMC-1, PLD 2 signaling appears to play a role in the regulation 
of both mTORC1 and mTORC2. Similarly to the role of PLD in mast cell 
priming, enhanced SphK signaling may also contribute to providing a signaling 
platform to allow and/or enhance IL-33-functional responses.  
 
Although a subordinate role is attributed to PLD 2 in the literature, its 
location at the plasma membrane places it in an optimal position for 
immediate activation [318, 319] and perhaps consistent with this, PLD 2 
appears to regulate the location, morphology and trafficking of signaling 
components [316]. Indeed, and of relevance to this study, siRNA studies 
revealed that downregulation of PLD 2 prevented localisation of FcεRI to 
signaling domains [287]. Interestingly, therefore, the reported dominance of 
PLD 1 signaling in FcεRI may be a reflection of its role in granule trafficking 
[314], crucial for degranulation but a process not stimulated by IL-33 [42, 60, 
62, 155, 268].  
 
 
7.3 Mast cell signaling and functional responses can 
be modulated by ES-62 
The ability of ES-62 to modulate mast cell responses to Ag (FcεRI), LPS (TLR4) 
(Table 3.3) or IL-33 (ST2) (Figure 5.12) in both murine MC (at different stages 
of maturation) and the human mast cell line, HMC-1 (Figure 6.19), indicates 
that its modulation is highly adaptable and not restricted to a specific 
receptor in mast cells. This is also evidenced by its inhibition of 
PMA/Ionomycin responses, which indicates that it is likely targeting one or 
more downstream elements common to these signaling pathways. Similarly, 
as ES-62 as the ability to inhibit both degranulation and cytokine responses, 
which are reported to be controlled by alternative signaling pathways [25, 
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452], this is further support for the proposal that ES-62 can modulate 
recruitment of multiple pathways, presumably at a convergent upstream 
point. One option is calcium signaling as this is crucial for both of these MC 
functional responses [192] and indeed the data presented here reveal that 
ES-62 can inhibit influx of calcium from extracellular locations induced by Ag-
mediated FcεRI crosslinking, LPS or IL-33 (Figure 7.2). Although this has not 
yet been investigated, this inhibition of calcium influx is interesting given 
that ES-62 subverts TLR4 signaling and classical LPS/TLR4 signaling acts to 
promote calcium influx in mast cells by upregulating Orai1, a component of 
SOCs [49]. Perhaps pertinent to this, evidence suggests that SphK2 may be 
involved in regulating calcium influx and hence, future studies, possibly using 
SphK1 or SphK2 KO mice could determine the potential role of individual SphK 
isoforms in ES-62 responses. 
Another candidate of convergent signaling potentially targeted by ES-62 is 
PKCα (Figure 7.2) as this PKC isoform, which plays a key role in Ag receptor 
signaling [187, 212] as well as that of TLR4 [453, 454] and FcεRI signaling 
[126, 455], is downregulated by ES-62 not only in PDMC, BMMC and CTMC 
(Figure 3.11 and [134]) but also in B and T cells. Importantly for a model of 
ES-62 inhibition of IL-33, PKCα can be placed either downstream or upstream 
of PLD, reported here to be key to licensing IL-33 responses.  Thus, PKCα, 
both via direct interaction and also combined with calcium, can activate both 
PLD isoforms [209, 210, 292, 293, 318, 319, 456, 457], whereas the PLD 
product, PA (in conjunction with DAG) can activate PKCα following FcεRI-
crosslinking in RBL-2H3, an activity which has been reported to be responsible 
for calcium signaling and degranulation [285, 286]. Although ES-62 
modulation of PLD activity has not been investigated here and previous 
studies [126] proposed that ES-62 targeted the former, the role of this PKC 
isoform in modulating calcium mobilisation suggests that by downregulating 
PKCα and hence suppressing both of these upstream and downstream roles, 
ES-62 may have developed an efficient strategy for inducing mast cell 
hyporesponsiveness. Alternatively, modulation of IL-33 responses may be 
mediated by downregulation of MyD88 as ES-62 has been shown to 
downregulate this key transducer of IL-1R/TLR family responses in BMMC 
[134], T cells [135] and macrophages (MA McGrath, DT Rodgers, RJ Eason, W 
Harnett & MM Harnett, unpublished). In the latter case, ES-62 has been found 
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to exploit this mechanism to inhibit TLR4-(LPS), TLR2- (BLP) and TLR9- (CpG) 
mediated pro-inflammatory signaling. Interestingly, therefore, evidence 
presented here suggests that ST2-signaling may also inhibits LPS-TLR4-
responses in mast cells, and ST2 -signaling has previously been reported to 
inhibit TLR4 signaling by a mechanism also suggested to involve MyD88 
sequestration and/or downregulation [179, 338]. If ST2 is restricting access to 
MyD88 in mast cells, under certain conditions ST2 may be functioning in a 
manner similar to ES-62, although the ST2-/- data presented here do not 
generally support a role for ST2 in transducing immunomodulation by ES-62. 
Interestingly, however, co-stimulation with IL-33 and LPS induced additive 
effects with respect to cytokine production by WT PDMC and BMMC (Figure 
5.14); these apparently contradictory effects relating to ST2/TLR4 signaling 
are extremely interesting and reflect the conflicting data previously 
published [178, 179, 235, 335, 336, 338, 339]. Perhaps signaling by IL-33 and 
LPS convergently signals via MyD88 to increase cytokine production while, in 
the absence of IL-33, ST2 sequesters MyD88 to limit the LPS response. 
Moreover, as ES-62 can inhibit this enhanced cytokine response in BMMC, this 
supports the proposal of MyD88 as a common signaling element(s) in the 
interaction between ST2 and TLR4. Interestingly, therefore, especially given 
that ES-62 does not downregulate MyD88 in PDMC [134], in the absence of ST2 
expression, ES-62-induced inhibition of LPS responses in these cells, but not 
BMMC, is lost. This result again highlights the functional plasticity of MC 
responses in response to their microenvironment. Thus, in BMMC, which 
produce a strong cytokine response upon TLR4 stimulation, ES-62 may use 
PKCα and/or MyD88 downregulation in order to mediate hyporesponsiveness, 
whereas in PDMC with their generally weak TLR4 responsiveness, ES-62 may 
only require to exploit, via its subversion of TLR4 signaling, ST2-mediated 
inhibition of TLR4 signaling to sequester, rather than degrade MyD88 (Figure 
5.18).  
The development of individual mast cell populations with the ability to 
interpret subtle signals of particular microenvironments to mould their 
response is crucial to the immune response as it increases efficiency and 
reduces unwanted or excessive responses, thereby limiting tissue damage and 
conserving energy.  Thus, as inflammatory disease can be restricted to a 
particular organ such as the lungs in asthma, translational research on 
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clinically relevant mast cell subtypes is required to develop appropriate 
therapeutics. Collectively, these studies highlight potential mechanisms for 
therapeutically targeting MC whilst the further characterisation of the 
distinct MC subtypes that can be generated in vitro will potential allow 
design of future studies to target phenotypically-relevant signals and mast 
cells for particular inflammatory conditions. Furthermore, the complex and 
overlapping signaling interactions identified amongst such receptors involved 
in the homeostatic and inflammatory regulation of mast cells suggests 
potential novel targets for existing therapeutics such as Imatinib or Dasatinib, 
due to their ability to suppress "harmful" or "hyper-inflammatory" cooperative 
signaling arising from crosstalk between FcεRI, TLR4 or ST2 and their target, 
cKIT, whilst still preserving sufficient signaling and functional responses to 
allow protective mast cell function. 
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Figure 7.1 Summary of IL-33 signaling and its interactions with FcεRI, cKIT 
and TLR4  
 
IgE-licensing of IL-33 (and SCF) signaling may be mediated by enhanced PLD 1, 
PLD 2 and SphK activity.  Similarly SCF-licensing of IL-33 is most likely 
mediated by an increase in PLD 2 activity. This allows further PLD 1 and, 
predominantly, PLD 2 activation by IL-33 that may be required for downstream 
calcium mobilisation, potentially via PA-stimulated S1P-S1PR mediated release 
from the ER and the mobilisation of STIM1 to form a complex with CRAC1 
allowing influx of calcium from the extracellular space. The increase in PLD 
signaling may also induce mTORC1 and mTORC2 activation via PA. In 
combination this cooperative signaling drives MC proliferation, increases 
survival and cytokine production. ST2 also has an inhibitory effect on TLR4 
signaling, potentially via MyD88 sequestration. 
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Figure 7.2 Model of the mechanism of action of ES-62 in the induction of 
hyporesponsiveness to the key mast cell activators, FcεRI-XL, 
IL-33/ST2 and LPS/TLR4.  
 
ES-62 may downregulate MyD88 expression in BMMC (A) to inhibit IL-33 
signaling or alternatively/additionally by targeting PKCα, upstream of PLD, for 
degradation (B), the latter mechanism providing a common signaling element 
shared by FcεRI, TLR4 and potentially ST2 signaling in PDMC and BMMC (C). 
PKCα degradation would uncouple PLD activation, inhibiting calcium 
mobilisation and subsequent activation of NFκB. Similarly ES-62-mediated 
inhibition of influx of extracellular calcium induced by FcεRI crosslinking, LPS 
or IL-33 may potentially be via inhibition of SphK2 or prevention of TLR4-
mediated upregulation of calcium channel components and assembly (D). In 
PDMC, rather than induce its degradation, ES-62 may exploit the ability of ST2 
(E) to inhibit TLR4 signaling via MyD88 sequestration (F).  
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